Insufficent data points (0) to generate a histogram of RSD values

( Species:Human)
ANOVA results for this metabolite where p-value <=0.05

Name Study_id Analysis_id ANOVA p-Value FDR Experimental Conditions (factors)
10-Hydroxy-octadec-12Z-enoate-9-beta-D-glucuronideST000444AN0006953.150E-25.280E-2Sample Treatment;Bubbled;Control
10-nonadecenoateST000923AN0015156.500E-31.690E-2Diagnosis;CD;nonIBD;UC
10-nonadecenoateST001192AN0019869.500E-31.060E-1Diet;-;Omnivore;Vegetarian
10-oxogeranialST000403AN0006431.180E-31.730E-2Glucose labelling;C13 glucose;unlabelled
1-(11Z-octadecenyl)-sn-glycero-3-phosphocholineST001204AN0020042.430E-34.600E-3cell_type;iRBC;unRBC
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001202AN0020003.320E-363.530E-35cell_type;iRBC;unRBC
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001204AN0020048.410E-231.380E-21cell_type;iRBC;unRBC
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerolST001205AN0020061.170E-35.670E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
1-(14 or 15-methyl)palmitoyl-GPC (a17:0 or i17:0)*ST000974AN0015951.840E-21.840E-1GROUP;case;control
11-Hydroxyeicosatetraenoate glyceryl esterST000241AN0003735.360E-59.230E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
11-O-Demethylpradimicinone II-13C0[+13CD3 QDA]+ST000148AN0002357.990E-34.100E-2Treatment;13C-Glc;unlabeled
12-(2-Cyclopenten-1-yl)-2-dodecanone-13C10[+QDA adduct]+ST000148AN0002351.930E-27.980E-2Treatment;13C-Glc;unlabeled
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylateST000923AN0015155.430E-42.080E-3Diagnosis;CD;nonIBD;UC
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylateST000923AN0015154.560E-22.960E-1sex;Female;Male
1-(2-(3-CYCLOHEXENYL)ETHYL)SILATRANEST001037AN0016981.400E-37.830E-3Description ;Blank;Reagent Blank;Serum Sample;Solvent
12-Hydroxynevirapine glucuronideST000444AN0006952.720E-25.210E-2Sample Treatment;Bubbled;Control
12-OPDAST000403AN0006426.590E-35.550E-2Glucose labelling;C13 glucose;unlabelled
12-OPDAST000403AN0006424.810E-24.280E-1timepoint;1 hour;20 hours
12-OPDAST000539AN0008183.500E-37.280E-3Cell type;Mature erythrocyte;Reticulocyte
1-3-7-trimethylurateST000923AN0015141.360E-34.870E-3Diagnosis;CD;nonIBD;UC
1-3-7-trimethylurateST001000AN0018793.930E-62.670E-5Diagnosis;CD;Control;UC
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016028.130E-191.400E-16Cox_RRT;.;N;Y
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016022.900E-182.120E-16Competitive_RRTvsDeath;.;N;RRT;DEATH
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMSST000978AN0016022.240E-65.470E-5Cox_Composite_DeathRRT;.;N;Y
13C-aminoadipicST000947AN0015553.560E-343.560E-34Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
13C-aminoadipicST000947AN0015552.680E-78.040E-7Group;control;PCOS
13C-aminoadipicST000948AN0015573.030E-24.540E-2Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
[13C]-ARGININEST000016AN0000331.460E-63.740E-6Material;Cells;Media
[13C]-ARGININEST000016AN0000331.720E-35.170E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-ARGININEST000016AN0000334.050E-31.610E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
[13C]-ARGININEST000043AN0000701.130E-23.880E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
[13C]-ARGININEST000044AN0000682.660E-21.750E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ARGININEST000105AN0001733.130E-25.450E-1CPAP;No CPAP;After CPAP
[13C]-ASPARTIC ACIDST000016AN0000331.080E-56.010E-5Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-ASPARTIC ACIDST000016AN0000331.940E-51.430E-4Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
[13C]-ASPARTIC ACIDST000016AN0000335.930E-39.570E-3Material;Cells;Media
[13C]-ASPARTIC ACIDST000044AN0000683.640E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ASPARTIC ACIDST000106AN0001752.650E-31.100E-1Constitution;Lean;Obese
[13C]-GLUTAMATEST000016AN0000331.100E-198.850E-19Material;Cells;Media
[13C]-GLUTAMATEST000016AN0000339.460E-32.390E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-GLUTAMATEST000043AN0000704.580E-21.150E-1Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
[13C]-GLUTAMATEST000044AN0000682.600E-21.740E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-HISTIDINEST000016AN0000333.800E-72.920E-6Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-HISTIDINEST000016AN0000335.170E-49.710E-4Material;Cells;Media
[13C]-HISTIDINEST000042AN0000641.660E-24.910E-1Condition;Acute lung injury;Healthy
[13C]-HISTIDINEST000044AN0000684.280E-22.050E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-ISOLEUCINEST000009AN0000239.230E-33.150E-2gender;female;male
[13C]-ISOLEUCINEST000044AN0000682.100E-21.570E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-LEUCINEST000009AN0000231.290E-43.200E-3AFTER_MEAL_TIME;30_MIN;NO_WAIT
[13C]-LEUCINEST000016AN0000332.880E-151.680E-14Material;Cells;Media
[13C]-LEUCINEST000044AN0000682.260E-21.640E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-LEUCINEST000106AN0001751.310E-33.210E-2Sampling time;0 min;60 min
[13C]-LYSINEST000016AN0000335.440E-267.770E-25Material;Cells;Media
[13C]-LYSINEST000016AN0000332.160E-36.230E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
[13C]-LYSINEST000044AN0000681.640E-21.380E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-LYSINEST000105AN0001731.080E-27.280E-2Sampling;After SWS onset;Morning fasting
[13C]-PHENYLALANINEST000016AN0000332.070E-33.550E-3Material;Cells;Media
[13C]-PHENYLALANINEST000044AN0000683.630E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-PROLINEST000016AN0000331.060E-362.780E-35Material;Cells;Media
[13C]-PROLINEST000044AN0000682.360E-21.690E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-PROLINEST000105AN0001733.130E-23.500E-1PCOS;No PCOS;PCOS
[13C]-PROLINEST000105AN0001734.410E-22.080E-1Sampling;After SWS onset;Morning fasting
[13C]-THREONINEST000016AN0000334.970E-246.210E-23Material;Cells;Media
[13C]-THREONINEST000044AN0000682.450E-21.720E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-TYROSINEST000016AN0000334.790E-183.470E-17Material;Cells;Media
[13C]-TYROSINEST000044AN0000682.150E-21.590E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-TYROSINEST000106AN0001752.890E-35.130E-2Sampling time;0 min;60 min
[13C]-VALINEST000016AN0000332.750E-346.550E-33Material;Cells;Media
[13C]-VALINEST000044AN0000682.020E-21.560E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
[13C]-VALINEST000106AN0001753.790E-24.680E-1Constitution;Lean;Obese
14-demethyl-14-dehydrolanosterolST000916AN0014924.350E-53.690E-4Diagnosis;Cirrhosis;NASH;Normal;Steatosis
15beta-hydroxycyproterone acetateST000444AN0006951.560E-25.210E-2Sample Treatment;Bubbled;Control
1-5-diazabicyclononaneST000539AN0008185.240E-37.400E-2timepoint;1 hour;20 hours
1-5-diazabicyclononane 2ST000539AN0008185.240E-37.400E-2timepoint;1 hour;20 hours
16:1 (n-7)ST001098AN0017861.380E-23.360E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholineST000445AN0006962.320E-31.670E-2Treatment;FSH;LH
16a-hydroxy DHEA 3-sulfateST000974AN0015954.900E-22.140E-1GENDER;F;M
16a-hydroxy DHEA 3-sulfateST000976AN0015974.340E-25.670E-1GROUP;case;control
16a-Hydroxyestrone-13C0[+QDA adduct+Na]+ST000142AN0002255.980E-326.130E-31Treatment;13C-Glc;unlabeled
16-a-HydroxypregnenoloneST000444AN0006952.600E-25.210E-2Sample Treatment;Bubbled;Control
16b-HydroxystanozololST000241AN0003731.240E-31.770E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
16-FeruloyloxypalmitateST000567AN0008712.230E-191.990E-18Time point;Post;Pre;Baseline
16-FeruloyloxypalmitateST000567AN0008718.750E-69.630E-5groups;Old-Curcumin;Old-Placebo;young
16-Oxo-palmitateST000248AN0003922.740E-27.260E-1Cell population;Fast-cycling cells;Slow-cyling cells
17a-EthynylestradiolST000444AN0006951.720E-25.210E-2Sample Treatment;Bubbled;Control
17a-Ethynylestradiol2-glucuronideST000046AN0000791.670E-32.380E-2Cognitive Status;AD;CN;MCI
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C0[+Na]+ST000148AN0002351.390E-26.240E-2Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+13CD3 QDA]+ST000148AN0002351.730E-27.400E-2Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+QDA adduct]+ST000148AN0002354.770E-21.620E-1Treatment;13C-Glc;unlabeled
17beta-Hydroxy-5alpha-androst-2-ene-2-carboxaldehyde-13C1[+QDA adduct]+ST000148AN0002353.130E-21.160E-1Treatment;13C-Glc;unlabeled
17?-Ethinyl estradiolST000553AN0008461.860E-72.320E-7Sample type;Plasma;Urine
17-phenyl trinor Prostaglandin E2 serinol amideST000567AN0008728.050E-51.660E-4Time point;Post;Pre;Baseline
18:3 (n-3)ST001098AN0017866.240E-32.650E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
18-HydroxycorticosteroneST000355AN0005813.980E-29.380E-2Stage;1;2;3;4;-
19/20-OH PGE2ST001214AN0020251.550E-42.520E-4BMI group;lean;obese;overweight
19/20-OH PGF2aST001214AN0020257.720E-41.140E-3BMI group;lean;obese;overweight
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfateST000046AN0000781.290E-26.950E-2Cognitive Status;AD;CN;MCI
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfateST000046AN0000799.910E-36.760E-2Cognitive Status;AD;CN;MCI
1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholineST001205AN0020062.440E-24.400E-1treatment_duration_(h);1;5;3
1-AG and 2-AGST000977AN0015992.400E-24.200E-2Group;Healthy Control;NAFLD
1-AG bST000096AN0001548.250E-111.070E-9Timepoint;18 hours;4 hours;NA
1-arachidonoylglyercophosphateST000974AN0015951.190E-101.280E-9REGION;AHRI;MRC;SUN
1-deoxynojirimycinST000403AN0006424.330E-22.180E-1Glucose labelling;C13 glucose;unlabelled
1-deoxyxylonojirimycinST000403AN0006424.600E-148.870E-13Cell type;Mature erythrocyte;Reticulocyte
1-deoxyxylonojirimycinST000539AN0008185.460E-152.870E-13Cell type;Mature erythrocyte;Reticulocyte
1-deoxyxylonojirimycinST001205AN0020063.170E-27.170E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*ST000974AN0015954.400E-21.980E-1GENDER;F;M
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*ST000975AN0015969.970E-59.560E-4GENDER;F;M
1-docosapentaenoylglycerophosphocholine (22:5n3)*ST000975AN0015961.600E-62.650E-5GENDER;F;M
1-docosapentaenoylglycerophosphocholine (22:5n6)*ST000975AN0015961.060E-24.470E-2GENDER;F;M
1-docosapentaenoylglycerophosphocholine (22:5n6)*ST000976AN0015975.960E-32.130E-1GENDER;F;M
1-Hexadecylpyridinium cationST000089AN0001415.230E-96.570E-9Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
1_iSTD PG (17:0/17:0)ST000342AN0005542.830E-36.330E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
1-LG and 2-LGST000977AN0015997.190E-31.440E-2Group;Healthy Control;NAFLD
1-LG bST000096AN0001544.250E-71.110E-6Timepoint;18 hours;4 hours;NA
1-Methyladenosine BST001211AN0020174.790E-31.810E-2Group;Control;Methotrexate
1-monoheptadecanoyl glyceride NISTST000910AN0014803.330E-22.390E-1Diagnosis;MECFS;MS;ND
1-NaphthoicacidglucuronideST000046AN0000781.070E-25.990E-2Cognitive Status;AD;CN;MCI
1-octadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphocholineST001205AN0020062.120E-24.380E-1treatment_duration_(h);1;5;3
1-octadecanoyl-rac-glycerolST000046AN0000772.210E-21.560E-1Cognitive Status;AD;CN;MCI
1-octadecanoyl-rac-glycerol+2.8676724ST000047AN0000811.030E-21.040E-1Cognitive Status;AD;CN;MCI
1-OG bST000096AN0001541.230E-85.310E-8Timepoint;18 hours;4 hours;NA
1-Oleoyl Lysophosphatidic AcidST000553AN0008461.430E-115.590E-11Sample type;Plasma;Urine
1-O-Methyl-myo-inositolST001204AN0020059.040E-113.440E-10cell_type;iRBC;unRBC
1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+Na]+ST000142AN0002254.740E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+QDA adduct+Na]+ST000142AN0002256.330E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C1[+QDA adduct+Na]+ST000142AN0002258.660E-326.130E-31Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C3[+QDA adduct+Na]+ST000142AN0002254.760E-326.130E-31Treatment;13C-Glc;unlabeled
1-PHENYLETHANOL (CAS# 1445-91-6); (M+H)+[-H2O]ST000741AN0011562.640E-21.290E-1subject type;Healthy control;Mild disease;POOLED;Severe dise...
1-stearoyl-rac-glycerolST000356AN0005826.550E-61.580E-5Diagnosis;breast cancer;control
1-stearoyl-rac-glycerolST000356AN0005821.140E-53.190E-5stage;-;2;3
1-tetradecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholineST001205AN0020064.020E-25.090E-1treatment_duration_(h);1;5;3
1-thio-beta-D-glucoseST001204AN0020053.940E-121.690E-11cell_type;iRBC;unRBC
20:2 (n-6)ST001098AN0017862.720E-24.210E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
20:3 (n-6)ST001098AN0017863.310E-32.650E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
20cooh AAST000916AN0014915.140E-123.960E-10Diagnosis;Cirrhosis;NASH;Normal;Steatosis
21-hydroxypregnenolone monosulfate (1)ST000974AN0015952.670E-31.080E-2REGION;AHRI;MRC;SUN
22:1 (n-9)ST001098AN0017866.750E-41.150E-2Treatment;Non-obese control;Obese control;Schizophrenia dx
24-DihydroxyacetophenoneST001193AN0019883.280E-24.810E-2Plasma;Cord blood;Plasma
24-DihydroxyacetophenoneST001193AN0019896.530E-41.080E-3Plasma;Cord blood;Plasma
2-(4-sulfophenyl)butyrateST001202AN0020001.090E-121.660E-12cell_type;iRBC;unRBC
2-(4-sulfophenyl)butyrateST001202AN0020008.240E-31.130E-2treatment_duration_(h);-;1.5;3;6;9
25-hydroxyvitaminD225-(beta-glucuronide)/25hydroxyergocalciferol25-(beta-glucuronide)ST000045AN0000724.260E-22.380E-1Treatment;Insulin Withdrawal;Saline Infusion
2-acetamidoglucalST001201AN0019984.220E-51.310E-3treatment;DHA;DMSO;OZ277;OZ439
2-(Acetamidomethylene)succinateST000403AN0006435.950E-92.900E-8Cell type;Mature erythrocyte;Reticulocyte
2-(Acetamidomethylene)succinateST000539AN0008191.910E-89.860E-8Cell type;Mature erythrocyte;Reticulocyte
2-Aceto-2-hydroxybutanoateST000292AN0004663.760E-39.180E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
2-(acetylamino)-1-5-anhydro-2-deoxy-3-O-b-D-galactopyranosyl-D-arabino-Hex-1-enitolST001204AN0020048.160E-51.910E-4cell_type;iRBC;unRBC
2-AG bST000096AN0001541.340E-31.580E-3Timepoint;18 hours;4 hours;NA
2(alpha-D-Mannosyl)-D-glycerateST000403AN0006438.890E-41.850E-3Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerateST000403AN0006431.240E-27.960E-2Glucose labelling;C13 glucose;unlabelled
2(alpha-D-Mannosyl)-D-glycerateST000539AN0008194.830E-71.990E-5Glucose labelling;C13 glucose;unlabelled
2(alpha-D-Mannosyl)-D-glycerateST000539AN0008192.740E-22.040E-1timepoint;1 hour;20 hours
2(alpha-D-Mannosyl)-D-glycerateST001201AN0019991.040E-65.590E-5treatment;DHA;DMSO;OZ277;OZ439
2(alpha-D-Mannosyl)-D-glycerateST001201AN0019991.040E-21.800E-2cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerateST001202AN0020013.890E-199.570E-19cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerateST001202AN0020011.690E-66.080E-6treatment_duration_(h);-;1.5;3;6;9
2(alpha-D-Mannosyl)-D-glycerateST001205AN0020071.350E-24.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
2-amino-2-deoxyglucitol-6-phosphateST001204AN0020041.360E-73.920E-7cell_type;iRBC;unRBC
2-AMINO-2-DEOXYHEXOPYRANOSEST000016AN0000337.930E-31.230E-2Material;Cells;Media
2-AMINO-2-DEOXYHEXOPYRANOSEST000106AN0001751.330E-24.280E-1Visit;1;2
2-AMINO-2-DEOXYHEXOPYRANOSEST000106AN0001754.190E-23.060E-1Sampling time;0 min;60 min
2-amino-2-deoxy-isochorismateST001201AN0019993.640E-25.590E-2cell_type;iRBC;unRBC
2-Amino-2-methyl-1-propanolST000047AN0000802.970E-22.150E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanolST000047AN0000813.460E-21.970E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanolST000421AN0006635.550E-31.210E-1treatment;ND;T1D poor glycemic control
2-Amino-2-methyl-1-propanol+3.3926477ST000047AN0000809.720E-43.870E-2Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+5.1998544ST000046AN0000771.370E-21.280E-1Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+5.204487ST000047AN0000814.200E-22.080E-1Cognitive Status;AD;CN;MCI
2-Amino-3-methyl-1-butanolST000242AN0003751.860E-101.670E-9Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-Amino-3-methyl-1-butanolST000566AN0008702.430E-71.220E-6Time point;Post;Pre;Baseline
2-Amino-3-methyl-1-butanol + 5.2393837ST000421AN0006634.020E-23.090E-1treatment;ND;T1D poor glycemic control
2-amino-6-methylaminohexanoic acidST000355AN0005806.670E-32.440E-2Stage;1;2;3;4;-
2-AMINOETHYL DIHYDROGEN PHOSPHATE;ETHANOLAMINE PHOSPHATEST000956AN0015691.660E-34.880E-3Treatment;Condition-1;Condition-2;Condition-3;Control
2-Aminomalonate semialdehydeST000403AN0006431.360E-64.210E-6Cell type;Mature erythrocyte;Reticulocyte
2-Aminomalonate semialdehydeST000539AN0008194.620E-72.010E-6Cell type;Mature erythrocyte;Reticulocyte
2-BenzothiazolesulfonamideST001201AN0019993.060E-251.470E-24cell_type;iRBC;unRBC
(2-Butylbenzofuran-3-yl)(4-hydroxyphenyl)ketone-13C0[+Na]+ST000142AN0002257.120E-44.200E-3Treatment;13C-Glc;unlabeled
2-chloro-3-methyl-maleylacetateST001201AN0019984.340E-563.390E-54cell_type;iRBC;unRBC
2-chloro-3-methyl-maleylacetateST001204AN0020041.120E-303.980E-29cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphateST001201AN0019992.780E-97.280E-9cell_type;iRBC;unRBC
2-C-Methyl-D-erythritol 4-phosphateST001201AN0019993.590E-32.660E-2treatment;DHA;DMSO;OZ277;OZ439
2-C-Methyl-D-erythritol 4-phosphateST001202AN0020019.320E-85.300E-7treatment_duration_(h);-;1.5;3;6;9
2-C-Methyl-D-erythritol 4-phosphateST001202AN0020013.610E-74.300E-7cell_type;iRBC;unRBC
2-Dehydro-3-deoxy-arabinonate-13C0[+Na]+ST000148AN0002357.440E-33.890E-2Treatment;13C-Glc;unlabeled
2-Dehydro-3-deoxy-L-rhamnonateST000403AN0006421.390E-42.560E-3Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonateST000403AN0006438.500E-62.450E-5Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonateST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonateST000539AN0008193.460E-25.700E-2Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonateST001205AN0020071.610E-41.540E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
2-Dehydro-D-xylonate 2ST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonate 2ST000539AN0008193.460E-25.700E-2Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-xylonate-13C0[+H]+ST000142AN0002258.530E-326.130E-31Treatment;13C-Glc;unlabeled
2-Demethylmenaquinone-13C0[+Na]+ST000142AN0002258.830E-326.150E-31Treatment;13C-Glc;unlabeled
2-deoxycytidineST000923AN0015132.430E-27.810E-2sex;Female;Male
2-deoxycytidineST000923AN0015134.660E-27.100E-2Diagnosis;CD;nonIBD;UC
2-deoxycytidineST001142AN0018754.440E-66.840E-6Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-deoxycytidineST001142AN0018753.170E-54.010E-5Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
2-deoxyerythritol NISTST000383AN0006181.580E-32.790E-2Health Status;diabetic;non-diabetic
2-deoxyglucose-6-phosphateST000450AN0007061.680E-42.490E-4gender;Female;Male
2-deoxyglucose-6-phosphateST001201AN0019991.690E-145.490E-14cell_type;iRBC;unRBC
2-DeoxyinosineST000553AN0008475.700E-111.470E-10Sample type;Plasma;Urine
2-Deoxymugineic acidST000403AN0006431.160E-32.350E-3Cell type;Mature erythrocyte;Reticulocyte
2-Deoxymugineic acidST000539AN0008191.230E-54.150E-5Cell type;Mature erythrocyte;Reticulocyte
2-deoxypentitol NISTST001211AN0020165.250E-31.110E-2Group;Control;Methotrexate
2-deoxytetronic acid nistST000420AN0006621.670E-74.790E-7Group;nonsmoker;smoker
2-deoxytetronic acid NISTST000368AN0006022.240E-44.050E-4Organ;Plasma;Serum;Serum or Plasma
2-deoxytetronic acid NISTST000385AN0006203.320E-156.390E-15Organ;Plasma;Serum;Serum or Plasma
2-deoxytetronic acid NISTST000385AN0006203.660E-41.800E-3Gender;F;M;NA
2-deoxytetronic acid NISTST000385AN0006207.350E-44.860E-3Smoking Status;Current;Former;NA
2-deoxytetronic acid NISTST001118AN0018171.340E-22.620E-2Treatment Group;Control;Wilson Disease
2-docosanamidoethanesulfonicacidST000046AN0000765.610E-34.820E-2Cognitive Status;AD;CN;MCI
2-docosanamidoethanesulfonicacidST000046AN0000772.300E-21.560E-1Cognitive Status;AD;CN;MCI
2E-Eicosenoic acidST001191AN0019831.280E-61.310E-5Treatment;Control;QC;Sample
2E-methyl-glutaconic acidST000567AN0008721.040E-31.500E-3Time point;Post;Pre;Baseline
2-ethylphenylsulfateST000974AN0015955.410E-34.500E-2GENDER;F;M
2-ethylphenylsulfateST000975AN0015962.360E-48.250E-3REGION;MAK;SUN
2-ethylphenylsulfateST000975AN0015968.000E-45.090E-3GENDER;F;M
2-FormaminobenzoylacetateST000403AN0006434.460E-21.870E-1Glucose labelling;C13 glucose;unlabelled
2-FormaminobenzoylacetateST000539AN0008193.020E-34.620E-2Glucose labelling;C13 glucose;unlabelled
2-FormaminobenzoylacetateST000539AN0008197.680E-31.230E-1timepoint;1 hour;20 hours
2-FormaminobenzoylacetateST000539AN0008194.390E-27.140E-2Cell type;Mature erythrocyte;Reticulocyte
2-HB (2-hydroxybutyric acid)ST000166AN0002594.310E-31.410E-2Group;3M;Control;HF
2-Heptyl-3-hydroxy-quinolone-13C0[+H]+ST000142AN0002258.630E-326.130E-31Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C1[+H]+ST000142AN0002251.910E-311.130E-30Treatment;13C-Glc;unlabeled
2-hexacosanamidoethanesulfonicacidST000047AN0000814.190E-22.080E-1Cognitive Status;AD;CN;MCI
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acidST000566AN0008698.180E-32.670E-2group;Old-Curcumin;Old-Placebo;young
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acidST000567AN0008715.870E-31.710E-2groups;Old-Curcumin;Old-Placebo;young
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoicacidST000047AN0000832.510E-32.980E-2Cognitive Status;AD;CN;MCI
2-hydroxy-3-methylpentanoic acid / leucinic acidST001000AN0018791.050E-22.420E-2Diagnosis;CD;Control;UC
2-hydroxybutyrate/2-hydroxyisobutyrateST000899AN0014653.890E-54.480E-4Type;Control;Crohn disease;Ulcerative Colitis
2-hydroxydecanoateST000976AN0015971.470E-23.710E-1GROUP;case;control
2-hydroxyglutarate+NaST000956AN0015685.930E-41.620E-3Treatment;Condition-1;Condition-2;Condition-3;Control
2-Hydroxyiminodibenzyl glucuronideST000242AN0003751.220E-83.370E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-Hydroxy-imipramine glucuronideST000444AN0006952.950E-25.280E-2Sample Treatment;Bubbled;Control
2-hydroxymethanesulfonateST000403AN0006431.240E-43.020E-4Cell type;Mature erythrocyte;Reticulocyte
2-hydroxymethanesulfonateST000539AN0008194.850E-72.100E-6Cell type;Mature erythrocyte;Reticulocyte
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST000403AN0006432.890E-151.410E-13Cell type;Mature erythrocyte;Reticulocyte
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST000539AN0008191.040E-42.990E-4Cell type;Mature erythrocyte;Reticulocyte
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST001201AN0019997.480E-41.460E-3cell_type;iRBC;unRBC
2-(Hydroxymethyl)-3-(acetamidomethylene)succinateST001201AN0019993.730E-21.540E-1treatment;DHA;DMSO;OZ277;OZ439
2-hydroxyoctanoateST000899AN0014643.400E-26.860E-2Type;Control;Crohn disease;Ulcerative Colitis
2-hydroxyoctanoateST000974AN0015951.910E-21.180E-1GENDER;F;M
2-hydroxyoctanoateST000974AN0015952.400E-27.490E-2REGION;AHRI;MRC;SUN
2-Hydroxyphenylalanine;L-TYROSINEST000956AN0015689.100E-31.710E-2Treatment;Condition-1;Condition-2;Condition-3;Control
2-Isopropyl-5-methyl-1-heptanolST000978AN0016022.580E-21.140E-1Cox_RRT;.;N;Y
2-ketoglucose dimethylacetal NISTST000063AN0001013.000E-31.350E-2Source;Group 1 - Score 0;Group 2 - Score 50
2-ketoglucose dimethylacetal NISTST000392AN0006289.840E-84.570E-7Organ;Plasma;Serum;Serum or Plasma
2-ketoglucose dimethylacetal NISTST000392AN0006281.980E-31.960E-2Gender;F;M;-
2-ketoglucose dimethylacetal NISTST000392AN0006282.990E-33.370E-2Smoking Status;Current;Former;-
2-ketoglucose dimethylacetal NISTST000392AN0006283.120E-31.370E-2Disease State;cancer;control;-
2-KetoleucineST000589AN0009043.070E-727.600E-72Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
2-Ketoleucine/ketoisoleucineST000586AN0009012.300E-371.960E-36Plasma Volume;0 uL;150 uL;700 uL
2-keto-l-gluconic acidST000092AN0001468.360E-61.220E-5Gender;N/A;Female;Male
2-keto-l-gluconic acidST000092AN0001468.660E-51.220E-4Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
2-keto-l-gluconic acidST000092AN0001464.570E-47.140E-4Solution Added;N/A;None;Urease;Water
2-keto-l-gluconic acidST000092AN0001462.000E-22.920E-2Urease Treatment;No treatment;Urease pre-treatment;Water pre...
2-KetovalineST000586AN0009013.340E-107.630E-10Plasma Volume;0 uL;150 uL;700 uL
2-KetovalineST000589AN0009049.360E-622.060E-61Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
2-LG bST000096AN0001545.090E-59.460E-5Timepoint;18 hours;4 hours;NA
2-MethylbutanalST000567AN0008723.780E-72.890E-6Time point;Post;Pre;Baseline
2-methylcitrate/homocitrateST000899AN0014643.670E-27.320E-2Type;Control;Crohn disease;Ulcerative Colitis
2-Methylmaleate/ItaconateST001317AN0021935.539E-375.601E-36SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-Methylmaleate/ItaconateST001317AN0021935.539E-375.601E-36SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-O-ethyl PAF C-16ST000553AN0008451.140E-114.390E-11Sample type;Plasma;Urine
2-OG bST000096AN0001542.510E-55.430E-5Timepoint;18 hours;4 hours;NA
2-OG bST000096AN0001544.760E-21.770E-1Sample Type;Adipocyte ;Co-culture ;Control ;Media blank
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)ST001317AN0021933.375E-181.228E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)ST001317AN0021933.375E-181.228E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate) / 3OH-MBP (Mono-(3-hydroxy-n-butyl) phthalate)ST001048AN0017177.600E-51.110E-4Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
2-O-methyl PAF C-16ST000553AN0008466.290E-77.410E-7Sample type;Plasma;Urine
2-O-methyl PAF C16ST000553AN0008457.740E-48.890E-4Sample type;Plasma;Urine
2-oxindole-3-acetateST000899AN0014621.320E-24.930E-2Type;Control;Crohn disease;Ulcerative Colitis
2-Oxo-10-methylthiodecanoic acidST000566AN0008702.280E-54.430E-5Time point;Post;Pre;Baseline
2-oxo-3-methylvaleric acidST000356AN0005821.610E-271.800E-26Diagnosis;breast cancer;control
2-oxo-3-methylvaleric acidST000356AN0005822.980E-193.770E-18stage;-;2;3
2-oxo-3-methylvaleric acidST000566AN0008702.520E-54.640E-5Time point;Post;Pre;Baseline
2-oxo-3-methylvaleric acidST000566AN0008704.700E-21.410E-1group;Old-Curcumin;Old-Placebo;young
2-oxo-4-methylvaleric acidST000355AN0005802.430E-31.070E-2Diagnosis;Breast cancer;Control
2-oxo-4-methylvaleric acidST000355AN0005804.490E-31.740E-2Stage;1;2;3;4;-
2-oxo-4-methylvaleric acidST000356AN0005822.670E-283.370E-27Diagnosis;breast cancer;control
2-oxo-4-methylvaleric acidST000356AN0005826.850E-209.880E-19stage;-;2;3
2-oxo-5-methylthiopentanoic-acidST001201AN0019982.050E-506.680E-49cell_type;iRBC;unRBC
2-Oxo-7-methylthioheptanoic acidST000567AN0008721.150E-53.050E-5Time point;Post;Pre;Baseline
2-Oxo-8-methylthiooctanoate-13C0[+Na]+ST000142AN0002257.960E-336.130E-31Treatment;13C-Glc;unlabeled
2-oxogluconic acid NISTST000369AN0006032.370E-41.590E-3Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
2-oxogluconic acid NISTST000369AN0006033.590E-39.150E-3Organ;Plasma;Serum
2-oxogluconic acid NISTST000369AN0006031.500E-24.690E-2Gender;F;M;NA
2-oxogluconic acid NISTST000369AN0006032.660E-26.950E-2Smoker;Current;Former;NA
2-oxogluconic acid NISTST000386AN0006213.650E-31.830E-2Gender;F;M;NA
2-oxogluconic acid NISTST000386AN0006214.190E-31.100E-2Organ;Plasma;Serum
2-oxogluconic acid NISTST000386AN0006211.330E-24.720E-2Smoker;Current;Former;NA
2-oxogluconic acid NISTST000386AN0006215.000E-21.560E-1Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
2-oxosuberateST000403AN0006434.130E-33.920E-2Glucose labelling;C13 glucose;unlabelled
2-oxosuberateST000539AN0008192.270E-33.790E-2Glucose labelling;C13 glucose;unlabelled
2-Oxovaleric acidST000421AN0006632.090E-22.140E-1treatment;ND;T1D poor glycemic control
2-OxovalericacidST000045AN0000752.790E-34.820E-2Treatment;Insulin Withdrawal;Saline Infusion
2-Phospho-D-glycerateST001201AN0019993.020E-26.950E-1treatment_duration_(h);-;0.5;1.5;3
2-Phospho-D-glycerateST001205AN0020076.090E-32.410E-1treatment_duration_(h);1;5;3
2-Propylisonicotinic acidST000422AN0006692.590E-21.000E+0treatment;ND;T1D good glycemic control
2-PyridylthioamideST000566AN0008691.730E-33.390E-3Time point;Post;Pre;Baseline
2-pyrrolidone-5-carboxylic acidST000356AN0005822.020E-44.160E-4Diagnosis;breast cancer;control
2-pyrrolidone-5-carboxylic acidST000356AN0005821.270E-32.780E-3stage;-;2;3
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoateST000539AN0008192.340E-45.700E-3Glucose labelling;C13 glucose;unlabelled
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate 2ST000539AN0008192.340E-45.700E-3Glucose labelling;C13 glucose;unlabelled
2-S-Glutathionyl acetateST001201AN0019983.450E-221.800E-21cell_type;iRBC;unRBC
2-S-Glutathionyl acetateST001204AN0020041.190E-191.220E-18cell_type;iRBC;unRBC
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C0[+QDA adduct+Na]+ST000142AN0002252.340E-326.130E-31Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C1[+QDA adduct+Na]+ST000142AN0002257.740E-326.130E-31Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C2[+QDA adduct+Na]+ST000142AN0002256.480E-326.130E-31Treatment;13C-Glc;unlabeled
2-(sulfomethyl)thiazolidine-4-carboxylateST000403AN0006433.320E-33.460E-2Glucose labelling;C13 glucose;unlabelled
2-(sulfomethyl)thiazolidine-4-carboxylateST000539AN0008198.730E-52.550E-4Cell type;Mature erythrocyte;Reticulocyte
3-(1-Pyrrolidinyl)-2-pentanoneST001202AN0020003.990E-146.480E-14cell_type;iRBC;unRBC
3-(1-Pyrrolidinyl)-2-pentanoneST001202AN0020003.820E-24.640E-2treatment_duration_(h);-;1.5;3;6;9
34-Dihydroxymandelic acidST001039AN0017131.800E-22.680E-2Sample.Matrix;Plasma;Urine
3-(4-hydroxyphenyl)propionateST000974AN0015954.120E-351.440E-33REGION;AHRI;MRC;SUN
3-(4-Hydroxyphenyl)propionic acidST000586AN0009013.310E-23.870E-2Plasma Volume;0 uL;150 uL;700 uL
3-(4-Hydroxyphenyl)Pyruvate / CaffeateST001040AN0017025.800E-42.630E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
3-acetyl pyridine adenine dinucleotideST000403AN0006434.440E-38.280E-3Cell type;Mature erythrocyte;Reticulocyte
3-acetyl pyridine adenine dinucleotideST000403AN0006432.310E-21.210E-1Glucose labelling;C13 glucose;unlabelled
3-acetyl pyridine adenine dinucleotideST000539AN0008191.580E-33.030E-2Glucose labelling;C13 glucose;unlabelled
3-(ADP)-2-phosphoglycerateST000403AN0006421.860E-54.880E-5Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerateST000539AN0008185.400E-31.080E-2Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerateST000539AN0008182.700E-21.840E-1timepoint;1 hour;20 hours
3-(ADP)-2-phosphoglycerateST001201AN0019981.340E-134.580E-13cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerateST001202AN0020018.470E-91.110E-8cell_type;iRBC;unRBC
3-(ADP)-2-phosphoglycerateST001202AN0020014.520E-82.890E-7treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerateST000403AN0006436.160E-125.460E-11Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-glycerateST000539AN0008198.120E-62.830E-5Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-glycerateST001201AN0019992.990E-139.430E-13cell_type;iRBC;unRBC
3-(ADP)-glycerateST001202AN0020011.150E-111.640E-10treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerateST001202AN0020013.300E-23.540E-2cell_type;iRBC;unRBC
3-AIB (a-amino[1-(14)C]isobutyric acid)ST000166AN0002591.280E-22.860E-2Group;3M;Control;HF
3alpha-HYDROXY-3-DEOXYANGOLENSICACIDMETHYLESTERST000047AN0000831.220E-28.350E-2Cognitive Status;AD;CN;MCI
3-(a-Naphthoxy)lactic acidST000422AN0006682.420E-22.680E-1treatment;ND;T1D good glycemic control
3-(a-Naphthoxy)lacticacidST000047AN0000832.790E-21.510E-1Cognitive Status;AD;CN;MCI
3-(a-Naphthoxy)lactic acid glucuronideST000421AN0006652.860E-24.500E-1treatment;ND;T1D poor glycemic control
3-APST001167AN0019291.060E-22.280E-2Time points;0.25h;0h;12h;24h;4h;6days
3-APST001167AN0019293.220E-26.260E-2Cell lines;RWPE1;VCaP
(3-Arylcarbonyl)-alanineST000291AN0004644.050E-31.690E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
(3-Arylcarbonyl)-alanineST000291AN0004653.910E-31.330E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
3-ButynoateST000403AN0006421.050E-117.380E-11Cell type;Mature erythrocyte;Reticulocyte
3-ButynoateST000539AN0008187.200E-72.740E-6Cell type;Mature erythrocyte;Reticulocyte
3-ButynoateST000566AN0008708.460E-41.100E-3Time point;Post;Pre;Baseline
3-ButynoateST001201AN0019988.210E-122.570E-11cell_type;iRBC;unRBC
3-ButynoateST001202AN0020003.650E-138.640E-12treatment_duration_(h);-;1.5;3;6;9
3-ButynoateST001205AN0020062.720E-24.400E-1treatment_duration_(h);1;5;3
3-CMPFP**ST000975AN0015961.910E-21.340E-1GROUP;case;control
3-CMPFP**ST000975AN0015962.750E-22.930E-1REGION;MAK;SUN
3-CMPFP**ST000976AN0015971.350E-23.710E-1GROUP;case;control
3-DechloroethylifosfamideST000444AN0006951.290E-25.210E-2Sample Treatment;Bubbled;Control
3-deoxy-D-galactoseST001201AN0019984.830E-388.580E-37cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001202AN0020012.310E-174.840E-17cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001202AN0020011.430E-43.420E-4treatment_duration_(h);-;1.5;3;6;9
3-deoxy-D-galactoseST001204AN0020051.580E-181.150E-17cell_type;iRBC;unRBC
3-deoxy-D-galactoseST001204AN0020051.800E-48.080E-3treatment_duration_(h);-;3;6;9
3-deoxy-D-galactoseST001205AN0020065.070E-82.310E-5treatment_duration_(h);1;5;3
3-deoxy-D-galactoseST001205AN0020068.310E-41.410E-1treatment;DHA;DMSO;OZ277;OZ439
3-Deoxy-D-manno-octulosonate 8-phosphateST001201AN0019993.960E-272.120E-26cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphateST001202AN0020011.000E-63.880E-6treatment_duration_(h);-;1.5;3;6;9
3-Deoxy-D-manno-octulosonate 8-phosphateST001202AN0020011.350E-21.460E-2cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphateST001204AN0020041.280E-351.240E-33cell_type;iRBC;unRBC
3-Deoxy-D-manno-octulosonate 8-phosphateST001205AN0020078.180E-32.780E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
3-Deoxy-glycero-galacto-2-nonulosonic acid-13C0[+QDA adduct+Na]+ST000142AN0002255.830E-326.130E-31Treatment;13C-Glc;unlabeled
3-dimethylsulfoniopropionaldehydeST000403AN0006437.120E-111.930E-8Glucose labelling;C13 glucose;unlabelled
3-dimethylsulfoniopropionaldehydeST000403AN0006434.350E-37.140E-2timepoint;1 hour;20 hours
3-dimethylsulfoniopropionaldehydeST000539AN0008191.450E-123.880E-10Glucose labelling;C13 glucose;unlabelled
3-dimethylsulfoniopropionaldehydeST000539AN0008192.700E-22.040E-1timepoint;1 hour;20 hours
3-Ethyl-3-methylheptaneST001037AN0016983.560E-31.500E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
3-EthylmalateST001201AN0019988.810E-41.620E-3cell_type;iRBC;unRBC
3-EthylmalateST001205AN0020061.830E-41.490E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
3-ethylphenylsulfateST000974AN0015954.770E-22.100E-1GENDER;F;M
3-ethylphenylsulfateST000975AN0015965.510E-55.860E-4GENDER;F;M
3-HB (3-hydroxybutyric acid)ST000166AN0002593.850E-26.650E-2Group;3M;Control;HF
3-hydroxyacyl group of bacterial toxinST000403AN0006431.260E-28.030E-2Glucose labelling;C13 glucose;unlabelled
3-hydroxyacyl group of bacterial toxinST000403AN0006431.530E-21.920E-1timepoint;1 hour;20 hours
3-hydroxyacyl group of bacterial toxinST000403AN0006431.570E-22.640E-2Cell type;Mature erythrocyte;Reticulocyte
3-hydroxyacyl group of bacterial toxinST000539AN0008191.670E-77.590E-7Cell type;Mature erythrocyte;Reticulocyte
3-hydroxybenzoic acid (likely)ST000420AN0006622.340E-33.820E-3Group;nonsmoker;smoker
3-hydroxybutyroylglycine**ST000975AN0015968.260E-42.560E-2GROUP;case;control
3-hydroxybutyroylglycine**ST000976AN0015973.130E-32.090E-1GROUP;case;control
3-Hydroxyethylbacteriochlorophyllide a-13C0[+Na]+ST000142AN0002252.980E-326.130E-31Treatment;13C-Glc;unlabeled
3-Hydroxyhexdecanedioyl-CoAST000241AN0003739.070E-41.330E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-hydroxykynurenateST001192AN0019852.210E-22.870E-1Diet;-;Omnivore;Vegetarian
3-hydroxyoxyisovaleric acidST000355AN0005803.400E-31.360E-2Stage;1;2;3;4;-
3-hydroxyoxyisovaleric acidST000356AN0005824.060E-71.140E-6Diagnosis;breast cancer;control
3-hydroxyoxyisovaleric acidST000356AN0005821.550E-54.220E-5stage;-;2;3
3-HydroxyphenytoinST000047AN0000831.620E-32.090E-2Cognitive Status;AD;CN;MCI
3-Hydroxytetradecanedioic acidST000444AN0006952.360E-25.210E-2Sample Treatment;Bubbled;Control
3-Indolelactic acidST000589AN0009047.810E-1213.550E-120Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Indolelactic acid/tryptophanST000586AN0009011.420E-62.530E-6Plasma Volume;0 uL;150 uL;700 uL
3-Iodo-4-hydroxyphenylpyruvate-13C0[+QDA adduct+Na]+ST000142AN0002256.910E-326.130E-31Treatment;13C-Glc;unlabeled
3-MethoxyanthranilateST000403AN0006429.590E-62.590E-5Cell type;Mature erythrocyte;Reticulocyte
3-MethoxyanthranilateST000539AN0008181.150E-43.100E-4Cell type;Mature erythrocyte;Reticulocyte
3-methoxycatechol sulfate (2)ST000899AN0014641.040E-22.550E-2Type;Control;Crohn disease;Ulcerative Colitis
3-methoxytyramine sulfateST000974AN0015953.490E-289.040E-27REGION;AHRI;MRC;SUN
3-methoxytyramine sulfateST000975AN0015969.000E-55.210E-3REGION;MAK;SUN
3-methoxytyramine sulfateST000975AN0015962.370E-21.540E-1GROUP;case;control
3-MethyglutarateST001040AN0017034.200E-28.820E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
3-MethyglutarateST001048AN0017173.270E-54.880E-5Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
3-methyl-3-hydroxybutyric acidST000092AN0001461.980E-93.760E-9Gender;N/A;Female;Male
3-methyl-3-hydroxybutyric acidST000092AN0001464.530E-88.470E-8Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
3-methyl-3-hydroxybutyric acidST000092AN0001463.920E-45.590E-4Volume Urine (µL);100;10;25;50;5
3-methyladipate-pimelateST001000AN0018791.660E-82.420E-7Diagnosis;CD;Control;UC
3-methyladipate/pimelateST000923AN0015147.130E-76.840E-6Diagnosis;CD;nonIBD;UC
3-methyladipate/pimelateST001142AN0018762.100E-281.630E-27Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
3-methyladipate/pimelateST001142AN0018764.270E-111.400E-10Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
3-methyl catechol sulfate (1)ST000899AN0014641.130E-33.830E-3Type;Control;Crohn disease;Ulcerative Colitis
3-methyl catechol sulfate (1)ST000974AN0015952.590E-32.740E-2TIMEPOINT;BL;M06;M18
3-methyl catechol sulfate (1)ST000975AN0015961.500E-38.580E-3GENDER;F;M
3-methyl catechol sulfate (1)ST000975AN0015964.800E-23.890E-1REGION;MAK;SUN
3-methyl catechol sulfate (1)ST000976AN0015978.690E-42.400E-1TIMEPOINT;BL;M06
3-methyl catechol sulfate (2)ST000974AN0015952.990E-41.550E-3REGION;AHRI;MRC;SUN
3-methyl catechol sulfate (2)ST000975AN0015965.330E-41.580E-2REGION;MAK;SUN
3-Methylglutaconic acidST000356AN0005831.110E-73.460E-7Diagnosis;breast cancer;control
3-Methylglutaconic acidST000356AN0005832.460E-57.640E-5stage;-;2;3
3-Methylglutarate/AdipateST001317AN0021936.165E-111.368E-10SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-Methylglutarate/AdipateST001317AN0021936.165E-111.368E-10SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-(Methylthio)propanoateST000292AN0004661.610E-22.020E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
3-nitro-2-pentanolST000539AN0008184.330E-26.750E-2Cell type;Mature erythrocyte;Reticulocyte
3-nitro-2-pentanolST001202AN0020009.710E-141.550E-13cell_type;iRBC;unRBC
3-nitro-2-pentanolST001202AN0020001.700E-81.030E-7treatment_duration_(h);-;1.5;3;6;9
3-OH-DL-KYNURENINEST000876AN0014134.390E-23.200E-1L-serine (mg/kg/day);100;200;300;400;50;-
3-O-Methyl-myo-inositolST000566AN0008704.660E-34.450E-2group;Old-Curcumin;Old-Placebo;young
3-O-Methyl-myo-inositolST000566AN0008701.840E-22.020E-2Time point;Post;Pre;Baseline
3-Oxotetradecanoate-13C0[+13CD3 QDA]+ST000148AN0002356.750E-33.650E-2Treatment;13C-Glc;unlabeled
3-Oxotetradecanoate-13C0[+QDA adduct]+ST000148AN0002352.540E-29.830E-2Treatment;13C-Glc;unlabeled
3-phosphoglucarateST001201AN0019991.500E-24.840E-1treatment_duration_(h);-;0.5;1.5;3
3-phosphoglucarateST001202AN0020015.990E-139.350E-13cell_type;iRBC;unRBC
3-phosphoglucarateST001202AN0020015.350E-61.690E-5treatment_duration_(h);-;1.5;3;6;9
3-PhosphonopyruvateST000403AN0006434.440E-124.140E-11Cell type;Mature erythrocyte;Reticulocyte
3-PhosphonopyruvateST000539AN0008191.440E-44.100E-4Cell type;Mature erythrocyte;Reticulocyte
3-PhosphonopyruvateST001201AN0019991.020E-419.100E-41cell_type;iRBC;unRBC
3-PhosphonopyruvateST001202AN0020013.090E-124.540E-12cell_type;iRBC;unRBC
3-PhosphonopyruvateST001202AN0020015.500E-105.420E-9treatment_duration_(h);-;1.5;3;6;9
3-propylphosphoenolpyruvateST001205AN0020061.750E-24.490E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
3-Pyridinebutanoic acidST000356AN0005831.940E-531.110E-51Diagnosis;breast cancer;control
3-Pyridinebutanoic acidST000356AN0005831.920E-301.100E-28stage;-;2;3
3-S-cysteinyl-2-methylpropanoate*ST000974AN0015957.790E-43.600E-3REGION;AHRI;MRC;SUN
3-S-cysteinyl-2-methylpropanoate*ST000974AN0015951.770E-32.240E-2TIMEPOINT;BL;M06;M18
3-S-cysteinyl-2-methylpropanoate*ST000975AN0015962.430E-31.020E-1TIMEPOINT;BL;M06;M18
3-S-cysteinyl-2-methylpropanoate*ST000975AN0015963.230E-21.870E-1GROUP;case;control
(3-sulfo)Galbeta-Cer(d18:0/18:0(2OH))ST000445AN0006962.270E-26.880E-2Treatment;FSH;LH
3-SulfolactateST000403AN0006433.860E-71.280E-6Cell type;Mature erythrocyte;Reticulocyte
3-SulfolactateST000539AN0008191.840E-56.010E-5Cell type;Mature erythrocyte;Reticulocyte
3-sulfopropanoateST000539AN0008194.220E-38.840E-3Cell type;Mature erythrocyte;Reticulocyte
3-ureidoacrylateST001201AN0019996.250E-61.380E-5cell_type;iRBC;unRBC
400671 carbohydrateST000369AN0006033.670E-31.670E-2Gender;F;M;NA
400671 carbohydrateST000369AN0006034.060E-31.500E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
400671 carbohydrateST000369AN0006037.310E-32.700E-2Smoker;Current;Former;NA
400671 carbohydrateST000386AN0006214.030E-43.840E-3Gender;F;M;NA
400671 carbohydrateST000386AN0006215.050E-32.690E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
400671 carbohydrateST000386AN0006219.540E-33.840E-2Smoker;Current;Former;NA
4-(1-methyl-5-hydroxy-2-pyrrolidinyl)-3-oxobutanoate methyl esterST000403AN0006426.450E-35.520E-2Glucose labelling;C13 glucose;unlabelled
4-8dimethylnonanoylcarnitineST000403AN0006428.670E-31.500E-2Cell type;Mature erythrocyte;Reticulocyte
4-8dimethylnonanoylcarnitineST000403AN0006422.870E-21.680E-1Glucose labelling;C13 glucose;unlabelled
4-allylphenol sulfateST000975AN0015969.110E-45.690E-3GENDER;F;M
4Alpha-hydroxymethyl-5alpha-cholesta-8-en-3beta-olST000241AN0003737.190E-81.800E-7Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-Amino-4-deoxychorismateST000403AN0006432.190E-45.100E-4Cell type;Mature erythrocyte;Reticulocyte
4-Amino-4-deoxychorismateST000539AN0008197.990E-31.550E-2Cell type;Mature erythrocyte;Reticulocyte
4-Amino-4-deoxychorismateST001201AN0019991.970E-23.160E-2cell_type;iRBC;unRBC
4-Amino-4-deoxychorismateST001202AN0020011.800E-225.830E-22cell_type;iRBC;unRBC
4-Amino-4-deoxychorismateST001202AN0020012.080E-67.200E-6treatment_duration_(h);-;1.5;3;6;9
4-Amino-4-deoxychorismateST001204AN0020052.350E-76.900E-7cell_type;iRBC;unRBC
4-Amino-4-deoxychorismateST001205AN0020072.570E-25.810E-1treatment_duration_(h);1;5;3
4-Amino-4-deoxychorismateST001205AN0020073.380E-28.690E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
4-amino-4-deoxy-L-arabinoseST001201AN0019989.770E-245.700E-23cell_type;iRBC;unRBC
4-amino-4-deoxy-L-arabinoseST001202AN0020006.470E-118.420E-10treatment_duration_(h);-;1.5;3;6;9
4aminobenzaldehyde1ST000614AN0009418.690E-81.300E-7Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
4aminobenzaldehyde1ST000614AN0009415.580E-49.120E-4Diagonsis;Benign;Cancer;Normal
4-Aminobenzoate / AnthranilateST001040AN0017028.390E-69.900E-5Sample Type/Matrix;Pooled quality control sample;urine;Water...
4-Aminobenzoate / AnthranilateST001048AN0017162.360E-93.460E-9Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
4-Aminobenzoate/AnthranilateST001317AN0021922.367E-22.549E-2SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Aminobenzoate/AnthranilateST001317AN0021922.367E-22.549E-2SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-AMINOBUTANOATE (GABA);2-AMINO-2-METHYLPROPANOATE;3-AMINOISOBUTANOATEST000956AN0015683.600E-105.560E-9Treatment;Condition-1;Condition-2;Condition-3;Control
4-Aminomethylcyclohexane carboxylic acidST001037AN0016982.420E-41.780E-3Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-Aminophenyl 1-thio-beta-D-glucuronideST000422AN0006671.190E-34.380E-2treatment;ND;T1D good glycemic control
4-Aminophenyl1-thio-beta-D-glucuronideST000047AN0000813.510E-35.470E-2Cognitive Status;AD;CN;MCI
4-Aminophenyl 1-thio-beta-D-glucuronide + 2.6188798ST000421AN0006633.120E-22.630E-1treatment;ND;T1D poor glycemic control
4-ethylphenylsulfateST000899AN0014642.330E-24.890E-2Type;Control;Crohn disease;Ulcerative Colitis
4-ethylphenylsulfateST000974AN0015954.380E-47.460E-3TIMEPOINT;BL;M06;M18
4-hydroxy-3-methylacetophenoneST000923AN0015132.670E-41.470E-3Diagnosis;CD;nonIBD;UC
4-hydroxy-3-methylacetophenoneST000923AN0015132.930E-28.360E-2sex;Female;Male
4-hydroxy-3-methylacetophenoneST001000AN0018785.060E-74.130E-6Diagnosis;CD;Control;UC
4-hydroxy-3-methylacetophenoneST001236AN0020543.760E-21.350E-1OS_Censor (1 means the time is a censoring time and 0 means ...
4-hydroxy-3-methylacetophenoneST001237AN0020552.350E-88.010E-7Time point;baseline;week 4;week 8
4-Hydroxy-4-(3-pyridyl)butanoic acidST001317AN0021922.629E-247.362E-24SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-(3-pyridyl)butanoic acidST001317AN0021922.629E-247.362E-24SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-methylglutamateST000403AN0006425.640E-41.160E-3Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxy-4-methylglutamateST000539AN0008187.380E-93.650E-8Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxy-4-methylglutamateST001202AN0020001.500E-182.980E-18cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamateST001202AN0020001.410E-88.620E-8treatment_duration_(h);-;1.5;3;6;9
4-Hydroxy-4-methylglutamateST001204AN0020043.460E-68.970E-6cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamateST001205AN0020076.090E-44.090E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Hydroxy-6-methylpyran-2-oneST000567AN0008721.370E-31.930E-3Time point;Post;Pre;Baseline
4-Hydroxybenzyl cyanideST000421AN0006641.040E-21.730E-1treatment;ND;T1D poor glycemic control
4-HydroxybenzylcyanideST000046AN0000774.890E-22.170E-1Cognitive Status;AD;CN;MCI
4-Hydroxybenzylcyanide+6.609466ST000046AN0000763.280E-21.340E-1Cognitive Status;AD;CN;MCI
4-hydroxychlorothalonilST000899AN0014642.970E-51.920E-4Type;Control;Crohn disease;Ulcerative Colitis
4-Hydroxylevamisole GlucuronideST000566AN0008692.040E-33.820E-3Time point;Post;Pre;Baseline
4-HydroxyphenylacetylglycineST000403AN0006433.040E-24.920E-2Cell type;Mature erythrocyte;Reticulocyte
4-HydroxyphenylacetylglycineST001202AN0020012.120E-311.940E-30cell_type;iRBC;unRBC
4-HydroxyphenylacetylglycineST001202AN0020012.500E-45.510E-4treatment_duration_(h);-;1.5;3;6;9
4-HydroxyphenylacetylglycineST001204AN0020054.870E-41.140E-3cell_type;iRBC;unRBC
4-hydroxypyridineST000420AN0006629.750E-131.020E-11Group;nonsmoker;smoker
4-HydroxypyridineST000046AN0000776.890E-39.840E-2Cognitive Status;AD;CN;MCI
4-HydroxypyridineST000589AN0009041.590E-131.880E-13Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
4-Hydroxypyridine+1.305617ST000046AN0000763.990E-21.530E-1Cognitive Status;AD;CN;MCI
4-Hydroxypyridine+1.305617ST000046AN0000774.540E-22.100E-1Cognitive Status;AD;CN;MCI
4-Hydroxypyridine+4.290232ST000047AN0000818.250E-39.130E-2Cognitive Status;AD;CN;MCI
4-HydroxytacrineST000047AN0000823.010E-21.600E-1Cognitive Status;AD;CN;MCI
4-Imidazolone-5-propanoateST000403AN0006429.030E-141.370E-12Cell type;Mature erythrocyte;Reticulocyte
4-Imidazolone-5-propanoateST000539AN0008182.430E-123.810E-11Cell type;Mature erythrocyte;Reticulocyte
4-Imidazolone-5-propanoateST001202AN0020008.720E-131.330E-12cell_type;iRBC;unRBC
4-Imidazolone-5-propanoateST001202AN0020006.530E-72.350E-6treatment_duration_(h);-;1.5;3;6;9
4-Ketoanhydrochlortetracycline-13C0[+H]+ST000142AN0002252.100E-326.130E-31Treatment;13C-Glc;unlabeled
4-Keto-ATC-13C0[+13CD3 QDA]+ST000142AN0002254.080E-326.130E-31Treatment;13C-Glc;unlabeled
4-keto pentadecanoic acidST000248AN0003924.080E-27.260E-1Cell population;Fast-cycling cells;Slow-cyling cells
4-MaleylacetoacetateST000292AN0004661.680E-22.050E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
4-METHYL-1-PENTENEST001037AN0016988.270E-32.930E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-Methyl-5-thiazoleethanol?ST001211AN0020173.480E-29.980E-2Group;Control;Methotrexate
4-methylcatechol sulfateST000899AN0014641.190E-59.760E-5Type;Control;Crohn disease;Ulcerative Colitis
4-Methylene-L-glutamateST000403AN0006433.370E-58.930E-5Cell type;Mature erythrocyte;Reticulocyte
4-Methylene-L-glutamateST000539AN0008192.700E-24.570E-2Cell type;Mature erythrocyte;Reticulocyte
4-methylhexanoylglutamineST000975AN0015963.080E-23.160E-1REGION;MAK;SUN
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronideST000444AN0006951.940E-25.210E-2Sample Treatment;Bubbled;Control
4-Methylumbelliferylbeta-D-glucuronideST000047AN0000822.500E-33.670E-2Cognitive Status;AD;CN;MCI
4-Methylumbelliferyl ?-D-glucuronideST000566AN0008691.990E-37.970E-3group;Old-Curcumin;Old-Placebo;young
4-Nitroestrone-13C0[+QDA adduct]+ST000148AN0002351.460E-67.450E-4Treatment;13C-Glc;unlabeled
4-Nitrophenyl-3-ketovalidamineST000403AN0006433.260E-101.890E-9Cell type;Mature erythrocyte;Reticulocyte
4-Nitrophenyl-3-ketovalidamineST000539AN0008191.470E-76.740E-7Cell type;Mature erythrocyte;Reticulocyte
4-oxo-4-(3-pyridyl)-butanoateST001205AN0020075.280E-31.960E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Oxocyclohexanecarboxylate-13C0[+QDA adduct]+ST000148AN0002353.020E-21.130E-1Treatment;13C-Glc;unlabeled
4-oxoproline;5-OXO-L-PROLINEST000954AN0015651.260E-21.550E-1race;1;2
4-oxo-Retinoic acidST000241AN0003739.630E-125.570E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-PhosphopantothenoylcysteineST000241AN0003735.210E-102.020E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-PIOLST000539AN0008183.430E-22.110E-1timepoint;1 hour;20 hours
4-Pyrodixic acid / XanthurenateST001048AN0017165.470E-171.170E-16Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007982.450E-42.160E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007987.460E-41.050E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000523AN0007989.070E-44.410E-3Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000725AN0011372.680E-35.560E-1gender;Female;Male
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012973.070E-224.100E-21Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012971.090E-151.060E-14Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+ST000818AN0012971.050E-68.560E-6Country;Ethiopia;Tanzania;Botswana
4-Sulfobenzaldehyde-13C0[+Na]+ST000142AN0002257.600E-326.130E-31Treatment;13C-Glc;unlabeled
4-Sulfobenzyl alcoholST000567AN0008719.560E-32.530E-2groups;Old-Curcumin;Old-Placebo;young
4-tert-OctylphenolST001037AN0016986.700E-57.880E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-(Trimethylammonio)but-2-enoateST001201AN0019981.120E-91.460E-7treatment;DHA;DMSO;OZ277;OZ439
4-(Trimethylammonio)but-2-enoateST001201AN0019986.350E-61.400E-5cell_type;iRBC;unRBC
4-(Trimethylammonio)but-2-enoateST001202AN0020001.200E-61.410E-6cell_type;iRBC;unRBC
4-(Trimethylammonio)but-2-enoateST001202AN0020004.820E-37.080E-3treatment_duration_(h);-;1.5;3;6;9
4-(Trimethylammonio)but-2-enoateST001205AN0020067.230E-32.260E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
5-(3-Pyridyl)-2-hydroxytetrahydrofuranST000567AN0008721.020E-31.190E-2groups;Old-Curcumin;Old-Placebo;young
5-(3-Pyridyl)-2-hydroxytetrahydrofuranST000567AN0008721.290E-21.410E-2Time point;Post;Pre;Baseline
5-6-DihydrouridineST001201AN0019981.220E-123.940E-12cell_type;iRBC;unRBC
5-6-DihydrouridineST001201AN0019988.640E-34.140E-2treatment;DHA;DMSO;OZ277;OZ439
5-6-DihydrouridineST001202AN0020006.290E-131.410E-11treatment_duration_(h);-;1.5;3;6;9
5-6-DihydrouridineST001202AN0020001.510E-71.830E-7cell_type;iRBC;unRBC
5-Acetamidopentanoate 2ST000539AN0008193.570E-47.970E-3Glucose labelling;C13 glucose;unlabelled
5-adenosylhomocysteineST001142AN0018753.890E-24.000E-2Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
5-alpha-Coprostanol or similar oxysterolST000586AN0009013.290E-23.870E-2Plasma Volume;0 uL;150 uL;700 uL
(5-Amino-1H-tetraazol-1-yl)acetic acidST000356AN0005827.490E-133.150E-12Diagnosis;breast cancer;control
(5-Amino-1H-tetraazol-1-yl)acetic acidST000356AN0005827.550E-102.930E-9stage;-;2;3
5-Amino-6-ribitylamino uracilST000356AN0005831.610E-444.580E-43Diagnosis;breast cancer;control
5-Amino-6-ribitylamino uracilST000356AN0005832.910E-266.220E-25stage;-;2;3
5-aminovaleric acid lactameST000420AN0006627.540E-199.490E-17Group;nonsmoker;smoker
5?-Androstan-3?-ol-17-one sulfateST000566AN0008692.100E-201.230E-19Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfateST000566AN0008691.460E-58.030E-5group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfateST000567AN0008717.040E-228.390E-21Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfateST000567AN0008717.010E-55.570E-4groups;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 7.5459185ST000566AN0008691.700E-157.880E-15Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 7.5459185ST000566AN0008691.810E-37.580E-3group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 7.7291727ST000566AN0008692.700E-251.830E-24Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 7.7291727ST000566AN0008692.730E-61.720E-5group;Old-Curcumin;Old-Placebo;young
5?-Androstan-3?-ol-17-one sulfate - 8.185043ST000566AN0008697.010E-316.170E-30Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 8.185043ST000566AN0008691.360E-91.990E-8group;Old-Curcumin;Old-Placebo;young
5b-PregnediolST000241AN0003732.240E-33.130E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
5-Chloro-2-hydroxymuconic semialdehyde-13C0[+Na]+ST000142AN0002251.090E-316.860E-31Treatment;13C-Glc;unlabeled
5-Dehydro-4-deoxy-D-glucarateST000403AN0006431.070E-21.450E-1timepoint;1 hour;20 hours
5-Dehydro-4-deoxy-D-glucarateST000566AN0008691.420E-24.310E-2group;Old-Curcumin;Old-Placebo;young
5-Deoxy-5-aminoshikimic acidST000403AN0006431.550E-163.490E-14Cell type;Mature erythrocyte;Reticulocyte
5-Deoxy-5-aminoshikimic acidST000539AN0008191.020E-42.940E-4Cell type;Mature erythrocyte;Reticulocyte
5-Formiminotetrahydrofolic acidST000566AN0008709.050E-73.060E-6Time point;Post;Pre;Baseline
5-Formiminotetrahydrofolic acidST000566AN0008703.830E-21.300E-1group;Old-Curcumin;Old-Placebo;young
5-guanidino-3-methyl-2-oxo-pentanoateST000403AN0006424.850E-31.060E-1timepoint;1 hour;20 hours
5-guanidino-3-methyl-2-oxo-pentanoateST000403AN0006421.040E-21.780E-2Cell type;Mature erythrocyte;Reticulocyte
5-guanidino-3-methyl-2-oxo-pentanoateST000539AN0008183.400E-36.160E-2timepoint;1 hour;20 hours
5-Guanidino-3-methyl-2-oxopentanoateST000292AN0004661.840E-22.060E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
5-HETrEST000916AN0014919.860E-56.320E-4Diagnosis;Cirrhosis;NASH;Normal;Steatosis
5-HETrEST001214AN0020251.140E-75.890E-7BMI group;lean;obese;overweight
5-?-Hydroxybutyl HydantoinST000567AN0008718.440E-93.020E-8Time point;Post;Pre;Baseline
5-HydroxycotinineST000403AN0006433.550E-36.670E-3Cell type;Mature erythrocyte;Reticulocyte
5-hydroxymethyl-2-furoic acid nistST000420AN0006622.880E-133.630E-12Group;nonsmoker;smoker
5-hydroxymethyl-2-furoylcarnitine*ST000974AN0015953.900E-207.380E-19REGION;AHRI;MRC;SUN
5-hydroxymethyl-2-furoylcarnitine*ST000974AN0015958.990E-36.750E-2GENDER;F;M
5-hydroxynorvaline NISTST000368AN0006027.800E-51.500E-4Organ;Plasma;Serum;Serum or Plasma
5-hydroxynorvaline NISTST000385AN0006201.060E-101.600E-10Organ;Plasma;Serum;Serum or Plasma
5-hydroxynorvaline NISTST000385AN0006202.510E-37.950E-3Health State;Adenocarcinoma;Healthy;NA
5-hydroxynorvaline NISTST000385AN0006208.620E-32.440E-2Smoking Status;Current;Former;NA
5-hydroxynorvaline NISTST000390AN0006263.570E-22.040E-1Diagnosis;adenocarcinoma;adenocarcinoma w/ BAC;adenocarcinom...
5-hydroxynorvaline NISTST000392AN0006289.640E-45.440E-3Disease State;cancer;control;-
5-iPF2a-VIST001214AN0020259.870E-108.960E-9BMI group;lean;obese;overweight
5-Methyl-2-furaldehyde-13C0[+QDA adduct]+ST000142AN0002251.840E-326.130E-31Treatment;13C-Glc;unlabeled
5-methyluridine NISTST001211AN0020168.830E-31.790E-2Group;Control;Methotrexate
5-NonanolST001037AN0016981.720E-25.230E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
5-O-Feruloylquinic acidST000566AN0008695.700E-39.830E-3Time point;Post;Pre;Baseline
5-Taurinomethyl-2-thiouridineST000241AN0003736.310E-123.760E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
5-Ureido-4-imidazole carboxylateST000292AN0004667.700E-131.790E-10Treatment ;Baseline plasma;Plasma after drinking apple juice...
6-(2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL)-1-PHENYL-2-THIOBIUREA-0.88713235ST000046AN0000783.260E-33.160E-2Cognitive Status;AD;CN;MCI
6-Acetamido-2-oxohexanoateST000403AN0006428.680E-51.830E-3Glucose labelling;C13 glucose;unlabelled
6-Acetamido-2-oxohexanoateST000403AN0006422.070E-23.380E-2Cell type;Mature erythrocyte;Reticulocyte
6-Acetamido-2-oxohexanoateST001201AN0019981.130E-42.770E-3treatment;DHA;DMSO;OZ277;OZ439
6-Acetamido-2-oxohexanoateST001204AN0020052.140E-24.160E-2cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST000403AN0006435.010E-81.900E-7Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucoseST000539AN0008195.090E-131.050E-11Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucoseST001202AN0020007.530E-191.540E-18cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001202AN0020002.570E-81.400E-7treatment_duration_(h);-;1.5;3;6;9
6-Acetyl-D-glucoseST001204AN0020041.530E-33.040E-3cell_type;iRBC;unRBC
6-Acetyl-D-glucoseST001204AN0020042.470E-22.530E-1treatment_duration_(h);-;3;6;9
6-Acetyl-D-glucose 2ST000539AN0008195.090E-131.050E-11Cell type;Mature erythrocyte;Reticulocyte
6-Azaequilenin-13C0[+H]+ST000142AN0002257.200E-326.130E-31Treatment;13C-Glc;unlabeled
6beta-hydroxybudesonideST000444AN0006952.480E-25.210E-2Sample Treatment;Bubbled;Control
6-bromotryptophanST000975AN0015961.590E-21.210E-1GROUP;case;control
6-bromotryptophanST000976AN0015974.050E-23.080E-1GENDER;F;M
6C-SUGAR ALCOHOLST000954AN0015642.490E-31.160E-1ethnicity;1;2;-
6-Dehydrotestosterone glucuronideST000355AN0005812.430E-27.300E-2Stage;1;2;3;4;-
6-deoxy-5-ketofructose-1-phosphateST001201AN0019981.860E-156.620E-15cell_type;iRBC;unRBC
6-deoxy-5-ketofructose-1-phosphateST001201AN0019981.700E-25.890E-2treatment;DHA;DMSO;OZ277;OZ439
6-deoxy-5-ketofructose-1-phosphateST001205AN0020063.900E-28.240E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
6-deoxyglucitol NISTST000369AN0006031.760E-39.370E-3Smoker;Current;Former;NA
6-deoxyglucitol NISTST000369AN0006035.020E-31.810E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
6-deoxyglucitol NISTST000369AN0006033.790E-29.390E-2Gender;F;M;NA
6-deoxyglucitol NISTST000386AN0006213.660E-21.210E-1Gender;F;M;NA
6-DeoxyhexoseST000586AN0009016.940E-333.420E-32Plasma Volume;0 uL;150 uL;700 uL
6-DeoxyhexoseST000589AN0009043.150E-808.530E-80Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
6-deoxy-mannoseST000355AN0005803.100E-28.090E-2Stage;1;2;3;4;-
6-diazo-5-oxonorleucineST001202AN0020001.430E-193.200E-19cell_type;iRBC;unRBC
6-diazo-5-oxonorleucineST001202AN0020002.130E-33.250E-3treatment_duration_(h);-;1.5;3;6;9
6-Hydroxy flavin adenine dinucleotideST000241AN0003736.150E-65.140E-5Concentration (uM);0;500
6-Hydroxy flavin adenine dinucleotideST000241AN0003731.380E-21.700E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
6-Hydroxykynurenate-13C0[+Na]+ST000142AN0002252.680E-326.130E-31Treatment;13C-Glc;unlabeled
6-oxopiperidine-2-carboxylic acidST000974AN0015951.890E-32.280E-2TIMEPOINT;BL;M06;M18
6-oxopiperidine-2-carboxylic acidST000975AN0015963.330E-23.990E-1TIMEPOINT;BL;M06;M18
6-oxopiperidine-2-carboxylic acidST000975AN0015963.800E-23.590E-1REGION;MAK;SUN
[6]-ParadolST001201AN0019993.000E-24.640E-2cell_type;iRBC;unRBC
[6]-ParadolST001202AN0020013.620E-94.780E-9cell_type;iRBC;unRBC
[6]-ParadolST001202AN0020015.060E-38.520E-3treatment_duration_(h);-;1.5;3;6;9
[6]-ParadolST001205AN0020071.640E-53.980E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
[6]-Shogaol-13C0[+H]+ST000148AN0002351.370E-31.450E-2Treatment;13C-Glc;unlabeled
715929 carbohydrateST000369AN0006036.670E-42.050E-3Organ;Plasma;Serum
715929 carbohydrateST000386AN0006218.300E-42.550E-3Organ;Plasma;Serum
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATEST000009AN0000244.230E-28.560E-2SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATEST000011AN0000283.150E-22.020E-1ETHNICITY_ASSIGNED;AMHARA;ARGOBBA;MURSI;SABUE;WEYTO;HADZABE;...
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000105AN0001741.150E-21.690E-1Gender;Female;Male
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000105AN0001741.790E-24.190E-1OSA;Negative;Positive
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)ST000106AN0001763.550E-21.990E-1Sampling time;0 min;60 min
7b-HydroxydehydroepiandrosteroneST000356AN0005834.100E-71.250E-6Diagnosis;breast cancer;control
7b-HydroxydehydroepiandrosteroneST000356AN0005831.060E-32.590E-3stage;-;2;3
7-DEACETOXY-7-OXOKHIVORINST000047AN0000803.540E-22.350E-1Cognitive Status;AD;CN;MCI
7-DeoxyadriamycinoneST000422AN0006681.670E-37.360E-2treatment;ND;T1D good glycemic control
7-DeoxyloganetinST000291AN0004641.200E-23.760E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
7-Hexadecenoic acid methyl esterST001000AN0018812.870E-28.680E-2Diagnosis;CD;Control;UC
7?-Hydroxy-3-oxo-4-cholestenoateST000567AN0008726.540E-74.050E-6Time point;Post;Pre;Baseline
7-Hydroxyfluphenazine glucuronideST000422AN0006681.580E-22.020E-1treatment;ND;T1D good glycemic control
7-HydroxyprochlorperazineglucuronideST000045AN0000732.450E-21.120E-1Treatment;Insulin Withdrawal;Saline Infusion
7-hydroxyTetranorIloprostST000046AN0000791.780E-29.010E-2Cognitive Status;AD;CN;MCI
7-hydroxyTetranorIloprostST000047AN0000833.810E-33.830E-2Cognitive Status;AD;CN;MCI
7-Methylhypoxanthine-13C0[+Na]+ST000142AN0002254.060E-326.130E-31Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C2[+Na]+ST000142AN0002253.280E-326.130E-31Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C4[+Na]+ST000142AN0002257.430E-326.130E-31Treatment;13C-Glc;unlabeled
(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinateST000291AN0004641.170E-66.990E-4Treatment ;Baseline urine;Urine after drinking apple juice;U...
8-Amino-7-oxononanoateST000046AN0000763.660E-33.960E-2Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST000047AN0000806.930E-31.370E-1Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST000047AN0000819.230E-39.580E-2Cognitive Status;AD;CN;MCI
8-Amino-7-oxononanoateST001201AN0019981.160E-24.700E-2treatment;DHA;DMSO;OZ277;OZ439
8-Amino-7-oxononanoateST001201AN0019984.280E-26.080E-2cell_type;iRBC;unRBC
8-Amino-7-oxononanoateST001202AN0020002.410E-195.260E-19cell_type;iRBC;unRBC
8-Amino-7-oxononanoateST001202AN0020002.130E-66.100E-6treatment_duration_(h);-;1.5;3;6;9
8-Amino-7-oxononanoateST001205AN0020067.190E-79.120E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
8-Amino-7-oxononanoate+4.7958198ST000047AN0000803.040E-22.150E-1Cognitive Status;AD;CN;MCI
8-HETrEST000916AN0014911.500E-24.110E-2Diagnosis;Cirrhosis;NASH;Normal;Steatosis
8-HETrEST001214AN0020251.820E-65.830E-6BMI group;lean;obese;overweight
8-hydroxymianseringlucuronideST000047AN0000822.420E-21.480E-1Cognitive Status;AD;CN;MCI
8-HydroxypromazineST000046AN0000772.480E-21.620E-1Cognitive Status;AD;CN;MCI
8-iso-15-keto-PGE2ST000241AN0003731.530E-131.480E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
8-keto-7-aminoperlagonateST000403AN0006433.650E-33.590E-2Glucose labelling;C13 glucose;unlabelled
8R-hydroxy-9Z-octadecenoic acidST000421AN0006661.260E-22.190E-1treatment;ND;T1D poor glycemic control
9-myristoleateST001322AN0021988.071E-43.127E-3treatment;expecting 2 month - human breast milk;expecting 2 ...
9-myristoleateST001322AN0021981.094E-28.480E-2group;OB;NW
Abscisic acid GLC ester-13C0[+Na]+ST000148AN0002355.820E-33.310E-2Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+QDA adduct]+ST000142AN0002255.900E-326.130E-31Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C16[+Na]+ST000148AN0002356.410E-33.520E-2Treatment;13C-Glc;unlabeled
Abscisic acid glucose esterST000403AN0006432.580E-34.940E-3Cell type;Mature erythrocyte;Reticulocyte
Abscisic acid glucose esterST000403AN0006438.620E-31.230E-1timepoint;1 hour;20 hours
Abscisic acid glucose esterST000403AN0006433.810E-21.720E-1Glucose labelling;C13 glucose;unlabelled
AC1MIY4GST000770AN0012173.410E-21.660E-1Timepoint;T0;T55
AC1MIY4GST000842AN0013605.020E-85.220E-8Sample type;Muscles;Plasma;Pooled sample
AC1MIY4GST000842AN0013611.870E-295.350E-29Sample type;Muscles;Plasma;Pooled sample
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007982.220E-41.310E-3Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007983.490E-46.160E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000523AN0007981.010E-35.910E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000713AN0011142.910E-75.500E-6malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000713AN0011148.160E-41.040E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
ACETAMINOPHEN (TN TYLENOL) (M+H)+ST000763AN0012024.600E-32.350E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007991.920E-82.090E-7Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007992.590E-75.180E-6Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000523AN0007993.330E-74.990E-6Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000713AN0011131.660E-97.930E-8malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000713AN0011132.400E-31.810E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000721AN0011281.570E-24.850E-1GOSE;4;5;6;7;8;NA
ACETAMINOPHEN (TN TYLENOL) (M-H)-ST000763AN0012011.410E-25.720E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007981.380E-48.810E-4Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007983.040E-46.130E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000523AN0007989.000E-45.520E-3Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000818AN0012971.960E-38.470E-3Country;Ethiopia;Tanzania;Botswana
ACETAMINOPHEN (TN TYLENOL) (M+Na)+ST000818AN0012973.340E-26.130E-2Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000713AN0011146.100E-69.600E-5malignant transformation;No;yes;Yes
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000713AN0011148.230E-41.040E-2level of dysplasia;HGD;HGD & PDA;LGD;N/A
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000742AN0011584.760E-28.080E-2Species;Homo sapiens;Mus musculus;-
ACETAMINOPHEN (TN TYLENOL) (M+NA)+ST000763AN0012028.610E-33.560E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
AcetominophenST000913AN0014831.360E-23.310E-1Diagnosis;MECFS;MS;ND
AcetominophenST000913AN0014832.550E-24.280E-1Sex;FEMALE;MALE
acetophenone NISTST000368AN0006021.200E-31.880E-3Organ;Plasma;Serum;Serum or Plasma
acetophenone NISTST000369AN0006039.910E-33.520E-2Gender;F;M;NA
acetophenone NISTST000381AN0006151.660E-24.550E-2Cohort;CSMC;INHA
acetophenone NISTST000385AN0006204.190E-211.030E-20Organ;Plasma;Serum;Serum or Plasma
acetophenone NISTST000385AN0006201.910E-62.230E-5Health State;Adenocarcinoma;Healthy;NA
acetophenone NISTST000385AN0006203.190E-65.400E-5Smoking Status;Current;Former;NA
acetophenone NISTST000385AN0006203.230E-64.920E-5Gender;F;M;NA
acetophenone NISTST000386AN0006211.780E-26.200E-2Smoker;Current;Former;NA
acetyl-galactosamineST001236AN0020543.910E-22.310E-1Nivolumab Dose (mg/kg);0.3;10;2
acetyl-galactosamineST001237AN0020552.020E-181.480E-17CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
acetyl-galactosamineST001237AN0020554.080E-82.980E-7OS_Censor (1 means the time is a censoring time and 0 means ...
Acetylneuraminic acidST001039AN0017131.180E-34.070E-3Sample.Matrix;Plasma;Urine
AcetylpseudotropineST001202AN0020006.310E-151.050E-14cell_type;iRBC;unRBC
AcetylpseudotropineST001202AN0020001.080E-31.710E-3treatment_duration_(h);-;1.5;3;6;9
AcetyphenylalanineST001039AN0017129.670E-44.130E-3Sample.Matrix;Plasma;Urine
acetytyrosineST000923AN0015153.560E-27.040E-2Diagnosis;CD;nonIBD;UC
acetytyrosineST001000AN0018802.910E-24.820E-2Diagnosis;CD;Control;UC
acetytyrosineST001192AN0019861.920E-34.260E-2Diet;-;Omnivore;Vegetarian
acisogaST000899AN0014643.410E-52.170E-4Type;Control;Crohn disease;Ulcerative Colitis
acisogaST000975AN0015961.420E-48.210E-3GROUP;case;control
acisogaST000975AN0015961.600E-26.040E-2GENDER;F;M
AcitretinST000444AN0006951.720E-25.210E-2Sample Treatment;Bubbled;Control
Ac-Tyr-OEtST000403AN0006421.110E-52.990E-5Cell type;Mature erythrocyte;Reticulocyte
Ac-Tyr-OEtST000539AN0008181.990E-21.600E-1timepoint;1 hour;20 hours
a Cysteine adductST000403AN0006422.630E-34.970E-3Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adductST000539AN0008181.010E-32.380E-3Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adductST001202AN0020004.380E-59.350E-5treatment_duration_(h);-;1.5;3;6;9
a Cysteine adductST001204AN0020051.310E-221.410E-21cell_type;iRBC;unRBC
a Cysteine adduct 2ST000539AN0008181.010E-32.380E-3Cell type;Mature erythrocyte;Reticulocyte
Adenosine 35-diphosphateST001091AN0017773.740E-67.180E-6Sample.Matrix;Colon Mucosal Tissue;Plasma
Adenosine 35-diphosphateST001193AN0019891.550E-42.860E-4Plasma;Cord blood;Plasma
Adenosylcobimide-GDPST000241AN0003733.240E-55.790E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
ADMA / ArgST000544AN0008266.110E-156.930E-14Sample Type;Control;Replicate
ADMA / ArgST000545AN0008292.590E-33.560E-2Sample Type;Control;Replicate
ADMA/SDMAST000923AN0015139.040E-61.450E-4Diagnosis;CD;nonIBD;UC
ADMA/SDMAST001000AN0018781.100E-34.170E-3Diagnosis;CD;Control;UC
Adrenaline(Epinephrine)ST001040AN0017022.240E-75.670E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
ADSGEGDFXAEGGGVR*ST000974AN0015951.720E-37.270E-3REGION;AHRI;MRC;SUN
AFN911ST000444AN0006953.360E-25.280E-2Sample Treatment;Bubbled;Control
A-KetoglutaricacidoximeST000403AN0006432.470E-45.660E-4Cell type;Mature erythrocyte;Reticulocyte
A-KetoglutaricacidoximeST000539AN0008194.150E-113.830E-10Cell type;Mature erythrocyte;Reticulocyte
A-KetoglutaricacidoximeST001201AN0019994.400E-51.180E-3treatment;DHA;DMSO;OZ277;OZ439
A-KetoglutaricacidoximeST001201AN0019994.870E-38.810E-3cell_type;iRBC;unRBC
A-KetoglutaricacidoximeST001201AN0019991.790E-24.950E-1treatment_duration_(h);-;0.5;1.5;3
Ala-Ala-Ala-SerST001202AN0020002.710E-322.060E-31cell_type;iRBC;unRBC
Ala-Ala-Ala-SerST001202AN0020007.700E-31.070E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Ala-Ala-SerST001204AN0020045.740E-132.630E-12cell_type;iRBC;unRBC
Ala-Ala-Ala-SerST001205AN0020064.320E-29.990E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Ala-Asp-TyrST001201AN0019994.300E-475.320E-46cell_type;iRBC;unRBC
Ala-Asn-Asn-SerST001201AN0019981.020E-24.530E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asn-Gln-GlnST001204AN0020054.090E-193.250E-18cell_type;iRBC;unRBC
Ala-Asp-Asp-AspST001201AN0019984.170E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Asp-AspST001201AN0019982.790E-24.070E-2cell_type;iRBC;unRBC
Ala-Asp-Asp-CysST001201AN0019981.110E-21.750E-2cell_type;iRBC;unRBC
Ala-Asp-Asp-CysST001202AN0020006.480E-314.150E-30cell_type;iRBC;unRBC
Ala-Asp-Asp-CysST001202AN0020001.470E-21.930E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Asp-GlnST000403AN0006421.850E-87.370E-8Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Asp-GlnST000539AN0008181.810E-99.710E-9Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Asp-HisST001201AN0019981.450E-31.460E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Asp-HisST001201AN0019982.190E-33.850E-3cell_type;iRBC;unRBC
Ala-Asp-Cys-GlyST000539AN0008185.680E-63.650E-4timepoint;1 hour;20 hours
Ala-Asp-Cys-SerST000403AN0006426.390E-152.510E-13Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Cys-SerST000539AN0008189.050E-167.530E-14Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Cys-SerST001201AN0019986.320E-243.740E-23cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001201AN0019984.550E-21.360E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Cys-SerST001202AN0020005.710E-387.430E-37cell_type;iRBC;unRBC
Ala-Asp-Cys-SerST001202AN0020004.930E-25.930E-2treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Cys-SerST001204AN0020041.720E-95.830E-9cell_type;iRBC;unRBC
Ala-Asp-Gly-ArgST001201AN0019982.320E-199.340E-19cell_type;iRBC;unRBC
Ala-Asp-Gly-ArgST001201AN0019981.490E-25.670E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Asp-Gly-TyrST001202AN0020003.130E-251.150E-24cell_type;iRBC;unRBC
Ala-Asp-Gly-TyrST001202AN0020002.150E-54.990E-5treatment_duration_(h);-;1.5;3;6;9
Ala-Asp-Pro-SerST000403AN0006426.650E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Pro-SerST000539AN0008181.070E-32.510E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Cys-Pro-SerST001201AN0019991.360E-27.050E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Cys-Pro-SerST001202AN0020014.120E-199.950E-19cell_type;iRBC;unRBC
Ala-Cys-Pro-SerST001204AN0020052.030E-51.100E-3treatment_duration_(h);-;3;6;9
Ala-Cys-Pro-SerST001204AN0020051.640E-33.790E-3cell_type;iRBC;unRBC
Ala-Cys-Pro-SerST001205AN0020071.290E-24.050E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Glu-Glu-HisST001201AN0019981.660E-332.410E-32cell_type;iRBC;unRBC
Ala-Glu-Glu-HisST001201AN0019982.310E-27.580E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Glu-Glu-HisST001204AN0020041.690E-95.770E-9cell_type;iRBC;unRBC
Ala-Glu-Glu-HisST001204AN0020041.000E-21.720E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Glu-Glu-HisST001205AN0020061.030E-41.120E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Leu-Asn-ProST001201AN0019988.510E-297.080E-28cell_type;iRBC;unRBC
Ala-Leu-Asn-ProST001201AN0019983.900E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Lys-AspST001201AN0019981.070E-21.700E-2cell_type;iRBC;unRBC
Ala-Leu-Lys-AspST001202AN0020001.050E-254.040E-25cell_type;iRBC;unRBC
Ala-Leu-Lys-AspST001202AN0020002.040E-54.770E-5treatment_duration_(h);-;1.5;3;6;9
Ala-Leu-Lys-ProST000403AN0006421.580E-111.070E-10Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Lys-ProST000539AN0008188.160E-62.680E-5Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Lys-ProST001205AN0020064.270E-31.510E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Leu-Thr-AlaST001201AN0019985.640E-33.110E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Thr-AlaST001202AN0020008.570E-263.350E-25cell_type;iRBC;unRBC
Ala-Leu-Thr-AlaST001202AN0020005.480E-51.150E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Leu-Thr-ProST000403AN0006423.070E-35.730E-3Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Thr-ProST000403AN0006422.700E-21.620E-1Glucose labelling;C13 glucose;unlabelled
Ala-Leu-Thr-ProST000539AN0008183.910E-26.190E-2Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Trp-SerST001201AN0019983.340E-201.430E-19cell_type;iRBC;unRBC
Ala-Leu-Trp-SerST001201AN0019984.090E-32.430E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001201AN0019983.270E-25.330E-1treatment_duration_(h);-;0.5;1.5;3
Ala-Leu-Trp-SerST001204AN0020044.910E-81.490E-7cell_type;iRBC;unRBC
Ala-Leu-Trp-SerST001204AN0020041.080E-21.750E-1treatment;DHA;DMSO;OZ277;OZ439
Ala-Leu-Trp-SerST001204AN0020041.300E-21.810E-1treatment_duration_(h);-;3;6;9
Ala-Lys-Ala-AlaST001201AN0019996.090E-242.760E-23cell_type;iRBC;unRBC
Ala-Lys-Ala-AlaST001201AN0019993.880E-32.710E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Lys-Asn-HisST000403AN0006425.150E-123.900E-11Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Asn-HisST000539AN0008187.940E-116.390E-10Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Asp-GlyST001201AN0019984.530E-408.430E-39cell_type;iRBC;unRBC
Ala-Lys-Asp-ProST001204AN0020041.420E-94.920E-9cell_type;iRBC;unRBC
Ala-Lys-Asp-ProST001204AN0020045.050E-43.360E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Lys-Lys-AspST001204AN0020049.370E-92.960E-8cell_type;iRBC;unRBC
Ala-Lys-Lys-AspST001204AN0020048.700E-44.230E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Met-Asp-TyrST001202AN0020011.860E-321.980E-31cell_type;iRBC;unRBC
Ala-Met-Asp-TyrST001202AN0020016.660E-41.360E-3treatment_duration_(h);-;1.5;3;6;9
Ala-Met-Pro-TyrST000403AN0006426.500E-136.730E-12Cell type;Mature erythrocyte;Reticulocyte
Ala-Met-Pro-TyrST000539AN0008187.510E-128.390E-11Cell type;Mature erythrocyte;Reticulocyte
Alanine / D-AlanineST001048AN0017161.750E-308.180E-30Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
ALANINE/SARCOSINEST000475AN0007395.190E-61.780E-5Treatment;-;MDH inhib
ALANINE/SARCOSINEST000956AN0015681.550E-56.340E-5Treatment;Condition-1;Condition-2;Condition-3;Control
Ala-Phe-Arg-HisST001204AN0020047.830E-261.690E-24cell_type;iRBC;unRBC
Ala-Phe-Tyr-TyrST001201AN0019996.290E-121.840E-11cell_type;iRBC;unRBC
Ala-Phe-Tyr-TyrST001204AN0020054.420E-121.860E-11cell_type;iRBC;unRBC
Ala-Thr-Ala-AspST001202AN0020007.080E-221.800E-21cell_type;iRBC;unRBC
Ala-Thr-Ala-AspST001202AN0020002.260E-44.220E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Thr-Ala-GlyST001201AN0019992.520E-32.130E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Thr-Ala-GlyST001201AN0019991.990E-23.180E-2cell_type;iRBC;unRBC
Ala-Thr-Ala-GlyST001205AN0020067.240E-59.780E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Thr-Ala-SerST001201AN0019981.470E-25.630E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Thr-Ala-SerST001202AN0020005.630E-282.770E-27cell_type;iRBC;unRBC
Ala-Thr-Ala-SerST001202AN0020005.100E-51.080E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Thr-Ala-SerST001205AN0020063.240E-55.410E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Ala-Trp-Gly-GlyST001202AN0020006.160E-139.480E-13cell_type;iRBC;unRBC
Ala-Trp-Gly-GlyST001202AN0020003.980E-47.040E-4treatment_duration_(h);-;1.5;3;6;9
Ala-Val-Asp-SerST001201AN0019981.720E-25.890E-2treatment;DHA;DMSO;OZ277;OZ439
Ala-Val-Asp-SerST001202AN0020006.450E-242.030E-23cell_type;iRBC;unRBC
Ala-Val-Asp-SerST001202AN0020007.590E-51.540E-4treatment_duration_(h);-;1.5;3;6;9
Albendazole sulfoneST001204AN0020055.040E-193.890E-18cell_type;iRBC;unRBC
Albendazole sulfoneST001204AN0020058.950E-31.210E-1treatment_duration_(h);-;3;6;9
ALDO/KETO-HEXOSEST000475AN0007392.150E-33.600E-3Treatment;-;MDH inhib
ALDO/KETO-HEXOSEST000956AN0015681.190E-22.210E-2Treatment;Condition-1;Condition-2;Condition-3;Control
AldopentosesST000586AN0009011.750E-297.450E-29Plasma Volume;0 uL;150 uL;700 uL
AldopentosesST000589AN0009042.110E-363.340E-36Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Alisol A-13C0[+13CD3 QDA]+ST000142AN0002259.600E-326.300E-31Treatment;13C-Glc;unlabeled
Allopregnanalone sulfateST000566AN0008695.090E-381.120E-36Time point;Post;Pre;Baseline
Allopregnanalone sulfateST000566AN0008693.980E-83.500E-7group;Old-Curcumin;Old-Placebo;young
AllotetrahydrocortisolST000421AN0006654.870E-24.500E-1treatment;ND;T1D poor glycemic control
Allothreonine/L-ThreonineST001317AN0021921.776E-411.658E-40SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Allothreonine/L-ThreonineST001317AN0021921.776E-411.658E-40SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
alloxanoic acidST000608AN0009317.420E-333.190E-32Sample_Type;blotter;serum
alloxanoic acid NISTST000392AN0006282.630E-162.590E-15Organ;Plasma;Serum;Serum or Plasma
alloxanoic acid NISTST000392AN0006288.830E-52.740E-3Gender;F;M;-
alloxanoic acid NISTST000392AN0006281.370E-43.620E-3Smoking Status;Current;Former;-
alloxanoic acid NISTST000392AN0006281.380E-41.360E-3Disease State;cancer;control;-
Aloinoside A-13C0[+13CD3 QDA]+ST000142AN0002256.210E-326.130E-31Treatment;13C-Glc;unlabeled
Alpha-acetyllysineST001039AN0017126.560E-43.900E-3Sample.Matrix;Plasma;Urine
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000919AN0015066.090E-34.240E-2Gender;Female;Male
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000954AN0015641.080E-21.560E-1race;1;2
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000954AN0015644.450E-24.160E-1ethnicity;1;2;-
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATEST000957AN0015702.940E-21.960E-1Milk fraction;fat;skim;whole
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE;L-2-Aminoadipic AcidST000956AN0015686.230E-73.090E-6Treatment;Condition-1;Condition-2;Condition-3;Control
alpha-Amylcinnamaldehyde-13C0[+QDA adduct]+ST000148AN0002356.010E-33.370E-2Treatment;13C-Glc;unlabeled
alpha-(Methylenecyclopropyl)glycineST000403AN0006431.470E-29.150E-2Glucose labelling;C13 glucose;unlabelled
alpha-MethylstyreneST000403AN0006423.800E-24.040E-1timepoint;1 hour;20 hours
alpha-MethylstyreneST000403AN0006424.350E-26.580E-2Cell type;Mature erythrocyte;Reticulocyte
Aminocaproate/AdenineST001317AN0021921.375E-162.800E-16SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Aminocaproate/AdenineST001317AN0021921.375E-162.800E-16SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
AminoDHS-13C0[+H]+ST000142AN0002259.200E-326.150E-31Treatment;13C-Glc;unlabeled
Aminodipic AcidST000876AN0014138.870E-31.000E-1L-serine (mg/kg/day);100;200;300;400;50;-
Aminofructose 6-phosphate/Glucosamine 6-phosphate-13C3[-H+]-ST000367AN0006013.030E-29.720E-2Tissue type;nontumor;tumor
AMINOHYDROXYBENZOIC ACIDST000016AN0000332.240E-23.290E-2Material;Cells;Media
AMINOHYDROXYBUTANOIC ACIDST000016AN0000332.720E-212.470E-20Material;Cells;Media
AMINOHYDROXYBUTANOIC ACIDST000016AN0000333.110E-41.260E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
AMINOHYDROXYBUTANOIC ACIDST000016AN0000333.740E-31.520E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
AMINOHYDROXYBUTANOIC ACIDST000041AN0000633.160E-27.450E-1Visit;1;2;3;4;5;6;7
AMINOHYDROXYBUTANOIC ACIDST000044AN0000683.960E-21.980E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOHYDROXYBUTANOIC ACIDST000044AN0000692.110E-28.660E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOHYDROXYBUTANOIC ACIDST000105AN0001734.980E-25.620E-1CPAP;No CPAP;After CPAP
AMINOHYDROXYBUTANOIC ACIDST000106AN0001753.410E-22.620E-1Sampling time;0 min;60 min
AMINOHYDROXYBUTANOIC ACIDST000106AN0001761.840E-21.410E-1Sampling time;0 min;60 min
aminoisobutyric acid/GABAST000923AN0015132.290E-41.310E-3Diagnosis;CD;nonIBD;UC
aminoisobutyric acid/GABAST000923AN0015133.010E-32.130E-2sex;Female;Male
Aminomuconic acid semialdehyde-13C0[+Na]+ST000142AN0002251.060E-316.700E-31Treatment;13C-Glc;unlabeled
AMINOPENTANOIC ACIDST000044AN0000692.560E-32.080E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
AMINOPENTANOIC ACIDST000105AN0001742.210E-24.190E-1OSA;Negative;Positive
AMINOPENTANOIC ACIDST000106AN0001763.120E-21.880E-1Sampling time;0 min;60 min
Aminophosphovaleric acidST000614AN0009431.460E-41.900E-4Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Aminophosphovaleric acidST000614AN0009431.870E-32.920E-3Diagonsis;Benign;Cancer;Normal
AmmoniaST000435AN0006855.840E-42.790E-3treatment;ND;T1D good glycemic control;T1D poor glycemic con...
Anaferine-13C0[+13CD3 QDA]+ST000148AN0002354.860E-32.940E-2Treatment;13C-Glc;unlabeled
ANGOLENSIN (R)ST000421AN0006648.540E-31.730E-1treatment;ND;T1D poor glycemic control
ANHYDROBRAZILICACIDST000046AN0000784.840E-21.600E-1Cognitive Status;AD;CN;MCI
Aniline-2-SulfonateST001048AN0017161.130E-326.240E-32Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Antheridiogen-AnST001204AN0020046.890E-71.860E-6cell_type;iRBC;unRBC
Anthranilate / 4-AminobenzoateST001040AN0017032.920E-41.400E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
Anthranilate/4-AminobenzoateST001317AN0021936.526E-233.959E-22SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Anthranilate/4-AminobenzoateST001317AN0021936.526E-233.959E-22SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
aOHglutarate-13C0ST001049AN0018642.580E-21.160E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
aOHglutarate-13C1ST001049AN0018643.790E-21.430E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
aOHglutarate-13C4ST001049AN0018643.170E-21.310E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
ApionicacidST000046AN0000792.520E-21.110E-1Cognitive Status;AD;CN;MCI
Aquayamycin-13C0[+13CD3 QDA]+ST000142AN0002252.660E-326.130E-31Treatment;13C-Glc;unlabeled
arachidiic acidST000416AN0006588.170E-55.520E-4Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
arachidiic acidST000416AN0006583.710E-21.430E-1Gender;Female;Male
arachidiic acidST000417AN0014482.230E-35.260E-3Group;AIR;NO2PM;PM
ARACHIDONATE #2 (M-H)-ST000818AN0012961.820E-54.940E-5Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ARACHIDONATE #2 (M-H)-ST000818AN0012963.950E-51.140E-4Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ARACHIDONATE #2 (M-H)-ST000818AN0012961.220E-33.860E-3Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ARACHIDONATE #2 (M-H)-ST000818AN0012962.880E-29.120E-2Sex;F;M;nan
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000105AN0001742.070E-89.870E-7Sampling;After SWS onset;Morning fasting
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000106AN0001769.850E-38.650E-2Sampling time;0 min;60 min
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)ST000105AN0001743.270E-65.680E-5Sampling;After SWS onset;Morning fasting
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)ST000106AN0001761.410E-31.840E-2Sampling time;0 min;60 min
Arachidonoyl PAF C-16ST000553AN0008467.090E-91.340E-8Sample type;Plasma;Urine
ArachidonoylPAF-C16ST000553AN0008453.110E-85.090E-8Sample type;Plasma;Urine
Arachidonyl lysolecithinST000422AN0006673.640E-25.290E-1treatment;ND;T1D good glycemic control
Arachidonyl lysolecithin + 10.70548ST000421AN0006653.160E-24.500E-1treatment;ND;T1D poor glycemic control
Arg/(Arg+Orn)ST000544AN0008268.220E-32.790E-2Sample Type;Control;Replicate
Arg-Asn-Pro-HisST000403AN0006426.410E-124.720E-11Cell type;Mature erythrocyte;Reticulocyte
Arg-Asn-Pro-HisST000539AN0008187.740E-93.800E-8Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-GlyST000403AN0006424.660E-148.870E-13Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-GlyST000539AN0008187.570E-104.760E-9Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-GlyST001201AN0019986.120E-31.020E-2cell_type;iRBC;unRBC
Arg-Asp-Asp-GlyST001202AN0020001.140E-121.730E-12cell_type;iRBC;unRBC
Arg-Asp-Asp-GlyST001202AN0020008.010E-51.610E-4treatment_duration_(h);-;1.5;3;6;9
Arg-Asp-Asp-GlyST001204AN0020048.910E-197.530E-18cell_type;iRBC;unRBC
Arg-Asp-Asp-GlyST001205AN0020062.160E-25.290E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Arg-Cys-Gln-TyrST000539AN0008195.430E-31.110E-2Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Asn-AspST000403AN0006421.640E-43.650E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Asn-AspST000539AN0008181.560E-44.090E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Val-AsnST000403AN0006439.310E-166.290E-14Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Val-AsnST000539AN0008198.810E-204.720E-17Cell type;Mature erythrocyte;Reticulocyte
Arg-Lys-Asp-AspST001204AN0020052.760E-22.760E-1treatment_duration_(h);-;3;6;9
Arg-Met-Asn-HisST000403AN0006429.720E-52.280E-4Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-HisST000539AN0008182.800E-24.630E-2Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-HisST000539AN0008183.400E-24.110E-1Glucose labelling;C13 glucose;unlabelled
Arg-Met-Val-AspST000403AN0006422.610E-57.330E-4Glucose labelling;C13 glucose;unlabelled
Arg-Phe-Phe-ArgST001201AN0019992.250E-291.290E-28cell_type;iRBC;unRBC
Arg-Phe-Phe-ArgST001201AN0019991.290E-26.940E-2treatment;DHA;DMSO;OZ277;OZ439
Arg-Phe-Phe-ArgST001202AN0020016.640E-98.720E-9cell_type;iRBC;unRBC
Arg-Phe-Phe-ArgST001202AN0020011.030E-31.960E-3treatment_duration_(h);-;1.5;3;6;9
Arg-Trp-Asp-CysST001204AN0020057.570E-75.110E-5treatment_duration_(h);-;3;6;9
ArsenobetaineST001202AN0020001.750E-41.960E-4cell_type;iRBC;unRBC
ArsenobetaineST001202AN0020005.080E-48.780E-4treatment_duration_(h);-;1.5;3;6;9
Ascorbate 2-sulfateST000567AN0008717.270E-43.540E-3groups;Old-Curcumin;Old-Placebo;young
Asn-Asn-Gly-HisST001201AN0019994.500E-46.300E-3treatment;DHA;DMSO;OZ277;OZ439
Asn-Asn-Gly-HisST001201AN0019991.760E-22.870E-2cell_type;iRBC;unRBC
Asn-Asn-Gly-HisST001202AN0020003.410E-186.670E-18cell_type;iRBC;unRBC
Asn-Asn-Gly-HisST001202AN0020003.400E-35.060E-3treatment_duration_(h);-;1.5;3;6;9
Asn-Asn-Pro-HisST000403AN0006423.260E-58.690E-4Glucose labelling;C13 glucose;unlabelled
Asn-Asp-Asp-ProST000403AN0006431.240E-108.360E-10Cell type;Mature erythrocyte;Reticulocyte
Asn-Asp-Asp-ProST000539AN0008197.460E-116.060E-10Cell type;Mature erythrocyte;Reticulocyte
Asn-Cys-Pro-SerST000403AN0006421.650E-111.090E-10Cell type;Mature erythrocyte;Reticulocyte
Asn-Cys-Pro-SerST000539AN0008181.740E-66.360E-6Cell type;Mature erythrocyte;Reticulocyte
Asn-Gln-Tyr-HisST000403AN0006433.710E-21.680E-1Glucose labelling;C13 glucose;unlabelled
Asn-Gly-Pro-ProST001201AN0019986.000E-316.380E-30cell_type;iRBC;unRBC
Asn-Gly-Pro-ProST001201AN0019981.140E-24.700E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Asn-TyrST000403AN0006423.160E-122.620E-11Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Asn-TyrST000539AN0008184.180E-139.310E-12Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Lys-AspST001201AN0019984.920E-81.250E-7cell_type;iRBC;unRBC
Asn-Leu-Lys-AspST001201AN0019984.940E-21.460E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001201AN0019982.170E-251.410E-24cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001201AN0019982.950E-32.260E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001202AN0020002.860E-196.160E-19cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001202AN0020003.860E-37.780E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001204AN0020043.270E-79.150E-7cell_type;iRBC;unRBC
Asn-Leu-Pro-ProST001204AN0020045.180E-43.360E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001205AN0020061.660E-31.410E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Leu-Pro-ProST001205AN0020061.080E-23.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Lys-Gly-GlyST001205AN0020063.010E-31.110E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Lys-Gly-ProST001201AN0019987.230E-339.430E-32cell_type;iRBC;unRBC
Asn-Lys-Gly-ProST001201AN0019982.910E-29.250E-2treatment;DHA;DMSO;OZ277;OZ439
Asn-Lys-Gly-ProST001204AN0020046.050E-112.380E-10cell_type;iRBC;unRBC
Asn-Lys-Gly-ProST001204AN0020048.160E-31.540E-1treatment;DHA;DMSO;OZ277;OZ439
Asn-Met-Thr-AspST001201AN0019994.440E-231.930E-22cell_type;iRBC;unRBC
Asn-Thr-Asn-AsnST001202AN0020006.110E-211.490E-20cell_type;iRBC;unRBC
Asn-Thr-Asn-AsnST001202AN0020001.570E-22.040E-2treatment_duration_(h);-;1.5;3;6;9
Asn-Thr-Asn-AsnST001204AN0020041.170E-201.300E-19cell_type;iRBC;unRBC
Asn-Thr-Trp-HisST001205AN0020071.840E-25.160E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Val-Gly-SerST001204AN0020047.760E-31.390E-2cell_type;iRBC;unRBC
Asparaginyl-HydroxyprolineST001202AN0020004.400E-157.380E-15cell_type;iRBC;unRBC
Asparaginyl-HydroxyprolineST001202AN0020001.260E-87.840E-8treatment_duration_(h);-;1.5;3;6;9
asparagylisoleucineST000974AN0015958.020E-41.170E-2TIMEPOINT;BL;M06;M18
asparagylisoleucineST000974AN0015959.860E-31.250E-1GROUP;case;control
Asp-Gly-Arg 2ST000539AN0008185.020E-92.570E-8Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Pro-SerST000403AN0006421.540E-64.700E-6Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Pro-SerST000539AN0008181.670E-33.750E-3Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Pro-SerST001201AN0019991.360E-297.990E-29cell_type;iRBC;unRBC
AspidofractineST000403AN0006423.540E-21.900E-1Glucose labelling;C13 glucose;unlabelled
AspidofractineST000539AN0008182.450E-35.340E-3Cell type;Mature erythrocyte;Reticulocyte
AspidofractineST000539AN0008183.250E-22.020E-1timepoint;1 hour;20 hours
Asp-Leu-Gln-ProST001202AN0020007.290E-201.660E-19cell_type;iRBC;unRBC
Asp-Leu-Gln-ProST001202AN0020001.400E-53.400E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Lys-AspST001202AN0020001.750E-224.740E-22cell_type;iRBC;unRBC
Asp-Leu-Lys-AspST001202AN0020002.410E-55.470E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Lys-AspST001204AN0020044.380E-24.260E-1treatment;DHA;DMSO;OZ277;OZ439
Asp-Leu-Lys-LysST000403AN0006433.990E-151.660E-13Cell type;Mature erythrocyte;Reticulocyte
Asp-Leu-Lys-LysST000539AN0008198.390E-156.420E-13Cell type;Mature erythrocyte;Reticulocyte
Asp-Leu-Lys-LysST001202AN0020009.150E-101.210E-9cell_type;iRBC;unRBC
Asp-Leu-Lys-LysST001202AN0020006.940E-61.820E-5treatment_duration_(h);-;1.5;3;6;9
Asp-Leu-Ser-HisST000403AN0006426.180E-74.560E-5Glucose labelling;C13 glucose;unlabelled
Asp-Met-Cys-CysST000403AN0006431.710E-159.270E-14Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Cys-CysST000539AN0008199.280E-143.820E-12Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Gln-GlnST001204AN0020042.280E-131.110E-12cell_type;iRBC;unRBC
Asp-Met-Pro-ProST000403AN0006429.620E-52.270E-4Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Pro-ProST000539AN0008184.020E-38.230E-3Cell type;Mature erythrocyte;Reticulocyte
Asp-Thr-Cys-CysST001201AN0019985.370E-101.520E-9cell_type;iRBC;unRBC
Asp-Trp-Gly-GlyST001204AN0020053.370E-307.580E-29cell_type;iRBC;unRBC
Asp-Val-Gly-SerST001202AN0020007.810E-242.440E-23cell_type;iRBC;unRBC
Asp-Val-Gly-SerST001202AN0020001.340E-42.580E-4treatment_duration_(h);-;1.5;3;6;9
Asp-Val-Pro-SerST001201AN0019991.260E-564.500E-55cell_type;iRBC;unRBC
Asp-Val-Pro-SerST001204AN0020047.500E-207.890E-19cell_type;iRBC;unRBC
Assymetrical dimethylarginineST000553AN0008471.730E-62.430E-6Sample type;Plasma;Urine
Asymmetrical dimethylarginineST001040AN0017025.170E-81.830E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
Atheroline-13C1[+H]+ST000142AN0002253.130E-326.130E-31Treatment;13C-Glc;unlabeled
Atheroline-13C6[+H]+ST000142AN0002258.280E-326.130E-31Treatment;13C-Glc;unlabeled
ATP-H2O-13C0+15N0ST000076AN0001214.080E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
ATP-H2O-13C2+15N0ST000076AN0001211.130E-24.230E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
Avenic acid AST001202AN0020011.470E-235.530E-23cell_type;iRBC;unRBC
Avenic acid AST001202AN0020011.240E-21.890E-2treatment_duration_(h);-;1.5;3;6;9
Avenic acid AST001205AN0020061.000E-69.120E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
AzaserineST000566AN0008701.060E-41.680E-4Time point;Post;Pre;Baseline
azelateST000923AN0015146.440E-64.630E-5Diagnosis;CD;nonIBD;UC
azelateST000923AN0015151.000E-56.070E-5Diagnosis;CD;nonIBD;UC
azelateST001000AN0018804.340E-61.620E-5Diagnosis;CD;Control;UC
AzelateST001048AN0017178.970E-41.100E-3Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
AzythromycinST000241AN0003746.490E-101.640E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Bacteriochlorophyllide a-13C0[+QDA adduct]+ST000142AN0002254.230E-326.130E-31Treatment;13C-Glc;unlabeled
b-DihydrotetrabenazineST000444AN0006952.090E-25.210E-2Sample Treatment;Bubbled;Control
benzi(ghi)peryleneST000614AN0009431.200E-83.120E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
benzi(ghi)peryleneST000614AN0009434.790E-36.030E-3Diagonsis;Benign;Cancer;Normal
benzi(ghi)perylene1ST000614AN0009413.600E-33.600E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
benzi(ghi)perylene1ST000614AN0009411.440E-21.730E-2Diagonsis;Benign;Cancer;Normal
BENZOIC ACID #2 (M-H)-ST000748AN0011724.570E-24.930E-2Sample type;Cells;Culture Media
Benzoquinoneacetate-13C0[+QDA adduct]+ST000148AN0002353.130E-21.160E-1Treatment;13C-Glc;unlabeled
Benzoquinoneacetate-13C1[+QDA adduct+Na]+ST000142AN0002252.960E-21.630E-1Treatment;13C-Glc;unlabeled
Benzyl dodecyl dimethylammonium cationST000077AN0001233.660E-94.910E-9Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Benzyl dodecyl dimethylammonium cationST000077AN0001233.160E-89.430E-8Treatment;100uM Met ;370uM Hcy ;quality check
Benzyl dodecyl dimethylammonium cation (disinfectant)ST000089AN0001412.450E-277.240E-27Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
BenzylserineST000553AN0008479.400E-71.400E-6Sample type;Plasma;Urine
Benzyl tetradecyl dimethylammonium cationST000077AN0001232.750E-73.060E-7Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Benzyl tetradecyl dimethylammonium cationST000077AN0001232.640E-54.460E-5Treatment;100uM Met ;370uM Hcy ;quality check
Benzyl tetradecyl dimethylammonium cation (disinfectant)ST000089AN0001412.130E-351.900E-34Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
BergamottinST001037AN0016983.460E-29.520E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
Beta-alanine methyl esterST000553AN0008477.090E-111.740E-10Sample type;Plasma;Urine
Beta-alanine methyl esterST001317AN0021926.364E-181.485E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Beta-alanine methyl esterST001317AN0021926.364E-181.485E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
beta-DIHYDROROTENONEST000422AN0006675.140E-71.420E-4treatment;ND;T1D good glycemic control
beta-HomophenylalanineST001211AN0020173.680E-31.410E-2Group;Control;Methotrexate
beta-hydroxymyristic acidST001133AN0018584.210E-32.540E-2CENPF;Control;KO
Betaine / L-Valine/ NorvalineST001040AN0017022.750E-25.600E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
beta-mannosylglycerateST000368AN0006021.210E-21.720E-2Organ;Plasma;Serum;Serum or Plasma
beta-mannosylglycerateST000385AN0006208.300E-81.120E-7Organ;Plasma;Serum;Serum or Plasma
beta-mannosylglycerateST000389AN0006252.360E-25.000E-1Emphysema/COPD;No;Yes
beta-Nicotinamide adenine dinucleotideST001211AN0020175.470E-103.760E-8Group;Control;Methotrexate
Bifemelane (M4)ST000421AN0006641.340E-21.980E-1treatment;ND;T1D poor glycemic control
Bifemelane(M4)ST000046AN0000791.480E-28.110E-2Cognitive Status;AD;CN;MCI
BiflorinST000356AN0005833.570E-427.620E-41Diagnosis;breast cancer;control
BiflorinST000356AN0005832.050E-265.020E-25stage;-;2;3
Bile saltST001201AN0019991.020E-31.970E-3cell_type;iRBC;unRBC
Bile saltST001201AN0019991.230E-37.900E-2treatment_duration_(h);-;0.5;1.5;3
Bile saltST001202AN0020015.240E-262.690E-25cell_type;iRBC;unRBC
Bile saltST001202AN0020017.480E-51.880E-4treatment_duration_(h);-;1.5;3;6;9
BillirubinST000919AN0015073.150E-32.370E-2Response;NR;R
biphosphoglyceric acidST000608AN0009319.730E-421.670E-40Sample_Type;blotter;serum
Bis(2-hydroxypropyl)amineST000047AN0000801.650E-41.570E-2Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amineST000047AN0000814.630E-22.150E-1Cognitive Status;AD;CN;MCI
Bis (2-hydroxypropyl) amine + 5.4315743ST000422AN0006674.990E-26.020E-1treatment;ND;T1D good glycemic control
Bis(2-hydroxypropyl)amine+5.4374814ST000047AN0000819.990E-59.760E-3Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.481559ST000046AN0000774.150E-22.020E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.586841ST000047AN0000811.320E-21.140E-1Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine+5.6003766ST000046AN0000776.660E-43.000E-2Cognitive Status;AD;CN;MCI
Bisacurone epoxideST001202AN0020007.010E-131.070E-12cell_type;iRBC;unRBC
Bis(glycerophospho)-glycerolST000403AN0006422.860E-163.380E-14Cell type;Mature erythrocyte;Reticulocyte
Bis(glycerophospho)-glycerolST000539AN0008182.390E-136.300E-12Cell type;Mature erythrocyte;Reticulocyte
Bisnorcholic acidST000355AN0005813.690E-42.610E-3Stage;1;2;3;4;-
Bisnorcholic acidST000355AN0005818.200E-46.110E-3Diagnosis;Breast cancer;Control
B-Norcholest-4-en-3-one-13C0[+Na]+ST000142AN0002255.690E-326.130E-31Treatment;13C-Glc;unlabeled
BOC-ALA (+NA)ST000043AN0000702.620E-27.870E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ALA (+NA)ST000105AN0001739.340E-51.670E-3Sampling;After SWS onset;Morning fasting
BOC-ALA (+NA)ST000105AN0001733.360E-25.450E-1CPAP;No CPAP;After CPAP
BOC-ALA-OHST000016AN0000331.210E-673.030E-65Material;Cells;Media
BOC-ALA-OHST000041AN0000636.680E-31.280E-1Group;Control;NAFLD
BOC-ALA-OHST000043AN0000703.090E-28.790E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ALA-OHST000044AN0000697.820E-34.400E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ALA-OHST000105AN0001746.830E-33.570E-2Sampling;After SWS onset;Morning fasting
BOC-ALA-OH (CAS# 15761-38-3); (M-H)-ST000697AN0010819.200E-37.550E-2Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
Boc-AsnST000403AN0006423.390E-91.530E-8Cell type;Mature erythrocyte;Reticulocyte
Boc-AsnST000539AN0008188.790E-83.660E-7Cell type;Mature erythrocyte;Reticulocyte
BOC-ASNST000009AN0000234.370E-31.260E-2SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
BOC-ASNST000009AN0000231.350E-23.750E-2POST_SURGERY_TIME;12MO;6MO;NO_SURGERY;PRE_SURGERY
BOC-ASNST000009AN0000234.560E-22.550E-1AFTER_MEAL_TIME;30_MIN;NO_WAIT
BOC-ASNST000010AN0000252.440E-37.520E-3FCS;FCS;NO_FCS
BOC-ASNST000010AN0000254.940E-21.120E-1Hours;72;0;12;24;2
BOC-ASNST000011AN0000274.770E-21.770E-1COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
BOC-ASNST000016AN0000334.550E-61.130E-5Material;Cells;Media
BOC-ASNST000044AN0000683.800E-21.940E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASNST000044AN0000693.200E-32.440E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASNST000106AN0001764.560E-25.150E-1Visit;1;2
BOC-ASN-OHST000106AN0001764.660E-25.150E-1Visit;1;2
BOC-ASP-OHST000016AN0000337.930E-32.020E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
BOC-ASP-OHST000041AN0000631.730E-21.960E-1Group;Control;NAFLD
BOC-ASP-OHST000043AN0000703.020E-31.310E-2Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-ASP-OHST000105AN0001741.640E-26.040E-1CPAP;No CPAP;After CPAP
BOC-ASP-OHST000105AN0001743.820E-25.090E-1OSA;Negative;Positive
BOC-ASP-OHST000106AN0001761.850E-23.570E-1Visit;1;2
BOC-HIS-OHST000016AN0000332.440E-151.450E-14Material;Cells;Media
BOC-HIS-OHST000016AN0000335.310E-32.080E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
BOC-HIS-OHST000016AN0000332.970E-26.510E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
BOC-HIS-OHST000105AN0001741.700E-27.220E-2Sampling;After SWS onset;Morning fasting
BOC-HIS-OHST000105AN0001743.690E-25.090E-1OSA;Negative;Positive
BOC-HIS-OHST000106AN0001756.650E-38.940E-2Sampling time;0 min;60 min
BOC-LYS-OHST000016AN0000333.470E-46.790E-4Material;Cells;Media
BOC-LYS-OHST000043AN0000705.680E-53.630E-4Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-MET-OHST000105AN0001743.100E-21.190E-1Sampling;After SWS onset;Morning fasting
BOC-MET-OHST000105AN0001743.930E-26.250E-1CPAP;No CPAP;After CPAP
BOC-MET-OHST000105AN0001744.610E-25.090E-1OSA;Negative;Positive
BOC-PHE-OHST000043AN0000706.690E-43.550E-3Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
BOC-PHE-OHST000044AN0000694.540E-32.860E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-PHE-OHST000105AN0001731.410E-31.660E-2Sampling;After SWS onset;Morning fasting
BOC-PHE-OHST000105AN0001742.480E-23.250E-1PCOS;No PCOS;PCOS
BOC-PRO-OHST000016AN0000338.260E-132.430E-11Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
BOC-PRO-OHST000016AN0000331.520E-123.310E-11Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
BOC-PRO-OHST000105AN0001733.830E-24.040E-1Gender;Female;Male
BOC-PRO-OHST000106AN0001753.100E-22.460E-1Sampling time;0 min;60 min
BOC-SER-OHST000044AN0000697.750E-41.090E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
bOHbutyrate-13C0ST000076AN0001223.090E-29.100E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-13C0ST000114AN0001941.440E-66.660E-5Treatment;None;Tetracycline
bOHbutyrate-13C0ST001049AN0018643.500E-21.340E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
bOHbutyrate-13C00ST000951AN0015602.720E-29.040E-1cell_type;CD8_T_memory;CD8_T_naive;NK
bOHbutyrate-13C1ST000114AN0001941.880E-31.340E-2Treatment;None;Tetracycline
bOHbutyrate-13C1ST001046AN0017102.510E-24.100E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
bOHbutyrate-13C2ST000076AN0001224.570E-32.100E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-13C4ST000076AN0001222.650E-42.430E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-ALLST000076AN0001221.430E-41.710E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
bOHbutyrate-ALLST000114AN0001943.010E-61.050E-4Treatment;None;Tetracycline
B-Sulfinyl pyruvateST000356AN0005835.230E-51.300E-4Diagnosis;breast cancer;control
B-Sulfinyl pyruvateST000356AN0005833.230E-48.510E-4stage;-;2;3
B-ureidoisobutyric acidST000422AN0006674.030E-42.240E-2treatment;ND;T1D good glycemic control
B-ureidoisobutyricacid-6.84278ST000046AN0000794.420E-33.930E-2Cognitive Status;AD;CN;MCI
Buspirone N-oxideST000444AN0006952.370E-25.210E-2Sample Treatment;Bubbled;Control
Butanoyl-PAFST000553AN0008456.650E-135.980E-12Sample type;Plasma;Urine
Butanoyl-PAFST000553AN0008466.370E-88.950E-8Sample type;Plasma;Urine
butylamine NISTST000379AN0006132.450E-26.030E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
butyrate / isobutytareST001000AN0018791.750E-46.880E-4Diagnosis;CD;Control;UC
C12 / C10ST000544AN0008272.610E-82.790E-7Sample Type;Control;Replicate
C12 / C10ST000545AN0008307.060E-89.800E-7Sample Type;Control;Replicate
C12 / C12:1ST000405AN0006451.850E-25.990E-1Group;No PA;PA;PoolAll
C12 / C8ST000544AN0008274.990E-74.560E-6Sample Type;Control;Replicate
C12 / C8ST000545AN0008307.890E-31.120E-2Sample Type;Control;Replicate
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+H)+ST000775AN0012232.270E-44.790E-3Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+HCOO)-ST000695AN0010759.320E-34.630E-2Race;Black;White;POOLED
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+Cl)-ST000818AN0012964.020E-26.850E-2Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+NA)+ST000744AN0011637.070E-32.000E-1Gender;female;male
C-132-Carboxypyropheophorbide a-13C0[+QDA adduct+Na]+ST000142AN0002257.880E-336.130E-31Treatment;13C-Glc;unlabeled
C14:1-OH / C10ST000544AN0008278.700E-34.180E-2Sample Type;Control;Replicate
C14:1-OH / C10ST000545AN0008301.390E-32.170E-3Sample Type;Control;Replicate
C16 / C16:1ST000405AN0006453.390E-25.630E-1Vaginal Bleeding;N;UNK;Y;-
C16-OH SulfatideST000567AN0008711.030E-167.760E-16Time point;Post;Pre;Baseline
C16-OH SulfatideST000567AN0008712.730E-38.860E-3groups;Old-Curcumin;Old-Placebo;young
C18:0e MAGST001000AN0018813.710E-71.140E-5Diagnosis;CD;Control;UC
c181hexcerumST000433AN0006831.480E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
C24:0 PCST001000AN0018811.470E-25.030E-2Diagnosis;CD;Control;UC
c241hexcerumST000433AN0006833.160E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
C29 N O20 S2ST000567AN0008725.290E-73.620E-6Time point;Post;Pre;Baseline
C2 / C0ST000544AN0008278.590E-34.180E-2Sample Type;Control;Replicate
C36:5 PC plasmalogen-AST001000AN0018818.270E-71.860E-5Diagnosis;CD;Control;UC
C38:5 PCST001142AN0018777.780E-162.890E-15Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
C38:5 PCST001142AN0018773.600E-141.070E-12Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
C3 / C4ST000544AN0008273.230E-42.070E-3Sample Type;Control;Replicate
C3 / C4ST000545AN0008304.040E-35.980E-3Sample Type;Control;Replicate
C4 / C0ST000545AN0008301.590E-32.470E-3Sample Type;Control;Replicate
C4 / C5ST000544AN0008273.530E-124.520E-11Sample Type;Control;Replicate
C4 / C5ST000545AN0008302.180E-54.120E-5Sample Type;Control;Replicate
C4 N O4 SST000566AN0008705.760E-87.450E-7Time point;Post;Pre;Baseline
C4 N O4 SST000567AN0008729.850E-81.860E-6Time point;Post;Pre;Baseline
C5-SUGAR ALCOHOLST000954AN0015642.390E-44.610E-2ethnicity;1;2;-
C5-SUGAR ALCOHOLST000956AN0015694.470E-31.120E-2Treatment;Condition-1;Condition-2;Condition-3;Control
C6H12O6-HEXOSE/KETOSE/INOSITOLST000292AN0004671.350E-31.450E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
C6H12O6-HEXOSE/KETOSE/INOSITOLST000919AN0015073.200E-21.310E-1Response;NR;R
C7 N O6 SST000566AN0008708.060E-87.450E-7Time point;Post;Pre;Baseline
C7 N O6 SST000567AN0008724.500E-81.860E-6Time point;Post;Pre;Baseline
C8-Ceramide m0ST000644AN0009761.180E-82.610E-8tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m0ST000644AN0009768.590E-42.490E-3time;48 hr;0 hr
C8-Ceramide m0ST000644AN0009762.290E-23.600E-1group ID;PHGDH;PSAT;PSPH
C8-Ceramide m+1ST000644AN0009765.500E-59.300E-5tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+1ST000644AN0009763.200E-41.170E-3time;48 hr;0 hr
C8-Ceramide m+10ST000644AN0009761.750E-251.100E-24tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+10ST000644AN0009763.090E-41.150E-3time;48 hr;0 hr
C8-Ceramide m+11ST000644AN0009762.320E-426.590E-41tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+11ST000644AN0009761.460E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+12ST000644AN0009762.500E-149.210E-14tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+12ST000644AN0009761.550E-34.070E-3time;48 hr;0 hr
C8-Ceramide m+13ST000644AN0009762.330E-469.470E-45tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+13ST000644AN0009761.370E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+14ST000644AN0009762.780E-96.630E-9tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+14ST000644AN0009766.370E-31.260E-2time;48 hr;0 hr
C8-Ceramide m+14ST000644AN0009762.560E-23.600E-1group ID;PHGDH;PSAT;PSPH
C8-Ceramide m+15ST000644AN0009761.790E-456.340E-44tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+15ST000644AN0009761.390E-48.430E-4time;48 hr;0 hr
C8-Ceramide m+17ST000644AN0009762.590E-261.750E-25tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+17ST000644AN0009762.890E-41.100E-3time;48 hr;0 hr
C8-Ceramide m+6ST000644AN0009767.860E-153.020E-14tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+6ST000644AN0009761.390E-33.710E-3time;48 hr;0 hr
C8-Ceramide m+7ST000644AN0009764.830E-344.570E-33tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+7ST000644AN0009761.850E-48.470E-4time;48 hr;0 hr
C8-Ceramide m+8ST000644AN0009765.670E-284.020E-27tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+8ST000644AN0009762.550E-41.050E-3time;48 hr;0 hr
C8-Ceramide m+9ST000644AN0009761.830E-393.460E-38tracer;13C-glucose;13C-glutamine;No label
C8-Ceramide m+9ST000644AN0009761.560E-48.430E-4time;48 hr;0 hr
C9 / C10:2ST000544AN0008276.450E-33.350E-2Sample Type;Control;Replicate
C9 / C10:2ST000545AN0008309.810E-31.380E-2Sample Type;Control;Replicate
C9 / C14ST000544AN0008274.120E-187.910E-17Sample Type;Control;Replicate
C9 / C14:1-OHST000544AN0008279.930E-226.360E-20Sample Type;Control;Replicate
C9 / C16:1-OHST000544AN0008271.600E-142.360E-13Sample Type;Control;Replicate
c-aconitate-13C0ST001049AN0018642.370E-33.440E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
c-aconitate-13C1ST001049AN0018645.670E-35.620E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
c-aconitate-13C5ST001049AN0018641.700E-32.980E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Caffeine-D3ST000424AN0006733.630E-27.400E-1SEX;F;M
Caffeine-D3ST000919AN0015073.770E-44.200E-3Response;NR;R
Caffeine-D3ST000919AN0015078.000E-35.400E-2Gender;Female;Male
Caffeine-D3ST000956AN0015687.430E-31.440E-2Treatment;Condition-1;Condition-2;Condition-3;Control
CAI-1ST000403AN0006433.240E-47.330E-4Cell type;Mature erythrocyte;Reticulocyte
CAI-1ST000539AN0008193.490E-42.230E-2timepoint;1 hour;20 hours
CAI-1-13C0[+13CD3 QDA]+ST000142AN0002253.540E-21.920E-1Treatment;13C-Glc;unlabeled
CAI-1-13C0[+13CD3 QDA]+ST000148AN0002354.410E-21.530E-1Treatment;13C-Glc;unlabeled
[calc GSH-13C]ST000114AN0001945.980E-46.620E-3Treatment;None;Tetracycline
CALCIDIOL (M+H)+[-H2O]ST000818AN0012974.040E-41.120E-3Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Calcium salicylateST000292AN0004667.670E-43.090E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
CaldarchaeolST000445AN0006967.930E-33.910E-2Treatment;FSH;LH
Candletoxin A-13C0[+13CD3 QDA]+ST000142AN0002256.320E-326.130E-31Treatment;13C-Glc;unlabeled
Capillone-13C0[+13CD3 QDA]+ST000148AN0002355.810E-33.310E-2Treatment;13C-Glc;unlabeled
Capillone-13C0[+QDA adduct]+ST000148AN0002351.700E-27.280E-2Treatment;13C-Glc;unlabeled
Capillone-13C1[+QDA adduct]+ST000148AN0002351.390E-26.250E-2Treatment;13C-Glc;unlabeled
carboxyibuprofenST000923AN0015152.940E-22.430E-1sex;Female;Male
CarboxyibuprofenST000421AN0006631.410E-21.910E-1treatment;ND;T1D poor glycemic control
Casein KST000403AN0006421.660E-35.620E-2timepoint;1 hour;20 hours
Casein KST000539AN0008181.850E-34.130E-3Cell type;Mature erythrocyte;Reticulocyte
Casein KST000539AN0008182.340E-21.650E-1timepoint;1 hour;20 hours
Casein K 2ST000539AN0008181.850E-34.130E-3Cell type;Mature erythrocyte;Reticulocyte
Casein K 2ST000539AN0008182.340E-21.650E-1timepoint;1 hour;20 hours
CBS 113AST000291AN0004642.240E-25.970E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
CCCPST000292AN0004665.680E-31.200E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
CD 1790ST000444AN0006951.270E-25.210E-2Sample Treatment;Bubbled;Control
cefamandole nafateST000421AN0006639.560E-66.530E-4treatment;ND;T1D poor glycemic control
cefamandole nafateST000422AN0006673.310E-31.020E-1treatment;ND;T1D good glycemic control
cefamandolenafateST000047AN0000813.000E-21.810E-1Cognitive Status;AD;CN;MCI
cefamandole nafate + 2.0600944ST000421AN0006632.640E-62.470E-4treatment;ND;T1D poor glycemic control
CeliprololST000566AN0008701.790E-29.110E-2group;Old-Curcumin;Old-Placebo;young
CeliprololST000566AN0008703.110E-23.260E-2Time point;Post;Pre;Baseline
cer160ST000433AN0006832.120E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
cer200ST000433AN0006832.870E-28.690E-2Group;Alzheimer disease dementia;Cognitively normal;Dementia...
Ceramide(d18:1/23:0) or Ceramide(d18:1/22:1 OH)ST000450AN0007052.110E-31.700E-2Disease;CFS;Normal
Cerebroside CST000421AN0006652.360E-24.280E-1treatment;ND;T1D poor glycemic control
CerH2O(d18:1/16:0)ST000608AN0009295.650E-269.290E-25Sample_Type;blotter;serum
CerH2O(d18:1/24:0)ST000608AN0009291.030E-41.390E-4Sample_Type;blotter;serum
CerH2O(d18:1/24:0);CerH2O(d19:1/23:0)ST000608AN0009294.620E-42.250E-3Factor;case;control
CerH2O(d18:1/26:0);CerH2O(d20:1/24:0)ST000608AN0009299.130E-215.580E-20Sample_Type;blotter;serum
CerH2O(d18:1/26:1)ST000608AN0009291.870E-263.280E-25Sample_Type;blotter;serum
CerH2O(d18:2/22:0)ST000608AN0009292.710E-84.340E-8Sample_Type;blotter;serum
CerH2O(d18:2/23:0)ST000608AN0009292.340E-73.570E-7Sample_Type;blotter;serum
CerH2O(d19:1/24:0)ST000608AN0009298.300E-121.670E-11Sample_Type;blotter;serum
CerP 21:0; [M-H]-@2.12ST000775AN0012244.770E-21.270E-1Treatment response;No;Yes;Pooled
CerP(t39:1)[M+H]+ST000992AN0016214.140E-23.460E-1Metabolic syndrome;No;Yes
C-glycosyltryptophanST000899AN0014641.220E-91.890E-7Type;Control;Crohn disease;Ulcerative Colitis
C-glycosyltryptophan*ST000974AN0015956.170E-39.670E-2GROUP;case;control
C-glycosyltryptophan*ST000975AN0015961.290E-25.210E-2GENDER;F;M
C-GLYCOSYLTRYPTOPHANST000016AN0000339.220E-103.340E-9Material;Cells;Media
C-GLYCOSYLTRYPTOPHANST000016AN0000339.840E-43.130E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
C-GLYCOSYLTRYPTOPHANST000016AN0000333.590E-31.480E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
C-GLYCOSYLTRYPTOPHAN (*)ST000105AN0001731.140E-22.920E-1OSA;Negative;Positive
C-GLYCOSYLTRYPTOPHAN (*)ST000106AN0001752.100E-31.060E-1Constitution;Lean;Obese
Chalcomycin-13C0[+QDA adduct]+ST000142AN0002251.950E-326.130E-31Treatment;13C-Glc;unlabeled
Chalcomycin-13C1[+QDA adduct]+ST000142AN0002256.120E-326.130E-31Treatment;13C-Glc;unlabeled
ChloramphenicolalcoholST000046AN0000773.050E-21.690E-1Cognitive Status;AD;CN;MCI
ChloramphenicolalcoholST000047AN0000811.910E-21.420E-1Cognitive Status;AD;CN;MCI
ChlordiazepoxideST000913AN0014833.440E-24.400E-1Sex;FEMALE;MALE
Chloroacetoacetanilide-13C0[+QDA adduct]+ST000142AN0002251.900E-326.130E-31Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C0[+QDA adduct+Na]+ST000148AN0002357.540E-33.930E-2Treatment;13C-Glc;unlabeled
Chloroacetoacetanilide-13C1[+QDA adduct+Na]+ST000148AN0002355.920E-33.340E-2Treatment;13C-Glc;unlabeled
Cholic acid or similar bile acidST000586AN0009012.220E-43.260E-4Plasma Volume;0 uL;150 uL;700 uL
Cholic acid or similar bile acidST000589AN0009045.310E-186.870E-18Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Cinchonain 1aST001204AN0020042.120E-296.870E-28cell_type;iRBC;unRBC
Cinncassiol C1-13C0[+QDA adduct+Na]+ST000142AN0002254.100E-326.130E-31Treatment;13C-Glc;unlabeled
Cinncassiol C2-13C0[+13CD3 QDA]+ST000142AN0002251.210E-317.410E-31Treatment;13C-Glc;unlabeled
cis-3-HexenyllactateST000355AN0005804.660E-21.190E-1Diagnosis;Breast cancer;Control
CIS-4-NONENEST001037AN0016982.340E-26.810E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
cis-AcetylacrylateST001205AN0020076.270E-44.950E-2treatment_duration_(h);1;5;3
cis-AcetylacrylateST001205AN0020073.440E-21.000E+0treatment;DHA;DMSO;OZ277;OZ439
cis Aconitate M0ST000507AN0007762.560E-57.230E-5Time (incubation);24 hours;72 hours
cis-Cyclo[L-ala-L-Pro]ST000974AN0015953.890E-753.020E-73REGION;AHRI;MRC;SUN
cis-Cyclo[L-ala-L-Pro]ST000974AN0015956.830E-34.490E-2TIMEPOINT;BL;M06;M18
cis-Cyclo[L-ala-L-Pro]ST000975AN0015963.230E-42.410E-3GENDER;F;M
cis-Cyclo[L-ala-L-Pro]ST000975AN0015961.800E-22.150E-1REGION;MAK;SUN
cis/trans-hydroxyprolineST001142AN0018752.010E-741.030E-73Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
cis/trans-hydroxyprolineST001142AN0018751.690E-41.950E-4Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Cit / ArgST000544AN0008263.430E-21.020E-1Sample Type;Control;Replicate
CitioloneST000242AN0003752.550E-64.590E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Cit / OrnST000405AN0006453.130E-35.630E-1Vaginal Bleeding;N;UNK;Y;-
Cit / OrnST000544AN0008264.950E-21.400E-1Sample Type;Control;Replicate
citraconic acid major TMS2ST000420AN0006626.740E-41.180E-3Group;nonsmoker;smoker
Citrate+Na;CITRATEST000956AN0015681.270E-33.160E-3Treatment;Condition-1;Condition-2;Condition-3;Control
Citrate+NH3ST000956AN0015681.870E-34.180E-3Treatment;Condition-1;Condition-2;Condition-3;Control
Citrate source fragment (+H and + NH3)ST000956AN0015681.050E-32.700E-3Treatment;Condition-1;Condition-2;Condition-3;Control
CL 72:10 (18:2/18:3/18:2/18:3) [M-2H](2-)ST001111AN0018061.460E-43.520E-4Sample;Benign;Cancer;Metastasis
CL 72:10 (18:3/14:0/20:3/20:4) [M-2H](2-)ST001111AN0018061.580E-107.820E-10Sample;Benign;Cancer;Metastasis
CL 74:10 (16:0/22:5/16:1/20:4) [M-2H](2-)ST001111AN0018064.400E-165.840E-15Sample;Benign;Cancer;Metastasis
CL 74:10 (16:0/22:5/20:4/16:1) [M-2H](2-)ST001111AN0018061.320E-22.240E-2Sample;Benign;Cancer;Metastasis
CL 74:10 (16:1/22:5/20:4/16:0) [M-2H](2-)ST001111AN0018067.520E-191.360E-17Sample;Benign;Cancer;Metastasis
CL 74:9 (18:0/20:4/18:2/18:3) [M-2H](2-)ST001111AN0018061.440E-213.410E-20Sample;Benign;Cancer;Metastasis
CL 74:9 (18:2/20:3/18:3/18:1) [M-2H](2-)ST001111AN0018065.670E-167.230E-15Sample;Benign;Cancer;Metastasis
CL 74:9 (20:3/18:2/20:4/16:0) [M-2H](2-)ST001111AN0018062.150E-23.450E-2Sample;Benign;Cancer;Metastasis
CL 76:11 (16:0/18:1/22:6/20:4) [M-2H](2-)ST001111AN0018065.450E-179.050E-16Sample;Benign;Cancer;Metastasis
CL 76:11 (18:2/18:2/20:4/20:3) [M-2H](2-)ST001111AN0018065.070E-41.110E-3Sample;Benign;Cancer;Metastasis
CL 76:12 (18:3/20:3/20:4/18:2) [M-2H](2-)ST001111AN0018063.250E-47.440E-4Sample;Benign;Cancer;Metastasis
CL 76:9 (18:0/16:0/22:5/20:4) [M-2H](2-)ST001111AN0018062.150E-261.780E-24Sample;Benign;Cancer;Metastasis
CL 76:9 (18:0/20:4/18:1/20:4) [M-2H](2-)ST001111AN0018062.700E-278.950E-25Sample;Benign;Cancer;Metastasis
CL 78:12 (18:1/20:4/18:1/22:6) [M-2H](2-)ST001111AN0018064.880E-41.090E-3Sample;Benign;Cancer;Metastasis
CL 78:13 (18:1/20:4/18:2/22:6) [M-2H](2-)ST001111AN0018063.740E-132.820E-12Sample;Benign;Cancer;Metastasis
CL 80:14 (18:0/20:4/20:4/22:6) [M-2H](2-)ST001111AN0018062.740E-35.110E-3Sample;Benign;Cancer;Metastasis
CL 80:14 (18:0/22:6/18:2/22:6) [M-2H](2-)ST001111AN0018061.550E-22.600E-2Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/20:0/22:5/22:6) [M-2H](2-)ST001111AN0018065.690E-123.570E-11Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/20:0/22:6/22:5) [M-2H](2-)ST001111AN0018062.060E-131.670E-12Sample;Benign;Cancer;Metastasis
CL 82:11 (18:0/22:5/20:0/22:6) [M-2H](2-)ST001111AN0018062.120E-111.280E-10Sample;Benign;Cancer;Metastasis
CL 82:12 (20:1/18:0/22:5/22:6) [M-2H](2-)ST001111AN0018061.480E-85.660E-8Sample;Benign;Cancer;Metastasis
Clitidine 5-phosphateST000403AN0006433.150E-71.060E-6Cell type;Mature erythrocyte;Reticulocyte
Clitidine 5-phosphateST000539AN0008198.300E-129.670E-11Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminateST000403AN0006436.630E-152.560E-13Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminateST000539AN0008195.770E-114.910E-10Cell type;Mature erythrocyte;Reticulocyte
CMP-N-trimethyl-2-aminoethylphosphonateST000403AN0006426.780E-136.900E-12Cell type;Mature erythrocyte;Reticulocyte
CMP-N-trimethyl-2-aminoethylphosphonateST000539AN0008181.090E-108.460E-10Cell type;Mature erythrocyte;Reticulocyte
CMP-N-trimethyl-2-aminoethylphosphonateST001201AN0019997.340E-49.090E-3treatment;DHA;DMSO;OZ277;OZ439
CMP-N-trimethyl-2-aminoethylphosphonateST001202AN0020001.290E-213.210E-21cell_type;iRBC;unRBC
CMP-N-trimethyl-2-aminoethylphosphonateST001202AN0020004.700E-59.980E-5treatment_duration_(h);-;1.5;3;6;9
CocamidopropylBetaineST000913AN0014832.650E-23.990E-1Diagnosis;MECFS;MS;ND
Cohibin CST001202AN0020005.620E-365.660E-35cell_type;iRBC;unRBC
Convallasaponin AST000437AN0006872.380E-53.760E-5Sample type;Spiked;Unknown
CoproporphyrinST000356AN0005833.960E-192.260E-18Diagnosis;breast cancer;control
CoproporphyrinST000356AN0005839.540E-166.270E-15stage;-;2;3
CoQ10H2ST000450AN0007052.210E-24.300E-2gender;Female;Male
Corey PG-Lactone DiolST000566AN0008705.840E-59.890E-5Time point;Post;Pre;Baseline
Corey PG-Lactone DiolST000566AN0008704.120E-21.350E-1group;Old-Curcumin;Old-Placebo;young
Corey PG-Lactone Diol + 6.739769ST000566AN0008709.270E-41.190E-3Time point;Post;Pre;Baseline
CotineST000614AN0009434.370E-124.260E-11Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
CotineST000614AN0009438.500E-53.320E-4Diagonsis;Benign;Cancer;Normal
cotinine1ST000614AN0009412.830E-161.700E-15Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
CotinineglucuronideST000241AN0003732.240E-185.270E-17Concentration (uM);0;500
CotinineglucuronideST000241AN0003731.750E-119.140E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Cotinine-goodST000614AN0009433.160E-99.490E-9Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Cotinine-goodST000614AN0009438.400E-41.550E-3Diagonsis;Benign;Cancer;Normal
CPT-I ratioST000544AN0008272.360E-31.370E-2Sample Type;Control;Replicate
CPT-I ratioST000545AN0008302.360E-33.580E-3Sample Type;Control;Replicate
Creatine-D3ST000424AN0006734.250E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
Creatine-D3ST000954AN0015641.800E-27.810E-1diplotype;1;2
creatine major dehydrated TMS3ST000416AN0006584.400E-52.380E-3Gender;Female;Male
creatine major dehydrated TMS3ST000416AN0006584.150E-31.270E-2Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
creatine major dehydrated TMS3ST000417AN0014482.680E-51.950E-4Group;AIR;NO2PM;PM
CrotanecineST001202AN0020001.500E-392.420E-38cell_type;iRBC;unRBC
CrotanecineST001205AN0020062.610E-54.950E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
CrotetamideST000913AN0014835.870E-96.810E-7Diagnosis;MECFS;MS;ND
crustecdysoneST001192AN0019864.370E-22.160E-1Diet;-;Omnivore;Vegetarian
CTABST000539AN0008182.340E-45.910E-4Cell type;Mature erythrocyte;Reticulocyte
CTABST001202AN0020002.130E-153.640E-15cell_type;iRBC;unRBC
CTABST001205AN0020061.750E-24.490E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)ST001317AN0021939.596E-41.343E-3SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)ST001317AN0021939.596E-41.343E-3SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Cyanidin-3-rhamnoglucoside chloride-13C0[+Na]+ST000142AN0002252.710E-21.500E-1Treatment;13C-Glc;unlabeled
cyano-L-alanineST000369AN0006031.380E-51.670E-4Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
cyano-L-alanineST000369AN0006031.060E-23.370E-2Smoker;Current;Former;NA
Cyclo(deltaAla-L-Val)ST000539AN0008189.080E-39.920E-2timepoint;1 hour;20 hours
cyclo-Dopa-glucuronylglucosideST000567AN0008717.360E-291.750E-27Time point;Post;Pre;Baseline
cyclo-Dopa-glucuronylglucosideST000567AN0008711.400E-51.250E-4groups;Old-Curcumin;Old-Placebo;young
cyclohexylammoniumST000046AN0000771.260E-21.250E-1Cognitive Status;AD;CN;MCI
cyclohexylammonium+2.7358363ST000046AN0000763.610E-21.430E-1Cognitive Status;AD;CN;MCI
cyclohexylammonium+5.197659ST000046AN0000762.730E-21.210E-1Cognitive Status;AD;CN;MCI
CycloleucineST000567AN0008722.700E-44.340E-4Time point;Post;Pre;Baseline
CycloleucineST000567AN0008722.790E-21.070E-1groups;Old-Curcumin;Old-Placebo;young
Cyclo(leucylprolyl)ST000553AN0008451.890E-116.380E-11Sample type;Plasma;Urine
cyclo(leu-pro)ST000974AN0015953.560E-36.900E-2GROUP;case;control
cyclo(leu-pro)ST000974AN0015956.000E-34.240E-2TIMEPOINT;BL;M06;M18
cyclo(leu-pro)ST000974AN0015952.700E-21.470E-1GENDER;F;M
cyclo(L-phe-L-pro)ST000974AN0015956.490E-39.670E-2GROUP;case;control
cyclo(L-phe-L-pro)ST000974AN0015956.810E-35.410E-2GENDER;F;M
cyclo(L-phe-L-pro)ST000974AN0015958.970E-35.360E-2TIMEPOINT;BL;M06;M18
cyclo(L-phe-L-pro)ST000974AN0015952.640E-28.080E-2REGION;AHRI;MRC;SUN
CyclopentolateST000444AN0006951.940E-25.210E-2Sample Treatment;Bubbled;Control
Cyclopiazonate-13C0[+Na]+ST000142AN0002252.290E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+QDA adduct]+ST000142AN0002255.160E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C19[+QDA adduct]+ST000142AN0002259.490E-326.250E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C1[+QDA adduct]+ST000142AN0002253.800E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C20[+QDA adduct]+ST000142AN0002252.810E-326.130E-31Treatment;13C-Glc;unlabeled
Cyclopiazonic AcidST000242AN0003754.050E-78.580E-7Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
cyclo(pro-arg)*ST000975AN0015961.400E-21.770E-1REGION;MAK;SUN
Cys-Cys-Pro-SerST001201AN0019983.690E-252.330E-24cell_type;iRBC;unRBC
Cys-Cys-Pro-SerST001201AN0019983.070E-44.610E-3treatment;DHA;DMSO;OZ277;OZ439
Cys-Gly-Pro-SerST001201AN0019992.130E-32.040E-2treatment;DHA;DMSO;OZ277;OZ439
Cys-Gly-Pro-SerST001201AN0019994.240E-26.440E-2cell_type;iRBC;unRBC
Cys-Gly-Pro-SerST001202AN0020012.450E-251.140E-24cell_type;iRBC;unRBC
Cys-Gly-Pro-SerST001202AN0020018.010E-41.580E-3treatment_duration_(h);-;1.5;3;6;9
Cys-Gly-Pro-SerST001204AN0020051.040E-22.080E-2cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001201AN0019992.830E-35.260E-3cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001201AN0019993.810E-21.540E-1treatment;DHA;DMSO;OZ277;OZ439
Cys-Leu-Cys-TyrST001202AN0020012.310E-322.360E-31cell_type;iRBC;unRBC
Cys-Leu-Cys-TyrST001202AN0020011.660E-43.870E-4treatment_duration_(h);-;1.5;3;6;9
Cys-Lys-Met-GlnST000403AN0006422.490E-57.330E-4Glucose labelling;C13 glucose;unlabelled
Cys-Met-Met-PheST000403AN0006431.590E-43.800E-4Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Met-PheST000539AN0008191.900E-34.450E-3Cell type;Mature erythrocyte;Reticulocyte
Cys-Met-Pro-HisST000403AN0006432.930E-33.230E-2Glucose labelling;C13 glucose;unlabelled
Cys-Met-Pro-HisST000539AN0008192.080E-21.890E-1Glucose labelling;C13 glucose;unlabelled
Cys-Met-Tyr-TyrST000403AN0006424.440E-72.620E-4timepoint;1 hour;20 hours
Cys-Met-Tyr-TyrST000403AN0006423.830E-34.190E-2Glucose labelling;C13 glucose;unlabelled
Cys-Met-Tyr-TyrST000539AN0008181.520E-41.100E-2Glucose labelling;C13 glucose;unlabelled
Cys-Met-Tyr-TyrST000539AN0008182.260E-41.010E-2timepoint;1 hour;20 hours
Cys-Phe-Trp-GlyST001201AN0019982.090E-26.980E-2treatment;DHA;DMSO;OZ277;OZ439
Cysteinyl-HydroxyprolineST001202AN0020004.210E-103.950E-9treatment_duration_(h);-;1.5;3;6;9
Cysteinyl-HydroxyprolineST001202AN0020001.300E-41.460E-4cell_type;iRBC;unRBC
Cys-Thr-Cys-CysST000403AN0006424.500E-34.660E-2Glucose labelling;C13 glucose;unlabelled
Cys-Thr-Cys-CysST000539AN0008182.800E-58.280E-5Cell type;Mature erythrocyte;Reticulocyte
Cys-Thr-Ser-TyrST000539AN0008197.860E-31.230E-1timepoint;1 hour;20 hours
Cys-Thr-Ser-TyrST000539AN0008191.220E-22.230E-2Cell type;Mature erythrocyte;Reticulocyte
cytidine-5-monophosphate NISTST000061AN0000993.150E-28.210E-2Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
cytidine-5-monophosphate NISTST000087AN0001391.030E-21.450E-2Time Point;18 hours;4 hours
cytidine-5-monophosphate NISTST000379AN0006131.980E-23.850E-2Time;10min;1hr;24hr;6hr
cytidine-5-monophosphate NISTST000379AN0006133.410E-27.700E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
cytidine-5-monophosphate NISTST000390AN0006261.290E-25.640E-2Tumor Present;No;Yes;-
D1-2-HydroxymethylethisteroneST000046AN0000782.380E-32.700E-2Cognitive Status;AD;CN;MCI
D1-2-HydroxymethylethisteroneST000422AN0006682.670E-38.430E-2treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone-11.471997ST000046AN0000781.030E-31.520E-2Cognitive Status;AD;CN;MCI
D1-2-Hydroxymethylethisterone - 13.49303ST000422AN0006701.610E-25.900E-1treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone - 14.2670965ST000422AN0006702.860E-25.900E-1treatment;ND;T1D good glycemic control
D1-2-Hydroxymethylethisterone - 1.9729741ST000421AN0006645.170E-31.710E-1treatment;ND;T1D poor glycemic control
D1-2-Hydroxymethylethisterone-2.831552ST000046AN0000796.700E-35.350E-2Cognitive Status;AD;CN;MCI
D-1-[(3-Carboxypropyl)amino]-1-deoxyfructoseST001202AN0020014.520E-141.930E-12treatment_duration_(h);-;1.5;3;6;9
d1-piperidine-dicarboxylateST000403AN0006424.350E-51.090E-4Cell type;Mature erythrocyte;Reticulocyte
d1-piperidine-dicarboxylateST000539AN0008188.580E-31.640E-2Cell type;Mature erythrocyte;Reticulocyte
D-2-Amino-hexano-6-lactamST000539AN0008186.490E-38.070E-2timepoint;1 hour;20 hours
D-2-Amino-hexano-6-lactamST000539AN0008184.690E-27.220E-2Cell type;Mature erythrocyte;Reticulocyte
D-2-Amino-hexano-6-lactamST000567AN0008722.680E-61.130E-5Time point;Post;Pre;Baseline
D5-L-Glutamine iSTDST001211AN0020172.960E-41.770E-3Group;Control;Methotrexate
D9-Choline iSTDST001211AN0020173.110E-29.160E-2Group;Control;Methotrexate
D-Alanyl-D-alanineST000356AN0005835.720E-41.170E-3Diagnosis;breast cancer;control
D-Alanyl-D-alanineST000356AN0005832.010E-34.650E-3stage;-;2;3
D-Alanyl-D-alanineST000539AN0008192.630E-39.520E-2timepoint;1 hour;20 hours
D-Alanyl-D-alanineST000539AN0008191.950E-21.860E-1Glucose labelling;C13 glucose;unlabelled
D-AlloseST000980AN0016062.470E-25.820E-2Classification;Mild;Moderate;Non-allergic;Severe
D-Arabino-Hexonic acidST001037AN0016982.800E-71.640E-5Description ;Blank;Reagent Blank;Serum Sample;Solvent
deacetylcolchicineST001201AN0019999.260E-264.660E-25cell_type;iRBC;unRBC
deacetylcolchicineST001202AN0020002.500E-383.600E-37cell_type;iRBC;unRBC
deacetylcolchicineST001202AN0020008.500E-31.150E-2treatment_duration_(h);-;1.5;3;6;9
Deamino-alpha-keto-demethylphosphinothricin-13C0[+QDA adduct]+ST000142AN0002251.550E-28.770E-2Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+13CD3 QDA]+ST000142AN0002251.970E-326.130E-31Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+Na]+ST000142AN0002252.850E-326.130E-31Treatment;13C-Glc;unlabeled
Decosahexaenoic acidST000356AN0005822.700E-222.280E-21Diagnosis;breast cancer;control
Decosahexaenoic acidST000356AN0005828.270E-178.360E-16stage;-;2;3
DecylubiquinolST000567AN0008725.330E-47.870E-4Time point;Post;Pre;Baseline
DecylubiquinolST000567AN0008721.160E-25.370E-2groups;Old-Curcumin;Old-Placebo;young
Dehydrocholic acidST001211AN0020171.520E-41.090E-3Group;Control;Methotrexate
Dehydro-fructose-13C0[+H]+ST000142AN0002259.470E-326.250E-31Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C1[+H]+ST000142AN0002256.630E-326.130E-31Treatment;13C-Glc;unlabeled
Dehydro-L-(+)-ascorbic acid dimerST000567AN0008716.820E-82.270E-7Time point;Post;Pre;Baseline
Dehydropantoate-13C0[+Na]+ST000142AN0002252.530E-326.130E-31Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C0[+QDA adduct+Na]+ST000142AN0002254.350E-22.340E-1Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C1[+QDA adduct+Na]+ST000142AN0002255.610E-326.130E-31Treatment;13C-Glc;unlabeled
delta-Guanidinovaleric acidST000567AN0008727.390E-73.200E-5groups;Old-Curcumin;Old-Placebo;young
delta-Guanidinovaleric acidST000567AN0008726.660E-62.060E-5Time point;Post;Pre;Baseline
DeoxyartemsininST000444AN0006953.380E-25.280E-2Sample Treatment;Bubbled;Control
Deoxycarminomycin-13C0[+QDA adduct]+ST000142AN0002257.550E-326.130E-31Treatment;13C-Glc;unlabeled
Deoxydaunorubicin-13C0[+QDA adduct]+ST000148AN0002353.020E-47.150E-3Treatment;13C-Glc;unlabeled
Deoxydihydro-artemisininST000444AN0006952.160E-25.210E-2Sample Treatment;Bubbled;Control
Deoxyribose phosphateST000450AN0007061.510E-323.070E-31gender;Female;Male
D-erythro-L-galacto-NonuloseST001202AN0020012.540E-333.430E-32cell_type;iRBC;unRBC
D-erythro-L-galacto-NonuloseST001202AN0020011.740E-43.980E-4treatment_duration_(h);-;1.5;3;6;9
D-Erythronic acid ?-lactoneST000614AN0009433.050E-87.420E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
D-Erythronic acid ?-lactoneST000614AN0009433.870E-83.770E-7Diagonsis;Benign;Cancer;Normal
deschlorobenzoyl IndomethacinST000422AN0006671.500E-23.190E-1treatment;ND;T1D good glycemic control
deschlorobenzoyl IndomethacinST000422AN0006682.090E-22.440E-1treatment;ND;T1D good glycemic control
deschlorobenzoylIndomethacinST000046AN0000761.330E-27.650E-2Cognitive Status;AD;CN;MCI
Desmethylmianserin glucuronideST000566AN0008705.590E-61.200E-5Time point;Post;Pre;Baseline
Desmethylmianserin glucuronideST000566AN0008703.270E-21.230E-1group;Old-Curcumin;Old-Placebo;young
DesmethylnimodipineST000047AN0000812.020E-34.190E-2Cognitive Status;AD;CN;MCI
desmethylnortriptylineglucuronideST000047AN0000835.350E-34.490E-2Cognitive Status;AD;CN;MCI
DG(36:2)>DG(18:1_18:1_0:0)ST001325AN0022067.228E-284.437E-27Sample type;batch pool;chear plasma;master pool;red cross pl...
DG(36:2)>DG(18:1_18:1_0:0)ST001325AN0022062.022E-55.999E-5Gender;-;female;male
DG 37:2 (18:2/19:0/0:0) [M+NH4]+ST001111AN0018051.560E-21.990E-2Sample;Benign;Cancer;Metastasis
D-GalacturonateST000403AN0006435.830E-125.260E-11Cell type;Mature erythrocyte;Reticulocyte
D-GalacturonateST000539AN0008192.110E-112.060E-10Cell type;Mature erythrocyte;Reticulocyte
D-GalacturonateST001201AN0019992.790E-24.350E-2cell_type;iRBC;unRBC
D-GalacturonateST001202AN0020015.920E-221.740E-21cell_type;iRBC;unRBC
D-GalacturonateST001202AN0020015.560E-41.170E-3treatment_duration_(h);-;1.5;3;6;9
D-GalacturonateST001205AN0020072.240E-25.990E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
D-glycero-L-galacto-OctuloseST001202AN0020016.430E-201.630E-19cell_type;iRBC;unRBC
D-glycero-L-galacto-OctuloseST001202AN0020013.810E-71.690E-6treatment_duration_(h);-;1.5;3;6;9
D-glycero-L-galacto-OctuloseST001205AN0020076.310E-76.650E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
DiacetylhydrazineST000403AN0006421.330E-43.020E-4Cell type;Mature erythrocyte;Reticulocyte
DiacetylhydrazineST000403AN0006425.000E-24.280E-1timepoint;1 hour;20 hours
DiacetylhydrazineST000539AN0008181.290E-33.450E-2timepoint;1 hour;20 hours
DiacetylmonoximeST000403AN0006421.660E-21.140E-1Glucose labelling;C13 glucose;unlabelled
DiacetylmonoximeST000539AN0008185.930E-31.730E-1Glucose labelling;C13 glucose;unlabelled
DiacetylmonoximeST000539AN0008182.250E-23.790E-2Cell type;Mature erythrocyte;Reticulocyte
DiacetylmonoximeST000539AN0008184.010E-22.330E-1timepoint;1 hour;20 hours
diacetylspermineST000923AN0015136.100E-55.680E-4Diagnosis;CD;nonIBD;UC
diacetylspermineST001000AN0018782.250E-37.240E-3Diagnosis;CD;Control;UC
diacetylspermineST001236AN0020541.580E-58.080E-4OS_Censor (1 means the time is a censoring time and 0 means ...
diacetylspermineST001237AN0020559.340E-185.980E-17CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
diacetylspermineST001237AN0020551.060E-166.790E-15OS_Censor (1 means the time is a censoring time and 0 means ...
diacetylspermineST001237AN0020552.190E-27.140E-2Time point;baseline;week 4;week 8
diacetylspermineST001237AN0020553.880E-21.240E-1Treatment;EVEROLIMUS;NIVOLUMAB
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000016AN0000334.810E-51.040E-4Material;Cells;Media
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000016AN0000332.630E-25.870E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)ST000106AN0001751.070E-21.200E-1Sampling time;0 min;60 min
DIACYL-PHOSPHATIDYLCHOLINEST000044AN0000688.300E-42.810E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
dibenzothiophene-5-oxideST001202AN0020005.880E-128.590E-12cell_type;iRBC;unRBC
dibenzothiophene-5-oxideST001202AN0020001.330E-101.460E-9treatment_duration_(h);-;1.5;3;6;9
dibenzothiophene-5-oxideST001204AN0020041.580E-84.930E-8cell_type;iRBC;unRBC
Dibucaine0cinchocaineST000444AN0006953.420E-25.280E-2Sample Treatment;Bubbled;Control
DichlorophenST000291AN0004644.080E-28.100E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
Dicyclohexyl phthalateST000583AN0008942.620E-21.850E-1time;12-weeks;baseline
Dicyclohexyl phthalateST000583AN0008943.340E-22.650E-1caries status;caries-active;caries-free
Dide-O-methylsimmondsinST001205AN0020077.030E-44.530E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Diethyl adipateST000403AN0006436.040E-31.100E-2Cell type;Mature erythrocyte;Reticulocyte
Diethyl adipateST000403AN0006432.170E-22.300E-1timepoint;1 hour;20 hours
Diethyl adipateST000539AN0008191.120E-76.010E-5timepoint;1 hour;20 hours
Diethyl OxalpropionateST000566AN0008701.670E-48.790E-3group;Old-Curcumin;Old-Placebo;young
Diethyl OxalpropionateST000566AN0008704.510E-24.640E-2Time point;Post;Pre;Baseline
Digitoxigenin bisdigitoxosideST000242AN0003756.820E-92.040E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Digitoxigenin bisdigitoxosideST000242AN0003771.140E-71.490E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
DiglycolicacidST000046AN0000783.180E-21.220E-1Cognitive Status;AD;CN;MCI
Digoxigenin bisdigitoxosideST000242AN0003774.600E-21.030E-1Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
DIHEXOSEST000016AN0000332.330E-315.060E-30Material;Cells;Media
DIHEXOSEST000105AN0001731.710E-101.760E-8Sampling;After SWS onset;Morning fasting
DIHEXOSEST000105AN0001747.890E-111.510E-8Sampling;After SWS onset;Morning fasting
DIHEXOSEST000106AN0001751.620E-47.560E-3Sampling time;0 min;60 min
DIHEXOSEST000106AN0001762.710E-54.980E-4Sampling time;0 min;60 min
dihomocitrateST000403AN0006433.880E-163.790E-14Cell type;Mature erythrocyte;Reticulocyte
dihomocitrateST000539AN0008193.710E-113.480E-10Cell type;Mature erythrocyte;Reticulocyte
Dihomo-?-Linolenic AcidST000553AN0008461.740E-131.280E-12Sample type;Plasma;Urine
Dihydrocarminomycin-13C0[+13CD3 QDA]+ST000142AN0002256.170E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydro Cer (d18:0/16:0)ST000553AN0008461.990E-83.120E-8Sample type;Plasma;Urine
Dihydrodaunorubicin-13C0[+13CD3 QDA]+ST000148AN0002353.340E-32.300E-2Treatment;13C-Glc;unlabeled
DIHYDROFISSINOLIDEST000046AN0000766.010E-61.680E-4Cognitive Status;AD;CN;MCI
DihydrogenphosphateST001204AN0020055.260E-193.950E-18cell_type;iRBC;unRBC
DihydrogenphosphateST001204AN0020056.660E-31.110E-1treatment_duration_(h);-;3;6;9
dihydrogeranylgeranyl-bacteriopheophytinST001205AN0020074.590E-31.770E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Dihydrogossypetin-13C0[+13CD3 QDA]+ST000142AN0002256.730E-326.130E-31Treatment;13C-Glc;unlabeled
dihydro-keto-PGF2a-13C0[+Na]+ST000142AN0002256.970E-326.130E-31Treatment;13C-Glc;unlabeled
DIHYDROMUNDULETONEST000046AN0000782.240E-32.630E-2Cognitive Status;AD;CN;MCI
DIHYDROSPATHELIACHROMENEST000047AN0000802.210E-21.880E-1Cognitive Status;AD;CN;MCI
DIHYDROSPATHELIACHROMENEST000422AN0006683.650E-38.430E-2treatment;ND;T1D good glycemic control
Dihydroxanthommatin-13C0[+13CD3 QDA]+ST000142AN0002253.550E-326.130E-31Treatment;13C-Glc;unlabeled
DihydroxyacetophenoneST001039AN0017121.280E-22.220E-2Sample.Matrix;Plasma;Urine
Dihydroxychromone-13C0[+H]+ST000142AN0002258.780E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C1[+H]+ST000142AN0002258.300E-326.130E-31Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C3[+H]+ST000142AN0002251.050E-316.700E-31Treatment;13C-Glc;unlabeled
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)ST000016AN0000339.240E-31.430E-2Material;Cells;Media
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)ST000016AN0000334.220E-21.170E-1Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (POSSIBLY)ST000041AN0000633.420E-23.160E-1Group;Control;NAFLD
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000331.020E-52.430E-5Material;Cells;Media
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000338.090E-42.710E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000016AN0000332.300E-31.040E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000105AN0001733.480E-58.440E-4Sampling;After SWS onset;Morning fasting
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)ST000105AN0001733.920E-37.680E-2Gender;Female;Male
DimenhydrinateST000444AN0006952.990E-25.280E-2Sample Treatment;Bubbled;Control
DimethylallylaminopurineST000553AN0008461.920E-104.880E-10Sample type;Plasma;Urine
DimethylallylpyrophosphateST000356AN0005835.980E-41.200E-3Diagnosis;breast cancer;control
DimethylallylpyrophosphateST000356AN0005831.380E-22.580E-2stage;-;2;3
Dimethylarsinous acidST000241AN0003731.330E-62.860E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
DIMETHYLCAFFEIC ACIDST000421AN0006642.570E-75.100E-5treatment;ND;T1D poor glycemic control
DIMETHYLCAFFEIC ACIDST000422AN0006688.490E-31.350E-1treatment;ND;T1D good glycemic control
DIMETHYLXANTHINEST000016AN0000335.180E-53.460E-4Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DIMETHYLXANTHINEST000016AN0000331.790E-43.600E-4Material;Cells;Media
DIMETHYLXANTHINEST000016AN0000333.890E-41.480E-3Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
DIMETHYLXANTHINEST000105AN0001731.060E-27.280E-2Sampling;After SWS onset;Morning fasting
DIMETHYLXANTHINE (*)ST000105AN0001732.400E-43.800E-3Sampling;After SWS onset;Morning fasting
DIMETHYLXANTHINE (*)ST000105AN0001734.790E-24.390E-1Gender;Female;Male
Dinoterb (herbicide)ST000583AN0008953.410E-21.830E-1time;12-weeks;baseline
di-n-UndecylamineST000403AN0006424.980E-152.260E-13Cell type;Mature erythrocyte;Reticulocyte
di-n-UndecylamineST000539AN0008186.430E-115.390E-10Cell type;Mature erythrocyte;Reticulocyte
DIOLEOYLPHOSPHATIDYLCHOLINEST000016AN0000334.600E-71.260E-6Material;Cells;Media
DIOLEOYLPHOSPHATIDYLCHOLINEST000016AN0000331.540E-25.270E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
DIOLEOYLPHOSPHATIDYLCHOLINEST000106AN0001758.250E-54.530E-3Sampling time;0 min;60 min
DiphenylmethylphosphineST000567AN0008716.890E-72.140E-6Time point;Post;Pre;Baseline
DiphenylmethylphosphineoxideST000046AN0000782.700E-47.070E-3Cognitive Status;AD;CN;MCI
Dipropylene glycolST000583AN0008943.360E-42.620E-2caries status;caries-active;caries-free
DisaccharideST000586AN0009015.980E-374.570E-36Plasma Volume;0 uL;150 uL;700 uL
DisaccharideST000589AN0009043.570E-1261.800E-125Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucoseST000475AN0007401.370E-22.160E-2Treatment;-;MDH inhib
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucoseST000956AN0015691.320E-34.000E-3Treatment;Condition-1;Condition-2;Condition-3;Control
Disialyllacto-N-tetraoseST000241AN0003731.430E-95.060E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Disialyllacto-N-tetraoseST000241AN0003731.770E-28.770E-2Concentration (uM);0;500
DityrosineST000444AN0006953.680E-25.570E-2Sample Treatment;Bubbled;Control
Divinylprotochlorophyllide-13C0[+QDA adduct]+ST000142AN0002256.730E-326.130E-31Treatment;13C-Glc;unlabeled
D/L Glucosamine / D/L GalactosamineST001040AN0017024.560E-28.310E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
D/L Glucosamine / D/L GalactosamineST001048AN0017169.910E-111.540E-10Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
D/L Glucosamine / D/L Galactosamine / D-MannosamineST001048AN0017161.190E-111.950E-11Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
DL-?-Lipoic AcidST000566AN0008701.160E-31.470E-3Time point;Post;Pre;Baseline
DL-Methionine sulfoneST000403AN0006424.960E-123.840E-11Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfoneST000539AN0008183.750E-61.320E-5Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfoneST001202AN0020005.570E-117.480E-10treatment_duration_(h);-;1.5;3;6;9
D/L N-Acetylgalactosamine / D/L N-Acetylglucosamine / D/L N-AcetylmannosamineST001040AN0017027.970E-69.900E-5Sample Type/Matrix;Pooled quality control sample;urine;Water...
D/L N-Acetylglucosamine / D/L N-Acetylgalactosamine / D/L N-AcetylmannosamineST001048AN0017165.780E-517.720E-50Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
D-MANNOSAMINE (CAS# 14307-02-9); (M+H)+[-H2O]ST000689AN0010641.520E-37.720E-3Construct;-;Control lentivirus;Noxa knockdown
D-Mannose /D-AlloseST000980AN0016061.600E-33.060E-2Classification;Mild;Moderate;Non-allergic;Severe
DMGVST001192AN0019841.280E-21.780E-1Diet;-;Omnivore;Vegetarian
DMGVST001236AN0020541.350E-26.930E-2OS_Censor (1 means the time is a censoring time and 0 means ...
DMGVST001236AN0020541.870E-21.940E-1Nivolumab Dose (mg/kg);0.3;10;2
DMGVST001237AN0020555.980E-205.110E-19CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
DMGVST001237AN0020552.960E-113.370E-10OS_Censor (1 means the time is a censoring time and 0 means ...
DMGVST001237AN0020551.350E-28.630E-2Prior antiangiogenic regimens (≥2);FALSE;TRUE
DMNTST000403AN0006427.820E-31.370E-2Cell type;Mature erythrocyte;Reticulocyte
DOCOSADIENOATEST000009AN0000243.130E-54.140E-4gender;female;male
DOCOSADIENOATE (*)ST000105AN0001745.610E-33.090E-2Sampling;After SWS onset;Morning fasting
docosahexaenoylcholineST000899AN0014632.130E-36.650E-3Type;Control;Crohn disease;Ulcerative Colitis
DOCOSAHEXAENOYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.350E-48.360E-4Material;Cells;Media
Docosahexaenoyl PAF C-16ST000553AN0008453.720E-109.140E-10Sample type;Plasma;Urine
Docosahexaenoyl PAF C-16ST000553AN0008466.510E-91.260E-8Sample type;Plasma;Urine
DOCOSAPENTAENOATE (*)ST000105AN0001745.380E-56.630E-4Sampling;After SWS onset;Morning fasting
DOCOSAPENTAENOATE (*)ST000106AN0001764.020E-102.320E-8Sampling time;0 min;60 min
DOCOSAPENTAENOATE (*)ST000106AN0001764.330E-25.150E-1Visit;1;2
Dolichyl beta-D-mannosyl phosphateST000241AN0003738.010E-102.980E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
DOPA/TyrST000544AN0008262.740E-31.030E-2Sample Type;Control;Replicate
DOPA/TyrST000545AN0008292.740E-33.560E-2Sample Type;Control;Replicate
D-O-PhosphoserineST001202AN0020001.800E-153.100E-15cell_type;iRBC;unRBC
D-O-PhosphoserineST001202AN0020004.550E-71.710E-6treatment_duration_(h);-;1.5;3;6;9
D-PhenyllacticacidST000046AN0000781.510E-27.650E-2Cognitive Status;AD;CN;MCI
D-Ribose;ALDOPENTOSEST000956AN0015685.250E-41.460E-3Treatment;Condition-1;Condition-2;Condition-3;Control
DSGEGDFXAEGGGVR*ST000974AN0015951.620E-25.340E-2REGION;AHRI;MRC;SUN
dXMPST000403AN0006433.910E-123.710E-11Cell type;Mature erythrocyte;Reticulocyte
dXMPST000539AN0008191.580E-111.590E-10Cell type;Mature erythrocyte;Reticulocyte
(E)-2-Butenyl-4-methyl-threonineST000567AN0008723.670E-45.310E-3groups;Old-Curcumin;Old-Placebo;young
(E)-2-Butenyl-4-methyl-threonineST000567AN0008723.790E-45.730E-4Time point;Post;Pre;Baseline
EB1213ST000047AN0000812.270E-21.610E-1Cognitive Status;AD;CN;MCI
EDOXUDINEST000422AN0006683.500E-38.430E-2treatment;ND;T1D good glycemic control
EdrophoniumST000444AN0006953.230E-25.280E-2Sample Treatment;Bubbled;Control
Eicosapentaenoyl PAF C-16ST000553AN0008452.900E-121.570E-11Sample type;Plasma;Urine
Eicosapentaenoyl PAF C-16ST000553AN0008462.740E-121.210E-11Sample type;Plasma;Urine
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINEST000016AN0000332.920E-141.550E-13Material;Cells;Media
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINEST000016AN0000335.890E-31.560E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE (*)ST000105AN0001731.830E-21.120E-1Sampling;After SWS onset;Morning fasting
Elaidate / Oleate /PetroselinateST001040AN0017036.700E-75.360E-6Sample Type/Matrix;Pooled quality control sample;urine;Water...
Elaidate / Oleate /PetroselinateST001048AN0017171.250E-236.660E-23Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
enolpyruvate NISTST000087AN0001399.390E-31.350E-2Time Point;18 hours;4 hours
enolpyruvate NISTST000381AN0006154.500E-31.700E-2Cohort;CSMC;INHA
EPC(d33:1)ST001202AN0020002.220E-81.280E-7treatment_duration_(h);-;1.5;3;6;9
EPC(d33:1)ST001202AN0020002.410E-32.640E-3cell_type;iRBC;unRBC
EPC(d37:1)ST001205AN0020065.990E-43.250E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d37:2)ST001205AN0020061.200E-35.780E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
EPC(d39:1)ST001205AN0020061.580E-36.780E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
EPIAFZELECHINTRIMETHYLETHERST000046AN0000794.100E-21.440E-1Cognitive Status;AD;CN;MCI
epibrassinolide+HCOOHST001325AN0022077.898E-127.437E-11Gender;-;female;male
epibrassinolide+HCOOHST001325AN0022074.327E-101.577E-9Sample type;batch pool;chear plasma;master pool;red cross pl...
EPICATECHINPENTAACETATEST000047AN0000811.410E-41.000E-2Cognitive Status;AD;CN;MCI
Epothilone C-13C0[+H]+ST000142AN0002256.420E-326.130E-31Treatment;13C-Glc;unlabeled
EpoxomicinST000567AN0008711.250E-84.370E-8Time point;Post;Pre;Baseline
epsilon-caprolactam (likely)ST000420AN0006621.450E-22.120E-2Group;nonsmoker;smoker
ErgineST000242AN0003774.900E-21.070E-1Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ErucateST001317AN0021935.968E-81.073E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
ErucateST001317AN0021935.968E-81.073E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
ErythrotetrofuranoseST000356AN0005824.360E-71.190E-6Diagnosis;breast cancer;control
ErythrotetrofuranoseST000356AN0005822.070E-44.870E-4stage;-;2;3
Erythrulose 1-phosphateST000403AN0006426.160E-92.620E-8Cell type;Mature erythrocyte;Reticulocyte
Erythrulose 1-phosphateST000539AN0008183.740E-51.090E-4Cell type;Mature erythrocyte;Reticulocyte
Estriol 3-sulfate 16-glucuronideST000241AN0003733.370E-88.730E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
ethanedisulfonateST000403AN0006431.050E-32.150E-3Cell type;Mature erythrocyte;Reticulocyte
ethanedisulfonateST000539AN0008194.700E-92.770E-8Cell type;Mature erythrocyte;Reticulocyte
Ethanol diglycine (EDTA decomposition product)ST000586AN0009017.510E-282.800E-27Plasma Volume;0 uL;150 uL;700 uL
EthosuximideM7ST000046AN0000771.370E-35.240E-2Cognitive Status;AD;CN;MCI
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000403AN0006433.080E-35.960E-2timepoint;1 hour;20 hours
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000403AN0006435.640E-34.790E-2Glucose labelling;C13 glucose;unlabelled
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000539AN0008193.390E-25.620E-2Cell type;Mature erythrocyte;Reticulocyte
ethyl-(2R)-methyl-(3S)-hydroxybutanoateST000539AN0008193.480E-22.630E-1Glucose labelling;C13 glucose;unlabelled
ETHYL 3-INDOLE ACETATEST000016AN0000333.900E-36.500E-3Material;Cells;Media
ETHYL 3-INDOLE ACETATEST000105AN0001732.080E-22.440E-1Gender;Female;Male
ETHYL 3-INDOLE ACETATEST000105AN0001732.330E-22.990E-1PCOS;No PCOS;PCOS
ETHYL 3-UREIDOPROPIONATE (M+H)+ST000726AN0011394.570E-34.400E-2DISEASE_STATE;Control;PCOS
ETHYL 3-UREIDOPROPIONATE (M+H)+ST000726AN0011393.190E-26.770E-2Timepoint;-;270;120;30;90
Ethylmalonate/Methyl MalonateST000614AN0009391.140E-61.720E-6Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Ethylmalonate/Methyl MalonateST000614AN0009396.340E-61.060E-5Diagonsis;Benign;Cancer;Normal
ethylpyruvateST000403AN0006437.770E-41.640E-3Cell type;Mature erythrocyte;Reticulocyte
ethylpyruvateST000539AN0008194.670E-41.250E-3Cell type;Mature erythrocyte;Reticulocyte
EuparinST000567AN0008711.910E-41.240E-3groups;Old-Curcumin;Old-Placebo;young
F1P/F6P/G1P/G6PST001142AN0018766.960E-141.420E-13Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
F1P/F6P/G1P/G6PST001142AN0018764.930E-131.820E-12Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
[FA (10:1/2:0)] 2E-Decenedioic acidST000403AN0006431.600E-51.980E-3timepoint;1 hour;20 hours
[FA (10:1/2:0)] 2E-Decenedioic acidST000403AN0006434.700E-34.360E-2Glucose labelling;C13 glucose;unlabelled
[FA (10:1/2:0)] 2E-Decenedioic acidST000539AN0008194.970E-27.880E-2Cell type;Mature erythrocyte;Reticulocyte
FA (14:1) (physeteric acid)ST001211AN0020192.260E-47.630E-4Group;Control;Methotrexate
[FA (8:1)] 2Z-octenoic acidST000403AN0006431.770E-33.540E-3Cell type;Mature erythrocyte;Reticulocyte
[FA (8:1)] 2Z-octenoic acidST000403AN0006431.770E-29.900E-2Glucose labelling;C13 glucose;unlabelled
[FA (8:1)] 2Z-octenoic acidST000539AN0008197.730E-41.990E-3Cell type;Mature erythrocyte;Reticulocyte
FA hydroxy(10:0)ST001202AN0020011.390E-172.980E-17cell_type;iRBC;unRBC
FA hydroxy(10:0)ST001202AN0020013.990E-51.060E-4treatment_duration_(h);-;1.5;3;6;9
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acidST000403AN0006432.930E-46.690E-4Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acidST000539AN0008191.320E-22.400E-2Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acidST000403AN0006434.990E-53.380E-3timepoint;1 hour;20 hours
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acidST000539AN0008198.060E-44.320E-2timepoint;1 hour;20 hours
FA hydroxy(16:0)] hexadecanoic acidST001202AN0020011.750E-82.210E-8cell_type;iRBC;unRBC
FA hydroxy(18:0)ST001202AN0020013.520E-74.210E-7cell_type;iRBC;unRBC
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acidST000403AN0006432.190E-77.510E-7Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acidST000539AN0008191.190E-22.180E-2Cell type;Mature erythrocyte;Reticulocyte
FA hydroxy(18:1)]ST001204AN0020043.160E-25.060E-2cell_type;iRBC;unRBC
FA hydroxy(18:1)]ST001205AN0020079.210E-33.060E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
[FA hydroxy(9:1)] 4-hydroxy-2-nonenalST000403AN0006423.890E-37.200E-3Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(9:1)] 4-hydroxy-2-nonenalST000539AN0008183.970E-36.760E-2timepoint;1 hour;20 hours
FA methyl(14:0)ST001202AN0020014.720E-137.470E-13cell_type;iRBC;unRBC
FA methyl(14:0)ST001202AN0020013.580E-25.060E-2treatment_duration_(h);-;1.5;3;6;9
[FA methyl(14:0)] 12-methyl-tetradecanoic acidST000403AN0006432.180E-55.920E-5Cell type;Mature erythrocyte;Reticulocyte
[FA methyl(14:0)] 12-methyl-tetradecanoic acidST000539AN0008191.120E-97.330E-9Cell type;Mature erythrocyte;Reticulocyte
FA methyl(16:1)ST001202AN0020013.220E-145.520E-14cell_type;iRBC;unRBC
FA methyl(16:1)ST001202AN0020012.460E-23.550E-2treatment_duration_(h);-;1.5;3;6;9
FA methyl(16:1)ST001205AN0020072.440E-26.440E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
FA methyl(18:0)ST001202AN0020019.430E-161.830E-15cell_type;iRBC;unRBC
FA methyl(18:0)ST001202AN0020014.770E-38.080E-3treatment_duration_(h);-;1.5;3;6;9
FA methyl(6:0)ST001202AN0020013.720E-231.320E-22cell_type;iRBC;unRBC
FA methyl(6:0)ST001202AN0020011.460E-43.470E-4treatment_duration_(h);-;1.5;3;6;9
[FA methyl(6:0)] 2-methyl-hexanoic acidST000403AN0006438.260E-42.530E-2timepoint;1 hour;20 hours
[FA methyl(6:0)] 2-methyl-hexanoic acidST000539AN0008191.140E-22.110E-2Cell type;Mature erythrocyte;Reticulocyte
FA methyl(8:0)ST001202AN0020011.110E-131.820E-13cell_type;iRBC;unRBC
FA methyl(8:0)ST001202AN0020012.020E-22.960E-2treatment_duration_(h);-;1.5;3;6;9
FA methyl (8:1)ST001202AN0020011.540E-235.710E-23cell_type;iRBC;unRBC
FA methyl (8:1)ST001202AN0020011.490E-22.220E-2treatment_duration_(h);-;1.5;3;6;9
FAMPRIDINEST000422AN0006682.430E-22.680E-1treatment;ND;T1D good glycemic control
FA oxo(16:0)ST001202AN0020011.630E-61.910E-6cell_type;iRBC;unRBC
FA oxo(18:0)ST001202AN0020014.220E-74.980E-7cell_type;iRBC;unRBC
FA oxo(19:0)ST001201AN0019987.550E-328.440E-31cell_type;iRBC;unRBC
FA oxo(21:0)ST001201AN0019982.710E-415.290E-40cell_type;iRBC;unRBC
[FA oxo(7:0)] 2-oxo-heptanoic acidST000403AN0006434.420E-48.060E-3Glucose labelling;C13 glucose;unlabelled
[FA oxo(7:0)] 2-oxo-heptanoic acidST000403AN0006431.100E-21.450E-1timepoint;1 hour;20 hours
[FA oxo(7:0)] 2-oxo-heptanoic acidST000539AN0008191.410E-22.550E-2Cell type;Mature erythrocyte;Reticulocyte
[FA oxo(8:0)] 3-oxo-octanoic acidST000403AN0006431.410E-31.870E-2Glucose labelling;C13 glucose;unlabelled
[FA oxo(8:0)] 3-oxo-octanoic acidST000539AN0008195.530E-51.700E-4Cell type;Mature erythrocyte;Reticulocyte
farnesolST000568AN0008741.660E-112.850E-11Genotype;AA;AC;CC
FBPST000302AN0004801.520E-22.870E-2Labelint time (hours);0;1;24;3;48;72
FenoterolsulfateST000047AN0000822.930E-21.590E-1Cognitive Status;AD;CN;MCI
Ferrous lactateST000291AN0004653.460E-26.800E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
F-Honaucin AST000242AN0003765.440E-45.930E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Fibrinopeptide A (3-15)**ST000975AN0015962.810E-23.780E-1TIMEPOINT;BL;M06;M18
Fibrinopeptide A (4-15)**ST000975AN0015966.060E-37.640E-2GROUP;case;control
Fibrinopeptide B (1-11)**ST000975AN0015963.190E-31.610E-2GENDER;F;M
Fibrinopeptide B (1-12)**ST000975AN0015961.710E-22.840E-1TIMEPOINT;BL;M06;M18
Fibrinopeptide B (1-13)**ST000974AN0015953.670E-21.060E-1REGION;AHRI;MRC;SUN
Fibrinopeptide B (1-9)**ST000974AN0015956.390E-95.880E-8REGION;AHRI;MRC;SUN
Fibrinopeptide B (1-9)**ST000975AN0015961.410E-33.550E-2GROUP;case;control
Fibrinopeptide B (1-9)**ST000975AN0015968.510E-32.080E-1TIMEPOINT;BL;M06;M18
Fisher ratioST000544AN0008267.830E-32.790E-2Sample Type;Control;Replicate
Fisher ratioST000545AN0008291.970E-41.470E-2Sample Type;Control;Replicate
FKGK 11ST000242AN0003755.550E-103.630E-9Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
FKGK 11ST000242AN0003771.770E-24.940E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Flavonoid or short-chain cholesterol esterST000586AN0009012.210E-63.710E-6Plasma Volume;0 uL;150 uL;700 uL
Flavonol 3-O-beta-glucosyl-(1->2)-beta-glucoside-13C0[+QDA adduct]+ST000142AN0002258.050E-326.130E-31Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C0[+13CD3 QDA]+ST000142AN0002259.430E-336.130E-31Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C1[+QDA adduct]+ST000148AN0002351.250E-105.430E-7Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C23[+QDA adduct]+ST000148AN0002351.610E-52.710E-3Treatment;13C-Glc;unlabeled
FluoresceinmonoglucuronideST000047AN0000811.960E-34.190E-2Cognitive Status;AD;CN;MCI
fluphenazineenanthateST000047AN0000814.610E-22.150E-1Cognitive Status;AD;CN;MCI
FluroxypyrST000566AN0008696.080E-51.530E-4Time point;Post;Pre;Baseline
FMLPST000403AN0006425.010E-102.570E-9Cell type;Mature erythrocyte;Reticulocyte
FMLPST000539AN0008181.260E-43.360E-4Cell type;Mature erythrocyte;Reticulocyte
Frctose-6-PhosphateST000614AN0009403.460E-35.100E-3Diagonsis;Benign;Cancer;Normal
Frctose-6-PhosphateST000614AN0009409.140E-31.130E-2Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
FructoselysineST000403AN0006422.200E-72.170E-5Glucose labelling;C13 glucose;unlabelled
FructoselysineST000539AN0008182.090E-23.580E-2Cell type;Mature erythrocyte;Reticulocyte
Fructoselysine 2ST000539AN0008182.090E-23.580E-2Cell type;Mature erythrocyte;Reticulocyte
fucose + rhamnoseST000369AN0006031.020E-23.300E-2Smoker;Current;Former;NA
fucose + rhamnoseST000369AN0006033.300E-28.530E-2Gender;F;M;NA
fucose+ rhamnoseST000390AN0006269.210E-34.550E-2Tumor Present;No;Yes;-
fumarate/maleate/alpha-ketoisovalerateST001142AN0018761.800E-175.300E-17Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
fumarate/maleate/alpha-ketoisovalerateST001142AN0018762.320E-22.680E-2Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
FumaricST000284AN0004524.470E-21.530E-1Patient group;CRC;Healthy;Polyp
Fummarate M0ST000507AN0007762.780E-35.790E-3Time (incubation);24 hours;72 hours
Fummarate M+4ST000507AN0007761.680E-33.690E-3Time (incubation);24 hours;72 hours
FuramizoleST000291AN0004655.790E-42.890E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
Furfural diethyl acetalST000403AN0006431.580E-31.940E-2Glucose labelling;C13 glucose;unlabelled
Furfural diethyl acetalST000539AN0008191.250E-33.030E-3Cell type;Mature erythrocyte;Reticulocyte
Furfuryl alcoholST000292AN0004663.370E-38.440E-2Treatment ;Baseline plasma;Plasma after drinking apple juice...
FurmecycloxST000567AN0008711.210E-63.700E-6Time point;Post;Pre;Baseline
furoylglycine NISTST000381AN0006151.960E-39.540E-3Cohort;CSMC;INHA
[Fv] Desmosdumotin CST000403AN0006425.260E-31.110E-1timepoint;1 hour;20 hours
[Fv] Desmosdumotin CST000403AN0006421.260E-22.130E-2Cell type;Mature erythrocyte;Reticulocyte
[Fv] Desmosdumotin CST000539AN0008181.650E-169.540E-14timepoint;1 hour;20 hours
[Fv] Desmosdumotin CST000539AN0008183.850E-24.280E-1Glucose labelling;C13 glucose;unlabelled
[Fv] HomofleminginST000403AN0006421.490E-32.860E-3Cell type;Mature erythrocyte;Reticulocyte
[Fv] HomofleminginST000539AN0008184.010E-41.660E-2timepoint;1 hour;20 hours
[Fv] Ovalitenin AST000403AN0006422.200E-44.840E-4Cell type;Mature erythrocyte;Reticulocyte
[Fv] Ovalitenin AST000539AN0008188.120E-89.410E-6timepoint;1 hour;20 hours
G3PST000301AN0004798.830E-88.240E-7Cell Line;L229;LN18;Pooled glioblastoma;U-138
G3PST000302AN0004801.210E-22.740E-2Labelint time (hours);0;1;24;3;48;72
GAB-13C0ST000114AN0001941.430E-949.960E-93Oxygen Condition;hypoxia;normoxia
GAB-13C0ST001045AN0017092.550E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
GAB-13C3ST001046AN0017105.330E-31.530E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
GAB-ALLST000110AN0001852.400E-26.370E-2Oxygen Condition;hypoxia;normoxia
GAB-ALLST000113AN0001912.400E-24.370E-1Oxygen Condition;hypoxia;normoxia
GAB-ALLST000114AN0001941.430E-949.960E-93Oxygen Condition;hypoxia;normoxia
GAB-ALLST001045AN0017097.970E-37.720E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Gal?1-3Gal?1-4GlcNAc?-SpST000242AN0003771.120E-46.330E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Galabiosylceramide (d18:1/16:0)ST000567AN0008724.960E-35.940E-3Time point;Post;Pre;Baseline
Galabiosylceramide (d18:1/26:0)ST000241AN0003736.080E-157.880E-14Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
GalactinoldihydrateST000403AN0006433.700E-91.870E-8Cell type;Mature erythrocyte;Reticulocyte
GalactinoldihydrateST000539AN0008191.590E-66.250E-6Cell type;Mature erythrocyte;Reticulocyte
Galacto-N-bioseST001211AN0020175.240E-66.260E-5Group;Control;Methotrexate
Galactose-N-acetylgalactosamineST001104AN0017964.990E-337.630E-33Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
Galactose-N-acetylgalactosamine-SLST001104AN0017969.310E-342.330E-33Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
Galacturonate / GlucuronateST001040AN0017028.370E-43.610E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))ST001202AN0020011.180E-81.510E-8cell_type;iRBC;unRBC
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))ST001202AN0020011.760E-33.230E-3treatment_duration_(h);-;1.5;3;6;9
gama-AminobutyrateST000284AN0004522.130E-21.150E-1Patient group;CRC;Healthy;Polyp
gamma-CEHC glucuronideST000899AN0014643.230E-41.380E-3Type;Control;Crohn disease;Ulcerative Colitis
gamma-CEHC glucuronide*ST000974AN0015952.690E-51.720E-4REGION;AHRI;MRC;SUN
gamma-glutamyl-2-aminobutyrateST000899AN0014621.960E-53.930E-4Type;Control;Crohn disease;Ulcerative Colitis
gamma-glutamyllysineST000975AN0015966.800E-33.090E-2GENDER;F;M
gamma-glutamyllysineST000976AN0015972.510E-22.830E-1GENDER;F;M
gamma-Hydroxyphenylbutazone glucuronideST000421AN0006661.940E-31.900E-1treatment;ND;T1D poor glycemic control
gamma-HydroxyphenylbutazoneglucuronideST000047AN0000833.820E-33.830E-2Cognitive Status;AD;CN;MCI
gamma-Muricholic acidST000553AN0008453.390E-108.720E-10Sample type;Plasma;Urine
gamma-Muricholic acidST000553AN0008463.000E-107.080E-10Sample type;Plasma;Urine
gamma-thiomethyl glutamateST001201AN0019982.430E-435.580E-42cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001202AN0020009.020E-591.820E-56cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001204AN0020041.840E-161.170E-15cell_type;iRBC;unRBC
gamma-thiomethyl glutamateST001205AN0020061.480E-36.620E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Ganglioside GA1 (d18:1/24:0)ST001202AN0020001.350E-122.030E-12cell_type;iRBC;unRBC
Ganglioside GA1 (d18:1/24:1(15Z))ST001205AN0020062.300E-24.380E-1treatment_duration_(h);1;5;3
Ganglioside GM3 (d18:0/16:0)ST000241AN0003731.360E-62.910E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ganglioside GM3 (d18:0/24:0)ST000241AN0003731.470E-42.350E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ganglioside GT3 (d18:1/18:1(11Z))ST000241AN0003731.830E-107.660E-10Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
GC(18:2/16:0)ST000450AN0007055.570E-92.170E-8gender;Female;Male
GD1b (36:2)-13C0[+13CD3 QDA]+ST000142AN0002251.030E-316.620E-31Treatment;13C-Glc;unlabeled
GemeprostST000421AN0006654.710E-24.500E-1treatment;ND;T1D poor glycemic control
Gemeprost + 11.412178ST000421AN0006654.410E-24.500E-1treatment;ND;T1D poor glycemic control
GemfibrozilM2ST000046AN0000783.700E-21.320E-1Cognitive Status;AD;CN;MCI
GentamicinST000444AN0006952.060E-25.210E-2Sample Treatment;Bubbled;Control
GentianaineST000539AN0008183.480E-37.280E-3Cell type;Mature erythrocyte;Reticulocyte
GentianaineST000539AN0008182.270E-21.640E-1timepoint;1 hour;20 hours
GentianaineST000539AN0008182.400E-23.640E-1Glucose labelling;C13 glucose;unlabelled
Geranylchrysin-13C0[+13CD3 QDA]+ST000142AN0002251.150E-317.100E-31Treatment;13C-Glc;unlabeled
Geranylgeranylacetone-13C0[+QDA adduct]+ST000148AN0002353.640E-32.440E-2Treatment;13C-Glc;unlabeled
Ginsenoside ReST001191AN0019832.220E-61.780E-5Treatment;Control;QC;Sample
Ginsenoside Rg3ST001191AN0019836.790E-63.920E-5Treatment;Control;QC;Sample
Gln-Leu-Lys-HisST000403AN0006421.010E-31.980E-3Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-HisST000403AN0006424.890E-22.310E-1Glucose labelling;C13 glucose;unlabelled
Gln-Leu-Lys-HisST000539AN0008181.030E-21.920E-2Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-HisST000539AN0008184.790E-22.570E-1timepoint;1 hour;20 hours
Gln-Leu-Lys-TyrST001202AN0020011.070E-182.440E-18cell_type;iRBC;unRBC
Gln-Leu-Lys-TyrST001202AN0020013.230E-35.630E-3treatment_duration_(h);-;1.5;3;6;9
Gln-Phe-Gln-HisST001205AN0020073.580E-29.130E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Gl-OH3PST000301AN0004794.000E-38.300E-3Cell Line;L229;LN18;Pooled glioblastoma;U-138
GLUCARIC/GULARIC/SACCHARIC ACIDST000016AN0000335.850E-71.580E-6Material;Cells;Media
GLUCARIC/GULARIC/SACCHARIC ACIDST000041AN0000639.810E-31.500E-1Group;Control;NAFLD
GlucocerebrosidesST000242AN0003773.060E-52.020E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Gluconic acid or similar sugar acidST000586AN0009011.190E-414.470E-40Plasma Volume;0 uL;150 uL;700 uL
Gluconic acid or similar sugar acid 2ST000586AN0009019.870E-355.810E-34Plasma Volume;0 uL;150 uL;700 uL
Glucosamine/GalactosamineST000614AN0009394.400E-186.780E-17Diagonsis;Benign;Cancer;Normal
Glucosamine/GalactosamineST000614AN0009391.670E-171.830E-16Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
GLUCOSAMINE/MANNOSAMINEST000424AN0006733.280E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
GLUCOSAMINE/MANNOSAMINEST000475AN0007397.440E-41.370E-3Treatment;-;MDH inhib
glucose-6-phosphate minorST000420AN0006621.750E-32.890E-3Group;nonsmoker;smoker
GLUCOSE/FRUCTOSE-PHOSPHATEST000424AN0006731.540E-22.970E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
GLUCOSE/FRUCTOSE-PHOSPHATEST000956AN0015681.260E-44.070E-4Treatment;Condition-1;Condition-2;Condition-3;Control
glucosylglycerolST000092AN0001462.800E-1393.550E-138Solution Added;N/A;None;Urease;Water
glucosylglycerolST000092AN0001461.440E-792.740E-78Volume Urine (µL);100;10;25;50;5
glucosylglycerolST000092AN0001461.500E-515.710E-50Gender;N/A;Female;Male
glucosylglycerolST000092AN0001463.050E-491.160E-47Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
glucosylglycerolST000092AN0001469.150E-126.130E-11Urease Treatment;No treatment;Urease pre-treatment;Water pre...
glucuronide of piperine metabolite C17H21NO3 (3)*ST000974AN0015951.610E-91.630E-8REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (3)*ST000974AN0015951.010E-33.270E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015963.190E-36.400E-2REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015966.450E-32.970E-2GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (3)*ST000975AN0015962.530E-21.600E-1GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000974AN0015951.530E-91.570E-8REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (4)*ST000974AN0015956.040E-42.820E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015961.490E-46.320E-3REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015961.990E-21.350E-1GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (4)*ST000975AN0015962.350E-28.290E-2GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (5)*ST000974AN0015951.670E-81.430E-7REGION;AHRI;MRC;SUN
glucuronide of piperine metabolite C17H21NO3 (5)*ST000974AN0015954.970E-42.480E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015962.330E-48.250E-3REGION;MAK;SUN
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015969.700E-38.800E-2GROUP;case;control
glucuronide of piperine metabolite C17H21NO3 (5)*ST000975AN0015962.170E-27.920E-2GENDER;F;M
Glu-Cys-Cys 2ST000539AN0008199.280E-84.400E-7Cell type;Mature erythrocyte;Reticulocyte
Glu-Cys-Gly-SerST001205AN0020064.260E-56.260E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
Glu-Glu-Gln-HisST001201AN0019986.800E-285.120E-27cell_type;iRBC;unRBC
Glu-Glu-Gln-HisST001201AN0019981.030E-24.530E-2treatment;DHA;DMSO;OZ277;OZ439
Glu-Lys-Lys-PheST001202AN0020015.360E-171.110E-16cell_type;iRBC;unRBC
Glu-Lys-Lys-PheST001202AN0020013.530E-25.020E-2treatment_duration_(h);-;1.5;3;6;9
Glu-Met-Cys-HisST000403AN0006432.400E-23.990E-2Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Cys-HisST000539AN0008196.740E-31.330E-2Cell type;Mature erythrocyte;Reticulocyte
Glu-Met-Met-HisST000403AN0006434.950E-34.460E-2Glucose labelling;C13 glucose;unlabelled
Glu-Met-Met-HisST000539AN0008191.250E-21.460E-1timepoint;1 hour;20 hours
Glu-Met-Met-HisST000539AN0008193.160E-25.270E-2Cell type;Mature erythrocyte;Reticulocyte
Glutamate semialdehyde-13C0[+13CD3 QDA]+ST000142AN0002254.230E-22.280E-1Treatment;13C-Glc;unlabeled
GlutaminolysisST000544AN0008262.320E-153.950E-14Sample Type;Control;Replicate
glutathione-sulfiteST000403AN0006436.610E-31.190E-2Cell type;Mature erythrocyte;Reticulocyte
glutathione-sulfiteST000539AN0008192.660E-39.520E-2timepoint;1 hour;20 hours
GLYCERALDEHYDE 3-PHOSPHATE DIETHYL ACETALST000016AN0000333.830E-25.380E-2Material;Cells;Media
GLYCERALDEHYDE/LACTATEST000475AN0007403.080E-61.400E-5Treatment;-;MDH inhib
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATEST000583AN0008954.180E-37.350E-2time;12-weeks;baseline
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATEST000956AN0015695.770E-42.210E-3Treatment;Condition-1;Condition-2;Condition-3;Control
glycine-d5 deuteratedST000865AN0013902.310E-356.470E-34Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
glycine-d5 deuteratedST000865AN0013903.090E-354.540E-34RACE;AA;Asian;EA;Hisp;Other;-
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)ST000105AN0001742.380E-53.130E-4Sampling;After SWS onset;Morning fasting
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)ST000106AN0001769.850E-51.660E-3Sampling time;0 min;60 min
glycodeoxycholate/glycochenodeoxycholateST001142AN0018767.320E-812.160E-79Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
glycodeoxycholate/glycochenodeoxycholateST001142AN0018766.990E-243.170E-23Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
glycodeoxycholate/glycochenodeoxycholateST001236AN0020542.220E-44.570E-3Time point;baseline;week 4;week 9
glycodeoxycholate/glycochenodeoxycholateST001237AN0020553.790E-49.130E-4CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
glycodeoxycholate/glycochenodeoxycholateST001237AN0020552.950E-21.080E-1Treatment;EVEROLIMUS;NIVOLUMAB
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATEST000009AN0000245.500E-63.500E-5AFTER_MEAL_TIME;30_MIN;NO_WAIT
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATEST000010AN0000262.840E-62.000E-5FCS;FCS;NO_FCS
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000105AN0001742.690E-23.320E-1PCOS;No PCOS;PCOS
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000105AN0001743.010E-21.160E-1Sampling;After SWS onset;Morning fasting
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)ST000106AN0001764.300E-22.210E-1Sampling time;0 min;60 min
glycolST000355AN0005808.320E-43.950E-3Stage;1;2;3;4;-
glycolST000355AN0005807.010E-32.720E-2Diagnosis;Breast cancer;Control
GLYCOLITHOCHOLIC ACID ETHYL ESTERST000016AN0000331.870E-24.420E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
glyoxalurea NISTST000369AN0006034.070E-72.210E-6Organ;Plasma;Serum
glyoxalurea NISTST000369AN0006033.670E-31.410E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
glyoxalurea NISTST000369AN0006032.850E-27.030E-2Smoker;Current;Former;NA
glyoxalurea NISTST000369AN0006033.250E-28.530E-2Gender;F;M;NA
glyoxalurea NISTST000386AN0006211.320E-77.960E-7Organ;Plasma;Serum
glyoxalurea NISTST000386AN0006212.410E-31.450E-2Gender;F;M;NA
glyoxalurea NISTST000386AN0006211.080E-24.170E-2Smoker;Current;Former;NA
glyoxalurea NISTST000386AN0006213.250E-21.180E-1Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphateST000403AN0006432.350E-77.960E-7Cell type;Mature erythrocyte;Reticulocyte
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphateST000539AN0008191.340E-98.540E-9Cell type;Mature erythrocyte;Reticulocyte
GPEtnNMe(16:0/18:1(9Z))ST000421AN0006641.840E-22.150E-1treatment;ND;T1D poor glycemic control
GQ1c (34:1)-13C0[+13CD3 QDA]+ST000142AN0002253.610E-326.130E-31Treatment;13C-Glc;unlabeled
GQ1 d18:1 N18:0ST000362AN0005947.670E-78.820E-6Gender;1;2
GQ1 d18:1 N20:0ST000362AN0005948.170E-53.130E-4Gender;1;2
GUANOSINE 5`-DIPHOSPHO-D-MANNOSEST000044AN0000693.600E-32.500E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
GulonolactoneST001039AN0017133.570E-37.750E-3Sample.Matrix;Plasma;Urine
GulonolactoneST001193AN0019891.130E-21.500E-2Plasma;Cord blood;Plasma
H2S2O3ST001201AN0019991.230E-24.390E-1treatment_duration_(h);-;0.5;1.5;3
HBAST000566AN0008704.510E-46.080E-4Time point;Post;Pre;Baseline
HBAST000567AN0008727.050E-74.160E-6Time point;Post;Pre;Baseline
HBAST000614AN0009402.410E-22.670E-2Diagonsis;Benign;Cancer;Normal
HBAST000614AN0009402.500E-22.980E-2Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
HECOGENINACETATEST000047AN0000804.150E-22.500E-1Cognitive Status;AD;CN;MCI
HEPESST000403AN0006431.340E-43.250E-4Cell type;Mature erythrocyte;Reticulocyte
HEPESST000539AN0008193.360E-124.860E-11Cell type;Mature erythrocyte;Reticulocyte
HEPESST001201AN0019993.490E-302.080E-29cell_type;iRBC;unRBC
HEPESST001202AN0020011.250E-497.990E-48cell_type;iRBC;unRBC
heptadecanoic acid NISTST000368AN0006021.250E-21.760E-2Organ;Plasma;Serum;Serum or Plasma
heptadecanoic acid NISTST000369AN0006031.890E-35.180E-3Organ;Plasma;Serum
heptadecanoic acid NISTST000385AN0006206.370E-88.650E-8Organ;Plasma;Serum;Serum or Plasma
heptadecanoic acid NISTST000385AN0006204.730E-31.260E-2Health State;Adenocarcinoma;Healthy;NA
heptadecanoic acid NISTST000385AN0006201.710E-23.940E-2Smoking Status;Current;Former;NA
heptadecanoic acid NISTST000386AN0006212.360E-36.380E-3Organ;Plasma;Serum
Heptadecanoic acid/Octadecanol 2ST000586AN0009011.530E-62.630E-6Plasma Volume;0 uL;150 uL;700 uL
HEPTADECENOATE (*)ST000044AN0000691.050E-52.480E-3Pancreas tissue type;Normal area of the pancreas with tumor;...
HEPTADECENOATE (*)ST000105AN0001743.780E-43.520E-3Sampling;After SWS onset;Morning fasting
HEPTADECENOATE (*)ST000106AN0001761.070E-94.310E-8Sampling time;0 min;60 min
HeptopyranosidesST001201AN0019993.060E-44.930E-3treatment;DHA;DMSO;OZ277;OZ439
HeptopyranosidesST001201AN0019991.570E-22.600E-2cell_type;iRBC;unRBC
HETEST001223AN0020362.760E-81.200E-7Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
HeterocladolST000291AN0004655.270E-42.810E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
HexadeceylaminST001202AN0020002.270E-271.030E-26cell_type;iRBC;unRBC
hexadecylglycerol NISTST001211AN0020163.630E-38.280E-3Group;Control;Methotrexate
HEXANESULFONIC ACID-SulfateST000957AN0015711.270E-21.380E-1Milk fraction;fat;skim;whole
hexanoylglutamineST000974AN0015953.820E-21.830E-1GENDER;F;M
hexanoylglutamineST000975AN0015962.570E-34.570E-2GROUP;case;control
HexazinoneST000242AN0003774.390E-31.650E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hexose Diphosphate PoolST000450AN0007062.950E-211.400E-20gender;Female;Male
HEXOSE-DISACCHARIDEST000424AN0006732.170E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
HEXOSE-DISACCHARIDEST000475AN0007392.280E-23.560E-2Treatment;-;MDH inhib
Hexose Disaccharide PoolST000450AN0007062.540E-54.020E-5gender;Female;Male
Hexose Monophosphate PoolST000450AN0007062.610E-421.460E-40gender;Female;Male
Hexose PoolST000450AN0007063.650E-108.670E-10gender;Female;Male
Hexose PoolST000465AN0007262.410E-21.340E-1Treatment;Control;Englerin (100 nM)
hexoses (HILIC neg)ST001142AN0018763.470E-474.100E-46Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
hexoses (HILIC neg)ST001142AN0018767.600E-464.480E-44Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
hexoses (HILIC pos)ST001142AN0018753.470E-431.340E-42Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
hexoses (HILIC pos)ST001142AN0018759.570E-243.350E-23Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Hinokitiol glucoside-13C0[+H]+ST000142AN0002258.870E-326.150E-31Treatment;13C-Glc;unlabeled
His-Met-Trp-SerST000403AN0006434.330E-51.110E-3Glucose labelling;C13 glucose;unlabelled
His-Thr-OHST000242AN0003772.520E-26.370E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Histidylproline diketopiperazineST000356AN0005835.410E-51.320E-4Diagnosis;breast cancer;control
Histidylproline diketopiperazineST000356AN0005831.260E-33.030E-3stage;-;2;3
HWESASXXST000553AN0008453.470E-111.100E-10Sample type;Plasma;Urine
HWESASXXST000553AN0008464.720E-132.830E-12Sample type;Plasma;Urine
HWESASXX*ST000974AN0015958.140E-43.160E-2GROUP;case;control
HWESASXX*ST000974AN0015951.140E-35.050E-3REGION;AHRI;MRC;SUN
Hydrocortisone sodium succinate-13C0[+13CD3 QDA]+ST000142AN0002253.900E-326.130E-31Treatment;13C-Glc;unlabeled
hydrogen iodideST000403AN0006432.040E-122.250E-11Cell type;Mature erythrocyte;Reticulocyte
hydrogen iodideST000539AN0008194.480E-114.070E-10Cell type;Mature erythrocyte;Reticulocyte
hydrogen iodideST001202AN0020011.050E-81.350E-8cell_type;iRBC;unRBC
HYDROLYSIS PRODUCT OF BUSSEINST000421AN0006643.080E-22.780E-1treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.4680848ST000421AN0006631.530E-21.980E-1treatment;ND;T1D poor glycemic control
HYDROLYSIS PRODUCT OF BUSSEIN + 1.9674853ST000421AN0006631.360E-21.910E-1treatment;ND;T1D poor glycemic control
Hydromorphone (anesthetic)ST000089AN0001411.660E-61.870E-6Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Hydroxyabscisate-13C0[+Na]+ST000148AN0002359.410E-34.640E-2Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C1[+H]+ST000142AN0002254.640E-22.470E-1Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C4[+H]+ST000142AN0002252.140E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C8[+H]+ST000142AN0002252.480E-326.130E-31Treatment;13C-Glc;unlabeled
HYDROXYACETAMINOPHEN SULFATE (*)ST000106AN0001761.350E-73.030E-6Sampling time;0 min;60 min
Hydroxyamoorstatin-13C0[+QDA adduct]+ST000142AN0002255.380E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxyandrosterone-13C0[+Na]+ST000148AN0002357.880E-34.060E-2Treatment;13C-Glc;unlabeled
Hydroxyanthraquinone-13C0[+QDA adduct+Na]+ST000142AN0002251.590E-319.480E-31Treatment;13C-Glc;unlabeled
Hydroxybutyrate3ST000137AN0002191.380E-31.140E-2Sample Group;Control;Patient
Hydroxy-carboxybenzalpyruvate-13C0[+H]+ST000142AN0002259.320E-326.180E-31Treatment;13C-Glc;unlabeled
Hydroxycholesterol speciesST000450AN0007053.440E-21.410E-1Disease;CFS;Normal
Hydroxycholesterol SpeciesST000465AN0007272.030E-34.330E-2Treatment;Control;Englerin (100 nM)
Hydroxycinnamyl aldehyde-13C0[+Na]+ST000142AN0002255.910E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+ST000148AN0002357.890E-34.060E-2Treatment;13C-Glc;unlabeled
hydroxy-CMPFST000975AN0015967.060E-37.640E-2GROUP;case;control
hydroxy-CMPFST000975AN0015967.240E-31.270E-1REGION;MAK;SUN
hydroxy-CMPFST000976AN0015972.800E-22.830E-1GENDER;F;M
hydroxy-CMPF*ST000975AN0015965.210E-39.850E-2REGION;MAK;SUN
hydroxy-CMPF*ST000975AN0015961.210E-29.890E-2GROUP;case;control
hydroxy-CMPF*ST000976AN0015971.760E-22.450E-1GENDER;F;M
Hydroxyglutaric acidST000356AN0005822.620E-66.620E-6Diagnosis;breast cancer;control
Hydroxyglutaric acidST000356AN0005823.590E-59.300E-5stage;-;2;3
Hydroxyhexanone-13C0[+QDA adduct]+ST000142AN0002254.300E-32.500E-2Treatment;13C-Glc;unlabeled
HydroxyibuprofenST000566AN0008695.680E-91.850E-8Time point;Post;Pre;Baseline
HydroxyibuprofenST000567AN0008717.970E-42.000E-3Time point;Post;Pre;Baseline
HYDROXYISOVALERATE (*)ST000044AN0000691.340E-26.190E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
HYDROXYISOVALERATE (*)ST000105AN0001742.580E-31.410E-1PCOS;No PCOS;PCOS
HYDROXYISOVALERATE (*)ST000106AN0001761.680E-56.810E-3Visit;1;2
hydroxyisovaleric acidST001000AN0018792.200E-36.320E-3Diagnosis;CD;Control;UC
Hydroxykynurenamine-13C0[+13CD3 QDA]+ST000148AN0002353.600E-32.410E-2Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct]+ST000142AN0002253.570E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct+Na]+ST000142AN0002254.120E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxymuconic semialdehyde-13C0[+QDA adduct+Na]+ST000142AN0002251.170E-317.200E-31Treatment;13C-Glc;unlabeled
hydroxymyristateST000923AN0015156.220E-31.660E-2Diagnosis;CD;nonIBD;UC
Hydroxy-naphthoquinone-13C0[+H]+ST000142AN0002252.770E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C0[+13CD3 QDA]+ST000148AN0002358.770E-34.400E-2Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C0[+QDA adduct]+ST000148AN0002352.300E-29.170E-2Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C1[+QDA adduct]+ST000148AN0002354.190E-21.470E-1Treatment;13C-Glc;unlabeled
Hydroxynonenal-13C5[+QDA adduct]+ST000148AN0002352.390E-29.450E-2Treatment;13C-Glc;unlabeled
Hydroxyproline/AminolevulinateST000284AN0004529.630E-36.800E-2Patient group;CRC;Healthy;Polyp
HydroxyprolinesST000586AN0009015.510E-71.020E-6Plasma Volume;0 uL;150 uL;700 uL
HydroxyprolinesST000589AN0009047.190E-291.040E-28Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Hydroxyprolyl-AsparagineST001205AN0020064.760E-29.690E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Hydroxyretinal-13C0[+H]+ST000142AN0002252.100E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxystreptomycin-13C0[+H]+ST000142AN0002257.880E-326.130E-31Treatment;13C-Glc;unlabeled
Hydroxytetrabenazine glucuronideST000242AN0003771.160E-71.490E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hygromycin A-13C0[+QDA adduct]+ST000142AN0002251.300E-317.850E-31Treatment;13C-Glc;unlabeled
Hyppuric AcidST000284AN0004523.160E-44.460E-3Patient group;CRC;Healthy;Polyp
IBUPROFEN CARBOXYLIC ACID (CAS# 15935-54-3); (M+CL)-ST000695AN0010759.320E-34.630E-2Race;Black;White;POOLED
IBUPROFEN CARBOXYLIC ACID (M-H)-ST000721AN0011283.070E-23.590E-1CT findings;Abnormal only;Normal
IBUPROFEN CARBOXYLIC ACID (M-H)-ST000743AN0011602.820E-25.870E-1Gender;female;male
Icosadienoic acidST000403AN0006433.440E-47.750E-4Cell type;Mature erythrocyte;Reticulocyte
Icosadienoic acidST000539AN0008194.930E-27.860E-2Cell type;Mature erythrocyte;Reticulocyte
Icosatrienoic acidST000403AN0006432.050E-44.810E-4Cell type;Mature erythrocyte;Reticulocyte
Icosatrienoic acidST000539AN0008191.370E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
idonic acid NISTST000379AN0006135.530E-31.690E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
idonic acid NISTST000379AN0006133.670E-26.590E-2Time;10min;1hr;24hr;6hr
IDP-D-mannoseST001201AN0019992.860E-128.780E-12cell_type;iRBC;unRBC
IDP-D-mannoseST001201AN0019995.750E-47.720E-3treatment;DHA;DMSO;OZ277;OZ439
IDP-D-mannoseST001205AN0020065.790E-43.220E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Ile-Ala/Leu-AlaST000230AN0003446.890E-38.710E-2Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
Ile-Met-Met-ThrST000403AN0006422.850E-61.680E-4Glucose labelling;C13 glucose;unlabelled
ImazosulfuronST000291AN0004647.570E-81.350E-4Treatment ;Baseline urine;Urine after drinking apple juice;U...
IndanofanST000291AN0004645.960E-62.050E-3Treatment ;Baseline urine;Urine after drinking apple juice;U...
indole-3-acetonitrile oxideST000403AN0006421.100E-32.140E-3Cell type;Mature erythrocyte;Reticulocyte
indole-3-acetonitrile oxideST000539AN0008181.750E-23.070E-2Cell type;Mature erythrocyte;Reticulocyte
indole-3-acetyl-valineST000403AN0006437.980E-41.680E-3Cell type;Mature erythrocyte;Reticulocyte
indole-3-acetyl-valineST000539AN0008193.020E-48.210E-4Cell type;Mature erythrocyte;Reticulocyte
inositol 1-phosphate (I1P)ST000974AN0015953.390E-36.770E-2GROUP;case;control
inositol allo-ST000396AN0006332.180E-21.340E-1Age Group;45-49;50-54;55-59;60-64;65-69;70-74
iodoacetateST001204AN0020053.360E-26.260E-2cell_type;iRBC;unRBC
iodoacetateST001204AN0020054.410E-28.320E-1treatment;DHA;DMSO;OZ277;OZ439
IS Ceramide;[M-H20]+ST000661AN0010091.000E-337.770E-33Study;CHOICE;CSU-143;POOLED
IS Ceramide;[M-H20]+ST000661AN0010091.000E-337.770E-33Type;Clinical;Preclinical;POOLED
IS Ceramide;[M-H20]+ST000661AN0010093.620E-312.710E-30Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
IS Ceramide;[M-H20]+ST000661AN0010091.630E-281.110E-27Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
IS Ceramide;[M-H20]+ST000661AN0010096.350E-111.760E-10Sample_Source;Plasma;POOLED;Mammary gland
IS Ceramide;[M-H20]+ST000661AN0010096.530E-119.870E-11Species;Homo sapiens;Rattus
IS Ceramide;[M-H20]+ST000661AN0010092.440E-22.710E-2Sample type;Plasma;Tissues
IS Ceramide;[M-H20]+ST000669AN0010252.230E-21.790E-1Matrix;Plasma;SRF;CB
IS Ceramide; [M-H2O]+ST000523AN0008001.000E-52.540E-5Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS Ceramide; [M-H2O]+ST000523AN0008001.080E-23.330E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
IS Ceramide; [M-H2O]+ST000523AN0008003.850E-21.250E-1Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
IS D31-TAGST000523AN0008008.330E-153.640E-13Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS D31-TAGST000523AN0008001.310E-38.170E-3Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
IS D31-TAGST000523AN0008002.920E-29.930E-2Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
IS D31-TAGST000669AN0010259.210E-32.530E-1Disease;AS-Control-P;AS-Control-S;Coats;JB-Coats-P
IS D31-TAGST000669AN0010251.050E-21.690E-1Matrix;Plasma;SRF;CB
IS d5-DAGST000523AN0008002.090E-22.890E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
isoamyl nitriteST000421AN0006654.000E-24.500E-1treatment;ND;T1D poor glycemic control
isoamyl nitriteST000422AN0006691.970E-21.000E+0treatment;ND;T1D good glycemic control
isoamylnitriteST000046AN0000764.320E-34.370E-2Cognitive Status;AD;CN;MCI
isoamylnitriteST000046AN0000771.770E-21.380E-1Cognitive Status;AD;CN;MCI
isoamylnitriteST000046AN0000784.440E-33.600E-2Cognitive Status;AD;CN;MCI
isoamylnitriteST000047AN0000812.660E-34.560E-2Cognitive Status;AD;CN;MCI
isobutene glycol NISTST000910AN0014801.540E-21.610E-1Diagnosis;MECFS;MS;ND
IsobutyrylglycinemethylesterST000047AN0000833.350E-21.650E-1Cognitive Status;AD;CN;MCI
Isocitrate M0ST000507AN0007761.150E-22.260E-2Time (incubation);24 hours;72 hours
isodeoxytetronic acidST000396AN0006336.810E-77.350E-5Sex;Male;Female
isodeoxytetronic acidST000396AN0006331.340E-21.080E-1Age Group;45-49;50-54;55-59;60-64;65-69;70-74
isohexonic acidST001211AN0020162.390E-35.680E-3Group;Control;Methotrexate
Isohomovanillic acidST000356AN0005834.110E-25.910E-2Diagnosis;breast cancer;control
Isohomovanillic acidST000356AN0005834.490E-27.390E-2stage;-;2;3
isohydroxybutyric acidST000092AN0001463.930E-2307.460E-229Solution Added;N/A;None;Urease;Water
isohydroxybutyric acidST000092AN0001462.000E-772.840E-76Volume Urine (µL);100;10;25;50;5
isohydroxybutyric acidST000092AN0001461.320E-321.070E-31Gender;N/A;Female;Male
isohydroxybutyric acidST000092AN0001461.360E-301.190E-29Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
isohydroxybutyric acidST000092AN0001461.990E-87.830E-8Urease Treatment;No treatment;Urease pre-treatment;Water pre...
isolinoleic acid NISTST000369AN0006031.230E-33.600E-3Organ;Plasma;Serum
isolinoleic acid NISTST000369AN0006032.760E-27.030E-2Smoker;Current;Former;NA
isolinoleic acid NISTST000386AN0006211.270E-33.640E-3Organ;Plasma;Serum
Isophenoxazine-13C0[+H]+ST000142AN0002255.900E-326.130E-31Treatment;13C-Glc;unlabeled
Isophenoxazine-13C10[+QDA adduct+Na]+ST000142AN0002255.620E-326.130E-31Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C0[+13CD3 QDA]+ST000148AN0002354.430E-21.530E-1Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C1[+13CD3 QDA]+ST000148AN0002359.130E-34.540E-2Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C5[+QDA adduct]+ST000148AN0002352.460E-29.630E-2Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C6[+QDA adduct]+ST000142AN0002256.800E-326.130E-31Treatment;13C-Glc;unlabeled
IsoquinolineN-oxideST000046AN0000786.960E-34.550E-2Cognitive Status;AD;CN;MCI
IsoquinolineN-oxideST000046AN0000793.820E-33.530E-2Cognitive Status;AD;CN;MCI
IS SM 35:1; [M+H]+ST000523AN0008007.780E-105.810E-9Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
IS SM 35:1; [M+H]+ST000523AN0008003.810E-31.790E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
IS SM 35:1;[M+H]+ST000661AN0010095.210E-302.960E-29Study;CHOICE;CSU-143;POOLED
IS SM 35:1;[M+H]+ST000661AN0010095.210E-302.960E-29Type;Clinical;Preclinical;POOLED
IS SM 35:1;[M+H]+ST000661AN0010095.690E-293.440E-28Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
IS SM 35:1;[M+H]+ST000661AN0010092.030E-251.030E-24Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
IS SM 35:1;[M+H]+ST000661AN0010097.300E-131.280E-12Species;Homo sapiens;Rattus
IS SM 35:1;[M+H]+ST000661AN0010099.430E-122.960E-11Sample_Source;Plasma;POOLED;Mammary gland
IS SM 35:1;[M+H]+ST000661AN0010099.830E-51.240E-4Sample type;Plasma;Tissues
Istamycin CST000242AN0003774.540E-74.840E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Istamycin C1ST000242AN0003771.010E-57.770E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
iSTD iSTD Ceramide (d18:1/17:0)ST000342AN0005542.100E-52.950E-4Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD Ceramide (d18:1/17:0)ST000346AN0005622.790E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD FA (16:0)-d3ST000342AN0005543.350E-41.480E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD FA (16:0)-d3ST000346AN0005621.590E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD MAG (17:0/0:0/0:0)ST000342AN0005547.630E-31.390E-2Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD MAG (17:0/0:0/0:0)ST000346AN0005621.900E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PC (12:0/13:0)ST000346AN0005621.900E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PE (17:0/17:0)ST000342AN0005543.350E-36.870E-3Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
iSTD iSTD PG (17:0/17:0)ST000346AN0005621.470E-21.750E-1Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
Ivermectin B1aST000421AN0006655.140E-31.530E-1treatment;ND;T1D poor glycemic control
Ivermectin B1a + 11.394018ST000421AN0006653.750E-24.500E-1treatment;ND;T1D poor glycemic control
(-)-jasmonoyl-L-isoleucineST000403AN0006423.200E-46.830E-4Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-isoleucineST000539AN0008182.170E-23.670E-2Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-valineST000403AN0006431.880E-76.500E-7Cell type;Mature erythrocyte;Reticulocyte
(-)-jasmonoyl-L-valineST000539AN0008194.970E-31.030E-2Cell type;Mature erythrocyte;Reticulocyte
Kanokoside DST000242AN0003752.860E-91.140E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ketoconazolST000403AN0006423.180E-81.230E-7Cell type;Mature erythrocyte;Reticulocyte
ketoconazolST000539AN0008182.680E-24.470E-2Cell type;Mature erythrocyte;Reticulocyte
ketodeoxycholateST000923AN0015157.390E-53.830E-4Diagnosis;CD;nonIBD;UC
ketodeoxycholateST001000AN0018802.460E-69.860E-6Diagnosis;CD;Control;UC
ketodeoxycholateST001192AN0019861.590E-21.090E-1Diet;-;Omnivore;Vegetarian
Ketoetiocholanolone-13C0[+Na]+ST000142AN0002255.390E-326.130E-31Treatment;13C-Glc;unlabeled
Ketohexanoate-13C0[+QDA adduct+Na]+ST000148AN0002356.690E-33.630E-2Treatment;13C-Glc;unlabeled
Ketohexanoate-13C1[+QDA adduct+Na]+ST000148AN0002352.270E-29.100E-2Treatment;13C-Glc;unlabeled
Ketohexanoate-13C5[+QDA adduct]+ST000142AN0002254.640E-22.470E-1Treatment;13C-Glc;unlabeled
KG M+1ST000507AN0007765.130E-51.270E-4Time (incubation);24 hours;72 hours
KG M+5ST000507AN0007762.890E-81.380E-7Time (incubation);24 hours;72 hours
Khellol glucoside-13C0[+13CD3 QDA]+ST000142AN0002252.100E-21.180E-1Treatment;13C-Glc;unlabeled
Kinetensin 4-7ST000241AN0003731.550E-42.490E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Kinetin-9-ribosideST001037AN0016988.900E-33.010E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
KINETIN RIBOSIDEST000422AN0006683.480E-52.520E-3treatment;ND;T1D good glycemic control
Kolanone-13C0[+H]+ST000142AN0002256.620E-326.130E-31Treatment;13C-Glc;unlabeled
KynorenateST000284AN0004522.580E-21.170E-1Patient group;CRC;Healthy;Polyp
Kyn/TrpST001237AN0020551.650E-169.640E-16CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Kyn/TrpST001237AN0020553.260E-122.230E-10Time point;baseline;week 4;week 8
Kyn/TrpST001237AN0020556.290E-73.790E-6OS_Censor (1 means the time is a censoring time and 0 means ...
Kyn/TrpST001237AN0020553.690E-43.600E-3Treatment;EVEROLIMUS;NIVOLUMAB
Kynurenine / TrpST000545AN0008299.110E-37.600E-2Sample Type;Control;Replicate
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M+H)+ST000689AN0010642.610E-31.200E-2Construct;-;Control lentivirus;Noxa knockdown
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000689AN0010632.330E-39.890E-3Construct;-;Control lentivirus;Noxa knockdown
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.260E-21.350E-1Chemotherapy;N;Y;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.650E-21.780E-1Taxane;N;Y;-
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.790E-21.850E-1CASE_CONTROL;Case;Control;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010752.910E-21.850E-1TIMEPOINT;3 Month;Baseline;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010753.350E-21.400E-1Race;Black;White;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010753.770E-22.060E-1Tamoxyfen;N;Y;-
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000695AN0010754.090E-22.620E-1Drug;Exemestane;Letrozole;POOLED
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000698AN0010833.690E-21.440E-1KD#2;yes;no;Pooled melanoma
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000698AN0010833.690E-22.040E-1KD#1;no;yes;Pooled melanoma
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012223.290E-31.630E-2Treatment response;No;Yes;Pooled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012224.260E-33.110E-2Timepoint;T0;T2;Pooled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-ST000775AN0012221.720E-27.160E-2Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000742AN0011584.600E-28.070E-2Species;Homo sapiens;Mus musculus;-
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000768AN0012154.840E-23.320E-1Media;3N media;E8 media
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+ST000768AN0012154.840E-23.320E-1Type;neurons;stem cells
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000708AN0011004.240E-21.570E-1GROUP;POOLED;Standard;VLED
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000708AN0011004.270E-21.940E-1VISIT;POOLED;visit 1;visit 2
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000721AN0011282.190E-61.260E-5Injury;1 month;3 months
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000726AN0011386.390E-31.210E-1AGE;12;13;14;15;16;17
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000726AN0011384.060E-21.400E-1Assay;BC TP;OGTT
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000748AN0011726.440E-68.550E-6Sample type;Cells;Culture Media
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000842AN0013569.570E-183.990E-17Sample type;Muscles;Plasma;Pooled sample
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-ST000992AN0016182.150E-26.470E-1Smoker;No;Yes
L-1-Pyrroline-3-hydroxy-5-carboxylateST000403AN0006425.780E-61.650E-5Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylateST000539AN0008182.140E-23.630E-2Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylateST001205AN0020073.820E-61.510E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
L-1-Pyrroline-3-hydroxy-5-carboxylate 2ST000539AN0008182.140E-23.630E-2Cell type;Mature erythrocyte;Reticulocyte
L-2-Amino-4-(hydroxymethylphosphinyl)butanoateST000291AN0004641.550E-24.620E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
L-2-Aminoadipate 6-semialdehydeST000403AN0006431.040E-27.310E-2Glucose labelling;C13 glucose;unlabelled
L-2-Aminoadipate 6-semialdehydeST000403AN0006434.560E-23.380E-1timepoint;1 hour;20 hours
L-2-Aminoadipate 6-semialdehydeST000539AN0008193.270E-34.870E-2Glucose labelling;C13 glucose;unlabelled
L-2-aminobutyric acidST000356AN0005822.440E-23.980E-2Diagnosis;breast cancer;control
L-4-Hydroxy-3-methoxy-a-methylphenylalanineST000421AN0006633.170E-62.470E-4treatment;ND;T1D poor glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanineST000422AN0006674.050E-42.240E-2treatment;ND;T1D good glycemic control
L-4-Hydroxy-3-methoxy-a-methylphenylalanine + 2.0514681ST000421AN0006637.690E-42.330E-2treatment;ND;T1D poor glycemic control
LabriformidinST000242AN0003771.830E-37.970E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
LACTATE-dimerST000954AN0015653.750E-22.880E-1race;1;2
LACTATE-dimerST000956AN0015694.590E-27.280E-2Treatment;Condition-1;Condition-2;Condition-3;Control
Lactose+KST000954AN0015643.380E-26.520E-1daily_dose;2;3;4;1
Lactosylceramide(d18ST001202AN0020001.770E-112.540E-11cell_type;iRBC;unRBC
Lactosylceramide(d18ST001202AN0020003.820E-24.640E-2treatment_duration_(h);-;1.5;3;6;9
Lactosylceramide (d18:1/12:0)ST000241AN0003742.210E-39.300E-3Concentration (uM);0;500
Lactosylceramide (d18:1/12:0)ST000241AN0003741.630E-21.650E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
L-a-glutamyl-L-LysineST000403AN0006425.470E-135.860E-12Cell type;Mature erythrocyte;Reticulocyte
L-a-glutamyl-L-LysineST000539AN0008182.030E-175.890E-15Cell type;Mature erythrocyte;Reticulocyte
L-a-glutamyl-L-LysineST001201AN0019983.910E-222.010E-21cell_type;iRBC;unRBC
L-a-glutamyl-L-LysineST001201AN0019981.310E-25.130E-2treatment;DHA;DMSO;OZ277;OZ439
L-a-glutamyl-L-LysineST001205AN0020061.920E-24.380E-1treatment_duration_(h);1;5;3
L-Ala-L-GluST000403AN0006431.320E-108.580E-10Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-GluST000539AN0008197.920E-42.010E-3Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-GluST001202AN0020014.390E-335.110E-32cell_type;iRBC;unRBC
L-Ala-L-Glu 2ST000539AN0008197.920E-42.010E-3Cell type;Mature erythrocyte;Reticulocyte
Lankamycin-13C0[+Na]+ST000148AN0002356.600E-33.600E-2Treatment;13C-Glc;unlabeled
Lankamycin-13C0[+QDA adduct]+ST000142AN0002254.800E-326.130E-31Treatment;13C-Glc;unlabeled
L-ArabinonateST000403AN0006431.990E-55.450E-5Cell type;Mature erythrocyte;Reticulocyte
L-ArabinonateST000539AN0008194.330E-92.580E-8Cell type;Mature erythrocyte;Reticulocyte
L-ARGININE-(GUANIDINEIMINO-15N2) [ISTD] (CAS# ); (M+H)+ST000695AN0010766.260E-32.270E-1Taxane;N;Y;-
L-Ascorbate 6-phosphateST001204AN0020051.350E-74.110E-7cell_type;iRBC;unRBC
L-Aspartic acid b-semialdehydeST000422AN0006683.450E-23.260E-1treatment;ND;T1D good glycemic control
L-Asparticacidb-semialdehydeST000047AN0000821.920E-33.430E-2Cognitive Status;AD;CN;MCI
L-Aspartyl-4-phosphateST000241AN0003739.100E-92.650E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
lathosterol NISTST000369AN0006036.010E-44.350E-3Gender;F;M;NA
lathosterol NISTST000369AN0006031.650E-39.080E-3Smoker;Current;Former;NA
lathosterol NISTST000369AN0006033.990E-31.500E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
lathosterol NISTST000379AN0006132.120E-35.090E-3Time;10min;1hr;24hr;6hr
lathosterol NISTST000379AN0006131.280E-23.620E-2Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
lathosterol NISTST000383AN0006182.330E-29.680E-1UCP-3 Polymorphism;g/a;g/g
lathosterol NISTST000386AN0006214.890E-32.460E-2Smoker;Current;Former;NA
lathosterol NISTST000386AN0006214.940E-32.290E-2Gender;F;M;NA
lathosterol NISTST000386AN0006212.010E-27.890E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
LaudanosineST000539AN0008195.220E-37.360E-2Glucose labelling;C13 glucose;unlabelled
LaudanosineST000539AN0008191.770E-23.090E-2Cell type;Mature erythrocyte;Reticulocyte
Laurencione diacetateST000567AN0008716.200E-261.270E-24Time point;Post;Pre;Baseline
Laurencione diacetateST000567AN0008713.070E-91.460E-7groups;Old-Curcumin;Old-Placebo;young
L-beta-aspartyl-L-alanineST001201AN0019986.600E-31.080E-2cell_type;iRBC;unRBC
L-beta-aspartyl-L-leucineST001204AN0020041.700E-74.840E-7cell_type;iRBC;unRBC
L-beta-aspartyl-L-leucineST001204AN0020041.920E-34.380E-2treatment_duration_(h);-;3;6;9
L-beta-aspartyl-L-phenylalanineST000356AN0005833.470E-161.690E-15Diagnosis;breast cancer;control
L-beta-aspartyl-L-phenylalanineST000356AN0005838.850E-134.880E-12stage;-;2;3
L-beta-aspartyl-L-serineST001201AN0019981.070E-31.190E-2treatment;DHA;DMSO;OZ277;OZ439
L-beta-HomoleucineST000913AN0014834.910E-24.480E-1Diagnosis;MECFS;MS;ND
L-cysteine sulfinateST001201AN0019994.040E-444.200E-43cell_type;iRBC;unRBC
L-ErythruloseST000403AN0006432.060E-88.490E-8Cell type;Mature erythrocyte;Reticulocyte
L-ErythruloseST000539AN0008191.020E-64.290E-6Cell type;Mature erythrocyte;Reticulocyte
L-ErythruloseST001201AN0019993.350E-362.630E-35cell_type;iRBC;unRBC
Leucomycin A3-13C0[+H]+ST000148AN0002351.050E-25.070E-2Treatment;13C-Glc;unlabeled
Levobunolol glucuronideST000566AN0008702.450E-32.960E-3Time point;Post;Pre;Baseline
LevonorgestrelST000444AN0006951.840E-25.210E-2Sample Treatment;Bubbled;Control
L-gamma-Cyano-gamma-aminobutyricacid+1.2438003ST000046AN0000773.220E-21.700E-1Cognitive Status;AD;CN;MCI
L-Glutamate methylesterST000403AN0006421.830E-44.040E-4Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylesterST000539AN0008185.380E-37.420E-2timepoint;1 hour;20 hours
L-Glutamate methylesterST000539AN0008185.450E-31.080E-2Cell type;Mature erythrocyte;Reticulocyte
L-Glutamate methylesterST000539AN0008184.780E-25.120E-1Glucose labelling;C13 glucose;unlabelled
L-Glutamic-13C2[-H+]-ST000367AN0006013.160E-29.800E-2Tissue type;nontumor;tumor
L-Glutamic-13C3[-H+]-ST000367AN0006011.940E-29.070E-2Tissue type;nontumor;tumor
L-Glutamic-13C4[-H+]-ST000367AN0006011.210E-29.070E-2Tissue type;nontumor;tumor
L-Glutamic acid dibutyl esterST000566AN0008702.610E-43.750E-4Time point;Post;Pre;Baseline
L-Glutamic acid dibutyl esterST000566AN0008705.570E-41.400E-2group;Old-Curcumin;Old-Placebo;young
L-Glutamic acid n-butyl esterST000566AN0008701.160E-63.590E-6Time point;Post;Pre;Baseline
L-Glutamic acid n-butyl esterST000566AN0008708.980E-35.240E-2group;Old-Curcumin;Old-Placebo;young
L-Glutamic acid n-butyl ester + 1.5990624ST000566AN0008701.050E-63.340E-6Time point;Post;Pre;Baseline
L-Glutamic acid n-butyl ester + 1.5990624ST000566AN0008707.530E-34.910E-2group;Old-Curcumin;Old-Placebo;young
L-Glutamic Acid / N-Methyl-D-aspartic acidST001048AN0017163.810E-1541.870E-152Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-SerineST000954AN0015652.210E-24.710E-1ethnicity;1;2;-
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-SerineST000956AN0015691.170E-22.330E-2Treatment;Condition-1;Condition-2;Condition-3;Control
L-Glutamyl 5-phosphateST001201AN0019981.290E-412.650E-40cell_type;iRBC;unRBC
L-HypoglycinST000403AN0006432.510E-34.820E-3Cell type;Mature erythrocyte;Reticulocyte
L-HypoglycinST000403AN0006431.940E-21.060E-1Glucose labelling;C13 glucose;unlabelled
L-HypoglycinST000539AN0008192.270E-45.700E-3Glucose labelling;C13 glucose;unlabelled
L-Isoleucine / NorleucineST001048AN0017169.370E-202.400E-19Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-Leucine-D10ST000424AN0006734.180E-23.080E-1DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
L-Leucine-D10ST000919AN0015064.190E-45.590E-3Gender;Female;Male
L-Leucine-D10ST000954AN0015644.560E-24.160E-1ethnicity;1;2;-
L-methioninamideST001204AN0020053.860E-485.120E-46cell_type;iRBC;unRBC
L(-)-Nicotine pestalST000241AN0003731.010E-217.610E-20Concentration (uM);0;500
L(-)-Nicotine pestalST000241AN0003734.800E-156.450E-14Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
L-NoradrenalineST000403AN0006431.420E-22.420E-2Cell type;Mature erythrocyte;Reticulocyte
L-NoradrenalineST000539AN0008194.470E-27.200E-2Cell type;Mature erythrocyte;Reticulocyte
L-NoradrenalineST001205AN0020072.790E-27.230E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
LorazepamglucuronideST000046AN0000762.070E-21.070E-1Cognitive Status;AD;CN;MCI
Lovastatin Hydroxy AcidST000553AN0008453.850E-34.330E-3Sample type;Plasma;Urine
L-proline amideST000403AN0006421.520E-32.040E-2Glucose labelling;C13 glucose;unlabelled
L-proline amideST000403AN0006422.030E-22.720E-1timepoint;1 hour;20 hours
L-proline amideST000539AN0008181.450E-33.450E-2timepoint;1 hour;20 hours
L-proline amideST000539AN0008184.370E-26.770E-2Cell type;Mature erythrocyte;Reticulocyte
L-pyroglutamic acid/ glutamic acidST000865AN0013904.180E-261.800E-25Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
L-pyroglutamic acid/ glutamic acidST000865AN0013907.370E-252.750E-24RACE;AA;Asian;EA;Hisp;Other;-
L-Sorbose/FructoseST000980AN0016061.860E-33.060E-2Classification;Mild;Moderate;Non-allergic;Severe
L-thiazolidine-4-carboxylateST000403AN0006423.460E-37.850E-2timepoint;1 hour;20 hours
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000475AN0007391.300E-68.480E-6Treatment;-;MDH inhib
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000919AN0015069.240E-35.910E-2Gender;Female;Male
L-VALINE/5-AMINOPENTANOATE/L-NORVALINEST000954AN0015642.960E-23.180E-1ethnicity;1;2;-
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE;BETAINEST000956AN0015681.330E-89.260E-8Treatment;Condition-1;Condition-2;Condition-3;Control
L-Valine/Methyl 4-AminobutyrateST001317AN0021928.944E-501.252E-48SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
L-Valine/Methyl 4-AminobutyrateST001317AN0021928.944E-501.252E-48SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Lys-Lys-Met-ProST000403AN0006421.020E-42.080E-3Glucose labelling;C13 glucose;unlabelled
Lys-Lys-Met-ProST000403AN0006423.330E-37.850E-2timepoint;1 hour;20 hours
Lys-Lys-Met-ProST000539AN0008182.430E-52.340E-3Glucose labelling;C13 glucose;unlabelled
Lys-Lys-Met-ProST000539AN0008181.000E-44.840E-3timepoint;1 hour;20 hours
Lys-Lys-Trp-ProST001204AN0020059.230E-134.080E-12cell_type;iRBC;unRBC
Lys-Lys-Trp-ProST001204AN0020054.690E-24.030E-1treatment_duration_(h);-;3;6;9
Lyso-PAF C-18ST000089AN0001411.340E-284.630E-28Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Lyso-PAF C18ST001223AN0020361.530E-91.990E-8Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
lysopalmitoyl monogalactosylglycerolST001322AN0021986.850E-42.740E-3treatment;expecting 2 month - human breast milk;expecting 2 ...
lysoPC a C16:0 / lysoPC a C16:1ST000545AN0008302.270E-68.290E-6Sample Type;Control;Replicate
lysoPC a C20:4 / lysoPC a C20:3ST000545AN0008303.020E-55.450E-5Sample Type;Control;Replicate
Lys-Ser-Ser-SerST000403AN0006421.860E-72.170E-5Glucose labelling;C13 glucose;unlabelled
L-ZeatineST000614AN0009393.870E-482.980E-46Diagonsis;Benign;Cancer;Normal
L-ZeatineST000614AN0009392.100E-471.620E-45Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
M1ST000291AN0004643.330E-27.190E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
MALATE;OXALOACETATE+2H-HST000956AN0015697.480E-53.740E-4Treatment;Condition-1;Condition-2;Condition-3;Control
Maleylpyruvate-13C0[+QDA adduct+Na]+ST000142AN0002252.510E-21.400E-1Treatment;13C-Glc;unlabeled
maltotriose minorST000058AN0000962.720E-52.390E-4Treatment;Group 1;Group 2;Group 3;Group 4;Group 5;Group 6;Gr...
Malyngamide JST000242AN0003754.670E-91.530E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Malyngamide JST000242AN0003778.870E-81.420E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Man6GlcNAc-VIST001037AN0016987.210E-61.770E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
MANDELIC ACID #2 (M-H)-ST000763AN0012019.540E-102.200E-8Type;Cath;Non-invasive
MANDELIC ACID #2 (M-H)-ST000763AN0012019.180E-81.810E-6Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
MANDELIC ACID #2 (M-H)-ST000763AN0012013.480E-51.600E-3Exercise;No;Yes
MANDELIC ACID #2 (M-H)-ST000842AN0013565.800E-109.350E-10Sample type;Muscles;Plasma;Pooled sample
Mannitol;HEXOSE ALCOHOLST000954AN0015655.860E-34.360E-1ethnicity;1;2;-
Mannitol;HEXOSE ALCOHOLST000956AN0015691.110E-22.310E-2Treatment;Condition-1;Condition-2;Condition-3;Control
MannopineST000292AN0004666.160E-31.220E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
mannose-6-phosphate NISTST000379AN0006131.780E-48.390E-4Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Manumycin A-13C0[+H]+ST000148AN0002357.440E-33.890E-2Treatment;13C-Glc;unlabeled
Manumycin A-13C16[+H]+ST000148AN0002353.460E-21.260E-1Treatment;13C-Glc;unlabeled
Manumycin A-13C17[+H]+ST000148AN0002351.110E-25.230E-2Treatment;13C-Glc;unlabeled
MarinobufageninST000566AN0008693.080E-121.230E-11Time point;Post;Pre;Baseline
MarinobufageninST000566AN0008692.490E-39.530E-3group;Old-Curcumin;Old-Placebo;young
MarinobufageninST000567AN0008717.610E-251.360E-23Time point;Post;Pre;Baseline
MarinobufageninST000567AN0008711.090E-51.120E-4groups;Old-Curcumin;Old-Placebo;young
masilinateST000923AN0015157.150E-31.800E-2Diagnosis;CD;nonIBD;UC
MBzPST001040AN0017034.790E-29.580E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
MCOAST000301AN0004792.950E-25.160E-2Cell Line;L229;LN18;Pooled glioblastoma;U-138
MCPP (Mono (3-carboxpropyl) phthalate)ST001048AN0017178.880E-163.770E-15Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
MECPP (Mono-2-ethyl-5-carboxypentyl phthalate)ST001048AN0017173.350E-44.180E-4Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
(-)-MedicocarpinST000403AN0006436.330E-61.860E-5Cell type;Mature erythrocyte;Reticulocyte
(-)-MedicocarpinST000539AN0008195.600E-51.720E-4Cell type;Mature erythrocyte;Reticulocyte
Melengestrol acetate-13C0[+Na]+ST000142AN0002258.110E-326.130E-31Treatment;13C-Glc;unlabeled
melibionateST000403AN0006433.670E-91.870E-8Cell type;Mature erythrocyte;Reticulocyte
melibionateST000539AN0008198.950E-117.060E-10Cell type;Mature erythrocyte;Reticulocyte
melibionateST001201AN0019992.950E-87.550E-8cell_type;iRBC;unRBC
melibionateST001202AN0020014.960E-391.270E-37cell_type;iRBC;unRBC
melibionateST001202AN0020011.020E-31.960E-3treatment_duration_(h);-;1.5;3;6;9
melibionateST001204AN0020051.730E-44.330E-4cell_type;iRBC;unRBC
MeradimateST000047AN0000805.080E-31.260E-1Cognitive Status;AD;CN;MCI
Meradimate+2.886999ST000047AN0000814.090E-22.080E-1Cognitive Status;AD;CN;MCI
MESST001201AN0019991.270E-26.940E-2treatment;DHA;DMSO;OZ277;OZ439
MESST001202AN0020002.390E-247.640E-24cell_type;iRBC;unRBC
MESST001202AN0020001.130E-42.210E-4treatment_duration_(h);-;1.5;3;6;9
MesaconateST000403AN0006434.440E-23.340E-1timepoint;1 hour;20 hours
MesaconateST000539AN0008191.660E-21.810E-1Glucose labelling;C13 glucose;unlabelled
MesaconateST001202AN0020011.280E-121.940E-12cell_type;iRBC;unRBC
MesaconateST001202AN0020012.310E-81.600E-7treatment_duration_(h);-;1.5;3;6;9
MesaconateST001205AN0020071.740E-38.850E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
metabolite 1ST000539AN0008181.740E-23.050E-2Cell type;Mature erythrocyte;Reticulocyte
metabolite 1ST000539AN0008191.910E-21.860E-1Glucose labelling;C13 glucose;unlabelled
metabolite 1ST000539AN0008193.140E-25.260E-2Cell type;Mature erythrocyte;Reticulocyte
metabolite 2ST000539AN0008185.140E-37.400E-2timepoint;1 hour;20 hours
metabolite 2ST000539AN0008192.780E-101.860E-8Glucose labelling;C13 glucose;unlabelled
metabolite 3ST000539AN0008189.090E-81.750E-5Glucose labelling;C13 glucose;unlabelled
methanofuran biosynththesis intermediate MF1ST001205AN0020076.960E-58.460E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
methiinST000403AN0006421.730E-33.310E-3Cell type;Mature erythrocyte;Reticulocyte
methiinST000539AN0008184.420E-41.090E-3Cell type;Mature erythrocyte;Reticulocyte
methiinST001202AN0020003.350E-491.500E-47cell_type;iRBC;unRBC
MethoxsalenMetaboliteST000047AN0000835.660E-84.540E-6Cognitive Status;AD;CN;MCI
Methoxycinnamaldehyde-13C0[+QDA adduct]+ST000148AN0002352.010E-28.250E-2Treatment;13C-Glc;unlabeled
MethoxytyramineST001039AN0017124.730E-31.150E-2Sample.Matrix;Plasma;Urine
Methyl 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-p-toluateST000539AN0008197.630E-31.230E-1timepoint;1 hour;20 hours
methyl-4-hydroxybenzoate sulfateST000899AN0014641.730E-23.780E-2Type;Control;Crohn disease;Ulcerative Colitis
METHYL7-DESHYDROXYPYROGALLIN-4-CARBOXYLATEST000046AN0000785.140E-65.100E-4Cognitive Status;AD;CN;MCI
methyl8-[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl]-octanoateST000046AN0000783.710E-48.410E-3Cognitive Status;AD;CN;MCI
Methyl butenal-13C0[+13CD3 QDA]+ST000148AN0002351.460E-26.480E-2Treatment;13C-Glc;unlabeled
Methylbutyric aid / Valeric / IsovalericST001000AN0018793.820E-62.670E-5Diagnosis;CD;Control;UC
Methyl CaprateST000978AN0016028.120E-35.410E-2Competitive_RRTvsDeath;.;N;RRT;DEATH
Methyl CaprateST000978AN0016028.750E-35.170E-2Cox_RRT;.;N;Y
Methyl CaprateST000978AN0016022.930E-21.820E-1Cox_Composite_DeathRRT;.;N;Y
Methyl deoxyadenosineST000614AN0009433.230E-101.260E-9Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl deoxyadenosineST000614AN0009431.370E-44.440E-4Diagonsis;Benign;Cancer;Normal
Methyl DocosanoateST000978AN0016022.600E-21.140E-1Cox_RRT;.;N;Y
Methyl DocosanoateST000978AN0016024.640E-21.700E-1Competitive_RRTvsDeath;.;N;RRT;DEATH
Methyl eicosatrienoateST000586AN0009013.530E-76.670E-7Plasma Volume;0 uL;150 uL;700 uL
Methyl eicosatrienoateST000589AN0009043.390E-1161.260E-115Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Methyl GuanineST000614AN0009432.650E-111.720E-10Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl GuanineST000614AN0009432.730E-46.650E-4Diagonsis;Benign;Cancer;Normal
methylhexadecanoic acidST000368AN0006021.210E-99.110E-9Organ;Plasma;Serum;Serum or Plasma
methylhexadecanoic acidST000369AN0006031.480E-38.350E-3Smoker;Current;Former;NA
methylhexadecanoic acidST000369AN0006031.510E-38.550E-3Gender;F;M;NA
methylhexadecanoic acidST000369AN0006035.670E-31.900E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
methylhexadecanoic acidST000385AN0006207.320E-416.180E-40Organ;Plasma;Serum;Serum or Plasma
methylhexadecanoic acidST000385AN0006202.270E-41.340E-3Gender;F;M;NA
methylhexadecanoic acidST000385AN0006201.500E-37.660E-3Smoking Status;Current;Former;NA
methylhexadecanoic acidST000385AN0006201.550E-35.630E-3Health State;Adenocarcinoma;Healthy;NA
methylhexadecanoic acidST000386AN0006214.130E-32.210E-2Smoker;Current;Former;NA
methylhexadecanoic acidST000386AN0006215.360E-32.430E-2Gender;F;M;NA
methylhexadecanoic acidST000386AN0006212.410E-29.270E-2Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
methylhexadecanoic acidST000389AN0006253.350E-22.910E-1Group;Benign;Cancer
MethylhippurateST000553AN0008472.750E-117.880E-11Sample type;Plasma;Urine
Methyl-isopropylhexadienal-13C0[+13CD3 QDA]+ST000142AN0002254.260E-22.290E-1Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+Na]+ST000142AN0002252.650E-326.130E-31Treatment;13C-Glc;unlabeled
MethylitaconateST001205AN0020064.840E-31.700E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Methyl LinocerateST000978AN0016023.630E-21.330E-1Cox_RRT;.;N;Y
Methyl methoxyacetateST000614AN0009413.760E-141.350E-13Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methyl methoxyacetateST000614AN0009411.750E-71.050E-6Diagonsis;Benign;Cancer;Normal
methylnaphthyl sulfate (2)*ST000974AN0015953.680E-21.060E-1REGION;AHRI;MRC;SUN
methylnaphthyl sulfate (2)*ST000975AN0015961.020E-51.730E-3REGION;MAK;SUN
methylnaphthyl sulfate (2)*ST000975AN0015961.670E-41.390E-3GENDER;F;M
MethylnoradrenalineST000356AN0005836.850E-286.890E-27Diagnosis;breast cancer;control
MethylnoradrenalineST000356AN0005836.060E-196.480E-18stage;-;2;3
Methyl palmitateST000586AN0009011.720E-351.100E-34Plasma Volume;0 uL;150 uL;700 uL
Methyl palmitateST000589AN0009046.410E-611.390E-60Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
MethylpicolinateST000553AN0008478.070E-81.360E-7Sample type;Plasma;Urine
MethylpicolinateST001317AN0021921.629E-72.225E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
MethylpicolinateST001317AN0021921.629E-72.225E-7SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
MethylprednisoneST000567AN0008715.880E-123.000E-11Time point;Post;Pre;Baseline
MethylprednisoneST000567AN0008717.540E-32.110E-2groups;Old-Curcumin;Old-Placebo;young
methylsuccinoylcarnitine (1)ST000974AN0015952.270E-531.130E-51REGION;AHRI;MRC;SUN
methylsuccinoylcarnitine (1)ST000975AN0015961.820E-33.750E-2GROUP;case;control
Methylthioribulose phosphate-13C0[+QDA adduct]+ST000142AN0002256.680E-326.130E-31Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C1[+QDA adduct]+ST000142AN0002252.700E-326.130E-31Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C6[+QDA adduct]+ST000142AN0002256.950E-326.130E-31Treatment;13C-Glc;unlabeled
?-Methyltryptamine (AMT)ST000242AN0003771.330E-23.980E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
MethyltyrosineST000356AN0005827.610E-31.370E-2Diagnosis;breast cancer;control
MethyltyrosineST000356AN0005823.220E-25.800E-2stage;-;2;3
Met-Met-Pro-TyrST000403AN0006431.660E-29.540E-2Glucose labelling;C13 glucose;unlabelled
Met-SO / MetST000545AN0008298.730E-37.600E-2Sample Type;Control;Replicate
Met-Trp-OHST000242AN0003754.610E-126.640E-11Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Met-Trp-Trp-TyrST000403AN0006425.900E-123.480E-9Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-TyrST000403AN0006424.000E-24.140E-1timepoint;1 hour;20 hours
Met-Trp-Trp-TyrST000539AN0008181.780E-101.030E-7Glucose labelling;C13 glucose;unlabelled
Met-Trp-Trp-TyrST000539AN0008184.320E-22.360E-1timepoint;1 hour;20 hours
MevalolactoneST001048AN0017164.310E-566.330E-55Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
MEVALOLACTONEST000016AN0000333.840E-63.050E-5Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
MEVALOLACTONEST000016AN0000332.130E-49.020E-4Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
MEVALOLACTONEST000016AN0000335.280E-38.620E-3Material;Cells;Media
MEVALOLACTONEST000105AN0001731.480E-236.090E-21Sampling;After SWS onset;Morning fasting
MG(18:0e/0:0/0:0)ST000241AN0003732.910E-99.670E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
m-hydroxybenzoic acidST001325AN0022072.036E-352.300E-34Sample type;batch pool;chear plasma;master pool;red cross pl...
m-hydroxybenzoic acidST001325AN0022079.617E-117.245E-10Gender;-;female;male
mildronateST000403AN0006423.930E-91.760E-8Cell type;Mature erythrocyte;Reticulocyte
mildronateST000539AN0008182.150E-101.540E-9Cell type;Mature erythrocyte;Reticulocyte
Molybdenum cofactor (sulfide)ST000241AN0003733.530E-246.640E-22Concentration (uM);0;500
Molybdenum cofactor (sulfide)ST000241AN0003731.180E-162.220E-15Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
MonodehydroascorbateST000292AN0004669.390E-31.530E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Monoethyl phthalate (mEP)ST000954AN0015653.160E-37.280E-2daily_dose;2;3;4;1
monohexsphST000362AN0005941.510E-45.210E-4Gender;1;2
monohexsphST000362AN0005942.420E-29.440E-1SmokingStatus;-;1
monohexsphST000362AN0005942.510E-21.310E-1Chronic_Bronchitis;1;-
Mono-N-depropylprobenecidST000046AN0000791.600E-28.450E-2Cognitive Status;AD;CN;MCI
Mono-N-depropylprobenecidST000047AN0000831.520E-29.740E-2Cognitive Status;AD;CN;MCI
Mono-N-depropylprobenecidST000421AN0006641.400E-85.570E-6treatment;ND;T1D poor glycemic control
Mono-N-depropylprobenecidST000422AN0006683.300E-52.520E-3treatment;ND;T1D good glycemic control
MontecristinST001202AN0020004.030E-282.030E-27cell_type;iRBC;unRBC
MOPSST001202AN0020006.460E-221.660E-21cell_type;iRBC;unRBC
MOPSST001202AN0020001.020E-52.560E-5treatment_duration_(h);-;1.5;3;6;9
MUFA (PC)ST000545AN0008301.860E-67.970E-6Sample Type;Control;Replicate
MUFA (PC) / SFA (PC)ST000545AN0008302.270E-122.170E-10Sample Type;Control;Replicate
Mycalamide AST000566AN0008707.440E-34.910E-2group;Old-Curcumin;Old-Placebo;young
Mycalamide AST000566AN0008703.210E-23.330E-2Time point;Post;Pre;Baseline
myo-Inositol 1-phosphate/myo-Inositol 3-phosphateST000230AN0003436.990E-34.930E-2Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
Myoinositol-2-phosphateST000586AN0009017.020E-131.790E-12Plasma Volume;0 uL;150 uL;700 uL
Myoinositol-2-phosphateST000589AN0009045.880E-369.210E-36Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Myxalamid DST001204AN0020041.890E-22.630E-1treatment;DHA;DMSO;OZ277;OZ439
Myxothiazol ZST000566AN0008701.830E-65.050E-6Time point;Post;Pre;Baseline
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000077AN0001231.410E-61.530E-6Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000077AN0001232.290E-64.590E-6Treatment;100uM Met ;370uM Hcy ;quality check
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enineST000089AN0001417.590E-201.510E-19Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N2-Acetyl-L-aminoadipate 2ST000539AN0008191.240E-64.990E-6Cell type;Mature erythrocyte;Reticulocyte
N2-Acetyl-L-aminoadipyl-delta-phosphateST001201AN0019983.780E-89.720E-8cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphateST001202AN0020001.160E-81.480E-8cell_type;iRBC;unRBC
N2-Acetyl-L-aminoadipyl-delta-phosphateST001202AN0020003.560E-81.860E-7treatment_duration_(h);-;1.5;3;6;9
N2-(D-1-Carboxyethyl)-L-arginineST000403AN0006425.190E-41.070E-3Cell type;Mature erythrocyte;Reticulocyte
N2-(D-1-Carboxyethyl)-L-arginineST000539AN0008183.330E-48.350E-4Cell type;Mature erythrocyte;Reticulocyte
N2-(D-1-Carboxyethyl)-L-arginineST001201AN0019983.440E-32.370E-2treatment;DHA;DMSO;OZ277;OZ439
N2-(D-1-Carboxyethyl)-L-arginineST001201AN0019983.550E-25.120E-2cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001202AN0020001.500E-402.630E-39cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001202AN0020008.170E-31.120E-2treatment_duration_(h);-;1.5;3;6;9
N2-(D-1-Carboxyethyl)-L-arginineST001204AN0020041.710E-127.390E-12cell_type;iRBC;unRBC
N2-(D-1-Carboxyethyl)-L-arginineST001204AN0020043.940E-23.080E-1treatment_duration_(h);-;3;6;9
N2-(D-1-Carboxyethyl)-L-arginineST001205AN0020062.020E-25.050E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
N2-FructopyranosylarginineST001205AN0020062.080E-41.580E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
N2-Succinyl-glutamic acid 5-semialdehyde-13C0[+H]+ST000142AN0002258.310E-326.130E-31Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C1[+H]+ST000142AN0002256.150E-326.130E-31Treatment;13C-Glc;unlabeled
N-(3-pyridyl)-Indomethacin amideST000242AN0003772.820E-26.760E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-(4-benzenesulfonamide) arachidonoyl amineST000242AN0003751.130E-21.380E-2Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008185.650E-37.440E-2timepoint;1 hour;20 hours
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008189.170E-32.120E-1Glucose labelling;C13 glucose;unlabelled
N5-acetyl-N5-hydroxy-L-ornithineST000539AN0008182.750E-24.560E-2Cell type;Mature erythrocyte;Reticulocyte
N5-acetyl-N5-hydroxy-L-ornithineST001201AN0019986.110E-51.280E-4cell_type;iRBC;unRBC
N5-acetyl-N5-hydroxy-L-ornithineST001201AN0019983.930E-26.150E-1treatment_duration_(h);-;0.5;1.5;3
N5-acetyl-N5-hydroxy-L-ornithineST001202AN0020001.940E-278.890E-27cell_type;iRBC;unRBC
N5-formyl-N5-hydroxy-L-ornithineST001201AN0019992.250E-188.240E-18cell_type;iRBC;unRBC
N5-formyl-N5-hydroxy-L-ornithineST001201AN0019991.570E-27.650E-2treatment;DHA;DMSO;OZ277;OZ439
N-(5-Methyl-3-oxohexyl)alanineST001202AN0020006.190E-77.420E-7cell_type;iRBC;unRBC
N-(5-Methyl-3-oxohexyl)alanineST001202AN0020007.990E-62.040E-5treatment_duration_(h);-;1.5;3;6;9
N-(6-Aminohexanoyl)-6-aminohexanoateST000292AN0004662.960E-22.550E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
N6-carboxymethyllysineST000899AN0014627.020E-44.880E-3Type;Control;Crohn disease;Ulcerative Colitis
N-(6-Quinolinyl)phthalimideST000978AN0016024.770E-21.540E-1Cox_RRT;.;N;Y
N-Ace-Asp-13C0ST001049AN0018642.190E-21.070E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C1ST001049AN0018643.090E-34.110E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C2ST001049AN0018641.050E-45.840E-3protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C3ST001049AN0018641.710E-32.980E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C4ST001049AN0018645.390E-35.570E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C5ST001049AN0018641.010E-28.270E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-acetyl-2-aminoctanoateST000974AN0015951.990E-21.180E-1GENDER;F;M
N-acetyl-2-aminoctanoateST000974AN0015953.110E-29.200E-2REGION;AHRI;MRC;SUN
N-acetyl-2-aminoctanoateST000975AN0015961.030E-49.590E-4GENDER;F;M
N-Acetyl-5-aminosalicylicacid-3.4608338ST000046AN0000793.460E-21.280E-1Cognitive Status;AD;CN;MCI
N-Acetyl-5-hydroxysulfapyridineST000046AN0000794.690E-33.950E-2Cognitive Status;AD;CN;MCI
N-Acetyl-5-hydroxysulfapyridineST000421AN0006643.640E-31.710E-1treatment;ND;T1D poor glycemic control
N-Acetyl-ala-ala-ala-methylesterST000403AN0006423.510E-21.900E-1Glucose labelling;C13 glucose;unlabelled
N-acetylalliinST000975AN0015963.290E-23.250E-1REGION;MAK;SUN
N-AcetylanthranilateST001201AN0019997.360E-57.900E-3treatment_duration_(h);-;0.5;1.5;3
N-AcetylanthranilateST001201AN0019996.670E-41.310E-3cell_type;iRBC;unRBC
N-AcetylanthranilateST001201AN0019992.880E-32.320E-2treatment;DHA;DMSO;OZ277;OZ439
N-AcetylanthranilateST001205AN0020074.490E-37.090E-1treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosaminateST000403AN0006432.250E-45.210E-4Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosaminateST000539AN0008192.220E-81.120E-7Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosaminateST001201AN0019998.310E-31.450E-2cell_type;iRBC;unRBC
N-Acetyl-D-glucosaminateST001204AN0020041.170E-22.010E-2cell_type;iRBC;unRBC
N-Acetyl-D-glucosaminateST001204AN0020041.570E-22.340E-1treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosamine 6-phosphateST000403AN0006431.650E-111.260E-10Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphateST000539AN0008192.410E-141.440E-12Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphateST001201AN0019993.920E-61.580E-4treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosamine 6-phosphateST001201AN0019991.570E-22.600E-2cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphateST001202AN0020013.590E-282.490E-27cell_type;iRBC;unRBC
N-Acetyl-D-glucosamine 6-phosphateST001202AN0020018.070E-62.400E-5treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-D-glucosamine 6-phosphateST001204AN0020055.480E-102.000E-9cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitolST000539AN0008181.200E-43.220E-4Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitolST001201AN0019985.380E-41.030E-3cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitolST001202AN0020011.010E-133.710E-12treatment_duration_(h);-;1.5;3;6;9
N-acetyl -D- glucosaminitolST001202AN0020013.110E-33.390E-3cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitolST001204AN0020044.890E-41.030E-3cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitol 2ST000539AN0008181.200E-43.220E-4Cell type;Mature erythrocyte;Reticulocyte
n-acetyl-d-hexosamineST001322AN0021983.197E-111.321E-9treatment;expecting 2 month - human breast milk;expecting 2 ...
n-acetyl-d-hexosamineST001322AN0021984.466E-21.870E-1group;OB;NW
N-acetyl-D-hexosamineST000412AN0006521.640E-96.370E-8Collection Time;1 Hr;2 Hr;3 Hr;-
N-ACETYL-D-HEXOSAMINEST000011AN0000285.990E-33.510E-2COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
N-ACETYL-D-HEXOSAMINEST000011AN0000282.410E-21.050E-1gender;male;female
N-ACETYL-D-HEXOSAMINEST000016AN0000331.020E-144.270E-13Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
N-ACETYL-D-HEXOSAMINEST000016AN0000332.810E-147.390E-13Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
N-ACETYL-D-HEXOSAMINEST000016AN0000338.760E-51.820E-4Material;Cells;Media
N-ACETYL-D-HEXOSAMINEST000106AN0001751.970E-31.060E-1Constitution;Lean;Obese
N-Acetylglutamic-13C1[-H+]-ST000367AN0006012.830E-29.640E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C2[-H+]-ST000367AN0006011.530E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C3[-H+]-ST000367AN0006011.950E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C4[-H+]-ST000367AN0006011.280E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C5[-H+]-ST000367AN0006011.430E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C6[-H+]-ST000367AN0006011.320E-29.070E-2Tissue type;nontumor;tumor
N-Acetylglutamic-13C7[-H+]-ST000367AN0006011.510E-29.070E-2Tissue type;nontumor;tumor
N-acetylglycine NISTST000062AN0001001.190E-26.800E-2Source;Group 1 - Score 0;Group 2 - Score 50
N-acetylglycine NISTST000385AN0006208.230E-101.200E-9Organ;Plasma;Serum;Serum or Plasma
N-acetylglycine NISTST000385AN0006208.140E-31.770E-2Gender;F;M;NA
N-acetylglycine NISTST000386AN0006211.170E-24.340E-2Smoker;Current;Former;NA
N-acetylglycine NISTST000389AN0006251.480E-25.000E-1Emphysema/COPD;No;Yes
N-acetylglycine NISTST000392AN0006281.590E-24.050E-2Organ;Plasma;Serum;Serum or Plasma
N-acetylglycine NISTST001131AN0018564.320E-21.810E-1Treatment;Healthy;Trauma
N-ACETYL-HEXOSAMINEST000475AN0007396.130E-74.910E-6Treatment;-;MDH inhib
N-ACETYL-HEXOSAMINEST000583AN0008953.780E-21.940E-1time;12-weeks;baseline
N-ACETYL-HEXOSAMINEST000954AN0015642.640E-21.820E-1race;1;2
N-ACETYL-HEXOSAMINEST000956AN0015685.580E-51.990E-4Treatment;Condition-1;Condition-2;Condition-3;Control
N-ACETYL-HEXOSAMINEST000956AN0015693.130E-25.580E-2Treatment;Condition-1;Condition-2;Condition-3;Control
N-acetylisoleucineST000899AN0014642.050E-24.340E-2Type;Control;Crohn disease;Ulcerative Colitis
N-acetylisoleucineST000974AN0015951.340E-27.360E-2TIMEPOINT;BL;M06;M18
N-acetylisoleucineST000976AN0015971.110E-22.940E-1TIMEPOINT;BL;M06
N-acetyl-isoputrenine*ST000974AN0015951.960E-44.560E-3TIMEPOINT;BL;M06;M18
N-acetyl-isoputrenine*ST000974AN0015951.420E-29.430E-2GENDER;F;M
N-acetyl-isoputrenine*ST000975AN0015961.040E-51.770E-3GROUP;case;control
N-ACETYL-L-ALANINE;3-AMINO-5-HYDROXYBENZOIC ACIDST000956AN0015688.720E-109.320E-9Treatment;Condition-1;Condition-2;Condition-3;Control
N-Acetyl LysineST000614AN0009391.250E-31.560E-3Diagonsis;Benign;Cancer;Normal
N-Acetyl LysineST000614AN0009392.490E-32.870E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
N-acetylmannosamine minorST000087AN0001391.450E-32.830E-3Time Point;18 hours;4 hours
N-Acetyl-O-acetylneuraminateST001204AN0020048.490E-231.380E-21cell_type;iRBC;unRBC
N-Acetyl-O-acetylneuraminateST001204AN0020042.660E-22.650E-1treatment_duration_(h);-;3;6;9
N-Acetyl-p-benzoquinonimineST000047AN0000813.000E-34.820E-2Cognitive Status;AD;CN;MCI
N-Acetylphenylalanine / Indole-3-EthanolST001040AN0017032.080E-38.340E-3Sample Type/Matrix;Pooled quality control sample;urine;Water...
N-acetyltheanineST000974AN0015955.370E-31.980E-2REGION;AHRI;MRC;SUN
N-acetyltheanineST000975AN0015961.740E-26.460E-2GENDER;F;M
N-acetyphenylalanineST001192AN0019843.390E-22.800E-1Diet;-;Omnivore;Vegetarian
Naloxone-3-glucuronideST000242AN0003779.460E-44.330E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N(alpha)-t-Butoxycarbonyl-L-leucineST000567AN0008721.230E-66.070E-6Time point;Post;Pre;Baseline
N-.alpha.-(tert-Butoxycarbonyl)-L-histidineST001211AN0020172.130E-41.430E-3Group;Control;Methotrexate
Na-methylhistamineST000553AN0008472.390E-84.360E-8Sample type;Plasma;Urine
N-Amidino-L-glutamateST000292AN0004661.550E-21.970E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Nanchangmycin-13C0[+Na]+ST000142AN0002254.090E-326.130E-31Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+QDA adduct+Na]+ST000142AN0002258.090E-326.130E-31Treatment;13C-Glc;unlabeled
Nanchangmycin-13C1[+QDA adduct+Na]+ST000142AN0002256.600E-326.130E-31Treatment;13C-Glc;unlabeled
Naphthoquinone-13C0[+H]+ST000142AN0002258.730E-326.130E-31Treatment;13C-Glc;unlabeled
Napthyl amineST000614AN0009431.280E-31.560E-3Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Napthyl amineST000614AN0009432.670E-23.060E-2Diagonsis;Benign;Cancer;Normal
N-BOC-D-GLUCOSAMINEST000016AN0000331.540E-85.010E-8Material;Cells;Media
N-BOC-D-GLUCOSAMINEST000016AN0000332.640E-25.870E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
N-BOC-L-TryptophanST000954AN0015646.870E-31.320E-1race;1;2
N-Butyl-beta-carboline-3-carboxylateST001202AN0020019.270E-182.010E-17cell_type;iRBC;unRBC
N-Butyl-beta-carboline-3-carboxylateST001202AN0020011.220E-21.870E-2treatment_duration_(h);-;1.5;3;6;9
N-desmethylimatinibST000444AN0006953.230E-25.280E-2Sample Treatment;Bubbled;Control
N-DidesethylquinagolideST000047AN0000823.420E-74.270E-5Cognitive Status;AD;CN;MCI
N-Didesethylquinagolide glucuronideST000421AN0006631.930E-22.080E-1treatment;ND;T1D poor glycemic control
N-dimethylethanolamineST000403AN0006429.500E-31.640E-2Cell type;Mature erythrocyte;Reticulocyte
N-dimethylethanolamineST001202AN0020001.470E-91.930E-9cell_type;iRBC;unRBC
Ne-AcetyllysineST001037AN0016983.850E-21.040E-1Description ;Blank;Reagent Blank;Serum Sample;Solvent
Neomenthyl acetateST000567AN0008721.590E-42.950E-4Time point;Post;Pre;Baseline
Neomenthyl acetateST000567AN0008726.590E-33.570E-2groups;Old-Curcumin;Old-Placebo;young
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000046AN0000763.020E-21.310E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000802.490E-21.950E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000811.360E-21.150E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000822.130E-21.420E-1Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamineST000047AN0000832.960E-21.530E-1Cognitive Status;AD;CN;MCI
N-Glycolyl-D-mannosamineST001201AN0019981.680E-63.840E-6cell_type;iRBC;unRBC
N-HISTIDYL-2-AMINONAPHTHALENE (betaNA)ST000421AN0006653.690E-24.500E-1treatment;ND;T1D poor glycemic control
N-HISTIDYL-2-AMINONAPHTHALENE(betaNA)ST000046AN0000766.580E-82.850E-6Cognitive Status;AD;CN;MCI
N-Hydroxy-1-aminonaphthaleneST000403AN0006436.620E-31.190E-2Cell type;Mature erythrocyte;Reticulocyte
N-Hydroxy-1-aminonaphthaleneST000539AN0008191.990E-45.500E-4Cell type;Mature erythrocyte;Reticulocyte
N-hydroxyisoleucineST000403AN0006431.220E-121.470E-11Cell type;Mature erythrocyte;Reticulocyte
N-hydroxyisoleucineST000539AN0008194.350E-103.030E-9Cell type;Mature erythrocyte;Reticulocyte
N-hydroxyisoleucineST001202AN0020005.440E-56.180E-5cell_type;iRBC;unRBC
N-hydroxyisoleucineST001202AN0020007.670E-41.240E-3treatment_duration_(h);-;1.5;3;6;9
N-HydroxymethylnicotinamideST000566AN0008702.500E-22.670E-2Time point;Post;Pre;Baseline
N-HydroxymethylnicotinamideST000566AN0008703.130E-21.220E-1group;Old-Curcumin;Old-Placebo;young
nicotinamide guanine dinucleotideST001201AN0019991.490E-124.600E-12cell_type;iRBC;unRBC
nicotinamide guanine dinucleotideST001201AN0019994.910E-21.910E-1treatment;DHA;DMSO;OZ277;OZ439
nicotinamide guanine dinucleotideST001202AN0020017.590E-118.830E-10treatment_duration_(h);-;1.5;3;6;9
nicotinamide guanine dinucleotideST001205AN0020071.220E-36.750E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Nicotine-1-N-oxideST001048AN0017163.070E-1672.260E-165Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Nigakilactone K-13C0[+13CD3 QDA]+ST000142AN0002252.760E-326.130E-31Treatment;13C-Glc;unlabeled
Nigakilactone M-13C0[+QDA adduct+Na]+ST000142AN0002255.520E-326.130E-31Treatment;13C-Glc;unlabeled
nitrocyclohexaneST000539AN0008181.060E-22.350E-1Glucose labelling;C13 glucose;unlabelled
nitrocyclohexaneST000539AN0008181.920E-23.340E-2Cell type;Mature erythrocyte;Reticulocyte
Nitrophenyl-ketovalidamine-13C0[+H]+ST000142AN0002255.450E-326.130E-31Treatment;13C-Glc;unlabeled
Nitro-Tyr1)ST000783AN0012393.570E-27.020E-1RACE;AA;EA
N-Methyl-2-oxoglutaramate-13C0[+Na]+ST000142AN0002252.340E-326.130E-31Treatment;13C-Glc;unlabeled
N-Methylalanine/2-Aminobutanoic acid/N-EthylglycineST000586AN0009013.900E-66.490E-6Plasma Volume;0 uL;150 uL;700 uL
N-METHYL-L-GLUTAMATE;ALPHA-AMINOADIPATE;L-2-Aminoadipic AcidST000956AN0015691.210E-45.480E-4Treatment;Condition-1;Condition-2;Condition-3;Control
N-methylundec-10-enamideST000242AN0003772.130E-38.880E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
NMMAST000923AN0015131.680E-23.420E-2Diagnosis;CD;nonIBD;UC
NMMAST001142AN0018753.410E-157.960E-15Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
NMMAST001142AN0018752.820E-95.050E-9Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
NMMAST001236AN0020541.180E-32.900E-2OS_Censor (1 means the time is a censoring time and 0 means ...
NMMAST001237AN0020553.030E-353.100E-33CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
NMMAST001237AN0020551.320E-166.790E-15OS_Censor (1 means the time is a censoring time and 0 means ...
NMMAST001237AN0020554.480E-21.610E-1Prior antiangiogenic regimens (≥2);FALSE;TRUE
NNAL-N-glucuronideST000444AN0006952.440E-25.210E-2Sample Treatment;Bubbled;Control
nocardicin GST000403AN0006433.450E-81.350E-7Cell type;Mature erythrocyte;Reticulocyte
nocardicin GST000539AN0008195.290E-72.270E-6Cell type;Mature erythrocyte;Reticulocyte
N-(octanoyl)-L-homoserineST000403AN0006424.270E-81.610E-7Cell type;Mature erythrocyte;Reticulocyte
N-(octanoyl)-L-homoserineST000539AN0008182.910E-61.030E-5Cell type;Mature erythrocyte;Reticulocyte
N-Oleoyl-L-SerineST000566AN0008707.520E-51.250E-4Time point;Post;Pre;Baseline
N-Oleoyl-L-SerineST000566AN0008701.640E-32.150E-2group;Old-Curcumin;Old-Placebo;young
nonulose 9-phosphateST000403AN0006431.100E-107.600E-10Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphateST000539AN0008195.380E-93.070E-8Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphateST001202AN0020019.490E-382.020E-36cell_type;iRBC;unRBC
nonulose 9-phosphateST001202AN0020014.680E-37.990E-3treatment_duration_(h);-;1.5;3;6;9
nonulose 9-phosphateST001204AN0020053.450E-48.310E-4cell_type;iRBC;unRBC
nonulose 9-phosphateST001204AN0020056.030E-31.090E-1treatment_duration_(h);-;3;6;9
nonulose 9-phosphateST001205AN0020072.670E-55.630E-4parasite_line;Cam3.IIR539T;Cam3.IIrev
nonulose 9-phosphate 2ST000539AN0008195.380E-93.070E-8Cell type;Mature erythrocyte;Reticulocyte
nornorcapsaicinST000403AN0006427.390E-36.060E-2Glucose labelling;C13 glucose;unlabelled
nornorcapsaicinST000403AN0006421.090E-21.830E-1timepoint;1 hour;20 hours
N-Stearoyl-4-sphingenyl-1-O-phosphorylcholineST000089AN0001416.750E-98.450E-9Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N-Succinyl-L-diaminopimelic acidST000242AN0003764.500E-71.350E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-tert-Butyloxycarbonyl-deacetyl-leupeptin-13C0[+13CD3 QDA]+ST000142AN0002255.550E-326.130E-31Treatment;13C-Glc;unlabeled
NVP-BEZ235ST000567AN0008713.280E-27.570E-2groups;Old-Curcumin;Old-Placebo;young
O-6-deoxy-a-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-D-Galactose-13C0[+13CD3 QDA]+ST000148AN0002354.660E-61.310E-3Treatment;13C-Glc;unlabeled
O-Acetyl-Lcarnitine:HCl (N-methyl-D3)ST000552AN0008433.230E-29.420E-1VTE;no;yes
O-Acetyl-L-homoserine 2ST000539AN0008193.040E-22.170E-1timepoint;1 hour;20 hours
O-Acetylneuraminic acidST000403AN0006423.390E-58.690E-4Glucose labelling;C13 glucose;unlabelled
O-Acetylneuraminic acidST000539AN0008185.740E-31.730E-1Glucose labelling;C13 glucose;unlabelled
O-Acetylneuraminic acidST001202AN0020004.790E-189.290E-18cell_type;iRBC;unRBC
O-Acetylneuraminic acidST001202AN0020001.260E-42.430E-4treatment_duration_(h);-;1.5;3;6;9
OBTUSAQUINONEST000422AN0006687.150E-31.290E-1treatment;ND;T1D good glycemic control
o-cresol sulfateST000899AN0014641.610E-23.580E-2Type;Control;Crohn disease;Ulcerative Colitis
o-cresol sulfateST000974AN0015952.200E-32.480E-2TIMEPOINT;BL;M06;M18
o-cresol sulfateST000975AN0015962.700E-42.040E-3GENDER;F;M
Octonyl CarnitineST000614AN0009391.340E-51.840E-5Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Octonyl CarnitineST000614AN0009391.430E-52.240E-5Diagonsis;Benign;Cancer;Normal
octulose 8-phosphateST000403AN0006438.110E-36.180E-2Glucose labelling;C13 glucose;unlabelled
octulose 8-phosphateST000403AN0006431.240E-22.110E-2Cell type;Mature erythrocyte;Reticulocyte
octulose 8-phosphateST000539AN0008192.980E-22.420E-1Glucose labelling;C13 glucose;unlabelled
octulose 8-phosphateST001201AN0019993.580E-241.700E-23cell_type;iRBC;unRBC
octulose 8-phosphateST001202AN0020011.650E-204.440E-20cell_type;iRBC;unRBC
octulose 8-phosphateST001202AN0020015.470E-51.420E-4treatment_duration_(h);-;1.5;3;6;9
octulose 8-phosphateST001204AN0020042.890E-111.150E-10cell_type;iRBC;unRBC
octulose 8-phosphateST001205AN0020072.100E-41.900E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Octulose-monophosphateST000450AN0007062.010E-251.600E-24gender;Female;Male
O-DesmethyloxotolrestatsulfateST000045AN0000721.840E-21.440E-1Treatment;Insulin Withdrawal;Saline Infusion
O-Desmethylverapamil (D-702)ST000444AN0006951.860E-25.210E-2Sample Treatment;Bubbled;Control
O-glucosyl-tomatidineST001204AN0020054.060E-27.460E-2cell_type;iRBC;unRBC
OH-dihexcer d18:1 N16:0ST000362AN0005947.700E-31.060E-1Chronic_Bronchitis;1;-
OH-dihexcer d18:1 N18:0ST000362AN0005942.380E-36.540E-3Gender;1;2
OH-dihexcer d18:1 N18:0ST000362AN0005941.690E-21.260E-1Chronic_Bronchitis;1;-
OH-MiNP (7-OH-(Mono-methyl-octyl) phthalate / Mono-(4-methyl-7-hydroxyloctyl) phthalate)ST001048AN0017173.460E-1182.940E-116Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
OH-monohexcer d18:1 N16:0ST000362AN0005942.520E-51.340E-4Gender;1;2
OH-monohexcer d18:1 N16:0ST000362AN0005943.460E-31.630E-1GoldStage;3;4;2;1;-
OH-monohexcer d18:1 N18:0ST000362AN0005942.120E-34.880E-2Chronic_Bronchitis;1;-
OH-monohexcer d18:1 N20:0ST000362AN0005947.590E-31.540E-2Gender;1;2
OH-monohexcer d18:1 N24:0ST000362AN0005947.420E-31.540E-2Gender;1;2
OHPro-13C0ST000114AN0001945.280E-46.620E-3Treatment;None;Tetracycline
OHPro-13C0ST001045AN0017091.610E-21.050E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-13C2ST001046AN0017101.700E-23.540E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-13C5ST000076AN0001227.330E-45.150E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
OHPro-13C5ST001045AN0017091.080E-28.410E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
OHPro-ALLST000110AN0001857.300E-53.400E-3Oxygen Condition;hypoxia;normoxia
OHPro-ALLST000114AN0001947.080E-46.620E-3Treatment;None;Tetracycline
OHPro-ALLST001045AN0017092.640E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
oleamide NISTST000412AN0006521.310E-32.050E-3Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
OLEANANOICACIDACETATEST000046AN0000762.520E-81.430E-6Cognitive Status;AD;CN;MCI
Oleandrosyl-oleandolide-13C0[+QDA adduct]+ST000148AN0002351.650E-31.610E-2Treatment;13C-Glc;unlabeled
Oleoyl amine + 12.276432ST000421AN0006651.480E-23.420E-1treatment;ND;T1D poor glycemic control
Oleoylglycerone phosphate-13C0[+H]+ST000148AN0002352.350E-29.320E-2Treatment;13C-Glc;unlabeled
Oleoylglycerone phosphate-13C0[+QDA adduct+Na]+ST000142AN0002256.230E-326.130E-31Treatment;13C-Glc;unlabeled
omega-Cyclohexylundecanoic acidST000403AN0006435.130E-71.660E-6Cell type;Mature erythrocyte;Reticulocyte
omega-Cyclohexylundecanoic acidST000539AN0008191.720E-122.800E-11Cell type;Mature erythrocyte;Reticulocyte
O-methylcatechol sulfateST000899AN0014641.740E-35.470E-3Type;Control;Crohn disease;Ulcerative Colitis
O-methylcatechol sulfateST000974AN0015952.970E-33.090E-2TIMEPOINT;BL;M06;M18
O-methylcatechol sulfateST000975AN0015962.800E-23.780E-1TIMEPOINT;BL;M06;M18
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-GlucST000241AN0003732.600E-86.890E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-GlucST000241AN0003738.810E-46.020E-3Concentration (uM);0;500
O-PHOSPHONOHEXOPYRANOSEST000016AN0000332.890E-56.440E-5Material;Cells;Media
O-PHOSPHONOHEXOPYRANOSEST000016AN0000331.440E-24.970E-2Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
O-PHOSPHONOHEXOPYRANOSEST000044AN0000693.050E-21.150E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
Orn / SerST000544AN0008261.690E-25.230E-2Sample Type;Control;Replicate
ORTHOTHYMOTINIC ACIDST000421AN0006642.480E-22.520E-1treatment;ND;T1D poor glycemic control
ORTHOTHYMOTINICACIDST000047AN0000822.320E-21.450E-1Cognitive Status;AD;CN;MCI
o-ToluenesulfamideST000046AN0000771.780E-21.380E-1Cognitive Status;AD;CN;MCI
o-toluideneST000614AN0009439.800E-92.730E-8Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
o-toluideneST000614AN0009435.980E-41.170E-3Diagonsis;Benign;Cancer;Normal
o-toluidene2ST000614AN0009414.200E-107.550E-10Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
o-toluidene2ST000614AN0009419.180E-51.840E-4Diagonsis;Benign;Cancer;Normal
Ovothiol A-cysteine disulfideST001201AN0019989.400E-653.680E-62cell_type;iRBC;unRBC
Ovothiol BST001204AN0020054.840E-31.050E-2cell_type;iRBC;unRBC
Ovothiol disulfideST000403AN0006427.720E-51.840E-4Cell type;Mature erythrocyte;Reticulocyte
Ovothiol disulfideST000539AN0008186.860E-82.880E-7Cell type;Mature erythrocyte;Reticulocyte
Ovothiol disulfideST001201AN0019994.270E-32.920E-2treatment;DHA;DMSO;OZ277;OZ439
Ovothiol disulfideST001201AN0019993.130E-24.820E-2cell_type;iRBC;unRBC
Ovothiol disulfideST001202AN0020001.590E-92.060E-9cell_type;iRBC;unRBC
Ovothiol disulfideST001204AN0020047.590E-31.360E-2cell_type;iRBC;unRBC
Oxalomalate-13C0[+H]+ST000142AN0002257.760E-326.130E-31Treatment;13C-Glc;unlabeled
Oxalomalate-13C1[+H]+ST000142AN0002252.920E-326.130E-31Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C0[+13CD3 QDA]+ST000148AN0002351.810E-27.610E-2Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C10[+QDA adduct]+ST000148AN0002351.550E-26.770E-2Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C1[+13CD3 QDA]+ST000148AN0002353.430E-21.250E-1Treatment;13C-Glc;unlabeled
Oxidized Latia luciferin-13C1[+QDA adduct]+ST000148AN0002354.030E-21.420E-1Treatment;13C-Glc;unlabeled
Oxo-4-phosphonobutanoate-13C0[+QDA adduct]+ST000142AN0002256.860E-326.130E-31Treatment;13C-Glc;unlabeled
Oxodecanoate-13C0[+13CD3 QDA]+ST000148AN0002352.450E-29.600E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C0[+QDA adduct]+ST000148AN0002351.060E-25.080E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C1[+13CD3 QDA]+ST000148AN0002356.930E-33.720E-2Treatment;13C-Glc;unlabeled
Oxodecanoate-13C1[+QDA adduct]+ST000148AN0002354.170E-21.460E-1Treatment;13C-Glc;unlabeled
Oxodecanoate-13C3[+QDA adduct]+ST000148AN0002356.360E-33.510E-2Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+13CD3 QDA]+ST000148AN0002354.190E-21.470E-1Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+QDA adduct]+ST000148AN0002358.390E-34.250E-2Treatment;13C-Glc;unlabeled
Oxododecanoate-13C1[+QDA adduct]+ST000148AN0002353.210E-21.180E-1Treatment;13C-Glc;unlabeled
OxonitineST000242AN0003761.670E-76.660E-7Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Oxononanoate-13C0[+13CD3 QDA]+ST000148AN0002352.360E-29.330E-2Treatment;13C-Glc;unlabeled
Oxononanoate-13C0[+QDA adduct]+ST000148AN0002353.360E-21.230E-1Treatment;13C-Glc;unlabeled
Oxononanoate-13C1[+13CD3 QDA]+ST000148AN0002354.760E-21.620E-1Treatment;13C-Glc;unlabeled
Oxononanoate-13C1[+QDA adduct]+ST000148AN0002352.240E-29.000E-2Treatment;13C-Glc;unlabeled
Oxononanoate-13C8[+QDA adduct]+ST000142AN0002252.010E-326.130E-31Treatment;13C-Glc;unlabeled
Oxooctanoate-13C0[+QDA adduct+Na]+ST000148AN0002353.030E-21.140E-1Treatment;13C-Glc;unlabeled
Oxooctanoate-13C1[+QDA adduct]+ST000148AN0002354.060E-21.430E-1Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+H]+ST000142AN0002251.110E-316.910E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+QDA adduct+Na]+ST000142AN0002251.690E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C1[+QDA adduct+Na]+ST000142AN0002255.980E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C4[+QDA adduct+Na]+ST000142AN0002252.580E-326.130E-31Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C5[+QDA adduct+Na]+ST000142AN0002254.840E-326.130E-31Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+H]+ST000142AN0002258.300E-326.130E-31Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+Na]+ST000148AN0002352.370E-31.850E-2Treatment;13C-Glc;unlabeled
Oxostearate-13C2[+QDA adduct]+ST000142AN0002251.450E-28.270E-2Treatment;13C-Glc;unlabeled
OxprenololST000421AN0006632.480E-22.380E-1treatment;ND;T1D poor glycemic control
Oxytetracycline hydrochloride-13C0[+13CD3 QDA]+ST000148AN0002352.400E-29.470E-2Treatment;13C-Glc;unlabeled
[PA(18:0)] 1-octadecanoyl-2-sn-glycero-3-phosphateST001205AN0020071.350E-24.100E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
PAF C-16ST000553AN0008451.110E-82.000E-8Sample type;Plasma;Urine
PAF C-16ST000553AN0008462.400E-52.510E-5Sample type;Plasma;Urine
PAF C-18ST000553AN0008452.050E-94.250E-9Sample type;Plasma;Urine
PAF C-18ST000553AN0008461.650E-72.100E-7Sample type;Plasma;Urine
palmithoylethanolamideST000923AN0015163.680E-25.370E-2Diagnosis;CD;nonIBD;UC
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000044AN0000691.670E-31.610E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001741.510E-41.640E-3Sampling;After SWS onset;Morning fasting
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001744.190E-32.000E-1OSA;Negative;Positive
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)ST000105AN0001744.230E-37.690E-2Gender;Female;Male
PantathonicacidST000614AN0009426.430E-61.160E-5Diagonsis;Benign;Cancer;Normal
PantathonicacidST000614AN0009422.170E-53.250E-5Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
pantotheteST001000AN0018797.050E-42.320E-3Diagnosis;CD;Control;UC
para-toluideneST000614AN0009435.340E-79.060E-7Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
para-toluideneST000614AN0009433.050E-34.110E-3Diagonsis;Benign;Cancer;Normal
Paraxanthine / Theobromine /TheophyllineST001048AN0017163.790E-178.430E-17Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
PC(14:1(9Z)/P-16:0)ST000241AN0003732.280E-31.380E-2Concentration (uM);0;500
PC(14:1(9Z)/P-16:0)ST000241AN0003733.180E-34.350E-3Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC(14:1(9Z)/P-18:1(11Z))ST000241AN0003739.260E-136.960E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholineST000403AN0006432.250E-89.220E-8Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholineST000539AN0008191.370E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/11:0(CHO))ST000608AN0009294.250E-244.650E-23Sample_Type;blotter;serum
PC(16:0/15:1(14))ST000624AN0009561.190E-51.290E-4Condition;Control;Glaucomatous
[PC (16:0/3:0)] 1-hexadecanoyl-2-(2E-propionyl)-sn-glycero-3-phosphocholineST000539AN0008189.610E-31.800E-2Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(CHO))ST000403AN0006421.480E-64.550E-6Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(CHO))ST000539AN0008181.360E-43.590E-4Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(CHO))ST000608AN0009291.080E-206.470E-20Sample_Type;blotter;serum
PC(16:0/5:0(COOH))ST000403AN0006421.200E-42.750E-4Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))ST000403AN0006428.610E-31.610E-1timepoint;1 hour;20 hours
PC(16:0/5:0(COOH))ST000539AN0008181.170E-22.410E-1Glucose labelling;C13 glucose;unlabelled
PC(16:0/5:0(COOH))ST000539AN0008181.410E-21.410E-1timepoint;1 hour;20 hours
PC(16:0/7:0(CHO))ST000608AN0009291.520E-143.850E-14Sample_Type;blotter;serum
PC(16:0/P-18:1(11Z))ST000403AN0006426.570E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
PC(18:0/5:0(COOH))ST000608AN0009295.650E-78.540E-7Sample_Type;blotter;serum
PC(18:0/8:0(COOH))ST000608AN0009291.040E-142.690E-14Sample_Type;blotter;serum
PC(18:0/9:0(CHO))ST000608AN0009293.670E-244.190E-23Sample_Type;blotter;serum
PC(18:0/9:0(COOH))ST000608AN0009298.220E-193.860E-18Sample_Type;blotter;serum
PC(18:0/P-18:1(11Z))ST000403AN0006422.770E-101.470E-9Cell type;Mature erythrocyte;Reticulocyte
PC(18:0/P-18:1(11Z))ST000539AN0008184.990E-126.720E-11Cell type;Mature erythrocyte;Reticulocyte
PC(22:0/P-18:1(11Z))ST000241AN0003731.980E-53.600E-5Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC(24:1(15Z)/P-18:1(11Z))ST000241AN0003734.830E-134.220E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PC 24:2 (2:0/22:2(13Z.16Z)) [M+HCOO]-ST001111AN0018063.190E-111.860E-10Sample;Benign;Cancer;Metastasis
PC 28:2 (2:0/26:2(5E.9Z)) [M+HCOO]-ST001111AN0018063.500E-59.510E-5Sample;Benign;Cancer;Metastasis
PC 33:3 (15:1(9Z)/18:2(2E.4E)) [M-Ac-H]-ST001111AN0018068.940E-31.590E-2Sample;Benign;Cancer;Metastasis
PC 34:2 (17:2(9Z.12Z)/17:0) [M-Ac-H]-ST001111AN0018066.350E-156.200E-14Sample;Benign;Cancer;Metastasis
PC 36:2 (18:0/18:2(2E.4E)) [M+HCOO]-ST001111AN0018062.560E-34.860E-3Sample;Benign;Cancer;Metastasis
PC 36:4 (16:0/20:4(5E.8E.11E.14E)) [M+HCOO]-ST001111AN0018064.820E-41.080E-3Sample;Benign;Cancer;Metastasis
PC 40:3 (20:0/20:3(5Z.8Z.11Z)) [M-Ac-H]-ST001111AN0018068.690E-52.200E-4Sample;Benign;Cancer;Metastasis
PC 40:3 (20:1(11E)/20:2(11Z.14Z)) [M-Ac-H]-ST001111AN0018069.500E-52.390E-4Sample;Benign;Cancer;Metastasis
PC 40:4 (18:0/22:4(7Z.10Z.13Z.16Z)) [M-Ac-H]-ST001111AN0018061.430E-32.860E-3Sample;Benign;Cancer;Metastasis
PC 40:5 (20:2(5Z.8Z)/20:3(5Z.8Z.11Z)) [M+HCOO]-ST001111AN0018063.060E-47.060E-4Sample;Benign;Cancer;Metastasis
PC 40:8 (20:4(5E.8E.11E.14E)/20:4(5E.8E.11E.14E)) [M-Ac-H]-ST001111AN0018062.230E-34.250E-3Sample;Benign;Cancer;Metastasis
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000403AN0006431.170E-119.150E-11Cell type;Mature erythrocyte;Reticulocyte
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000539AN0008191.190E-21.410E-1timepoint;1 hour;20 hours
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholineST000539AN0008191.220E-22.230E-2Cell type;Mature erythrocyte;Reticulocyte
PC aa C28:1 / PC aa C40:2ST000405AN0006454.470E-25.990E-1Group;No PA;PA;PoolAll
PC aa C40:3 / PC aa C42:5ST000545AN0008306.050E-51.050E-4Sample Type;Control;Replicate
PC aa C40:5 / PC aa C42:5ST000545AN0008304.960E-61.210E-5Sample Type;Control;Replicate
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholineST000403AN0006421.290E-118.880E-11Cell type;Mature erythrocyte;Reticulocyte
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholineST000539AN0008185.660E-37.440E-2timepoint;1 hour;20 hours
PC ae C44:5 / PC ae C42:5ST000545AN0008307.720E-51.300E-4Sample Type;Control;Replicate
PC(O-12:0/O-1:0)ST000624AN0009561.470E-26.320E-2Condition;Control;Glaucomatous
PD116740-13C0[+QDA adduct]+ST000142AN0002257.770E-326.130E-31Treatment;13C-Glc;unlabeled
PD116740-13C1[+QDA adduct]+ST000142AN0002257.280E-326.130E-31Treatment;13C-Glc;unlabeled
P-DPDST000403AN0006432.360E-45.440E-4Cell type;Mature erythrocyte;Reticulocyte
P-DPDST000539AN0008191.380E-33.290E-3Cell type;Mature erythrocyte;Reticulocyte
P-DPDST001201AN0019996.760E-48.700E-3treatment;DHA;DMSO;OZ277;OZ439
P-DPDST001202AN0020015.420E-149.060E-14cell_type;iRBC;unRBC
P-DPDST001202AN0020019.650E-62.810E-5treatment_duration_(h);-;1.5;3;6;9
P-DPDST001204AN0020052.190E-151.180E-14cell_type;iRBC;unRBC
PE(14:0/P-18:1(11Z))ST000241AN0003731.200E-62.630E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(14:1(9Z)/P-16:0)ST000241AN0003732.680E-123.250E-11Concentration (uM);0;500
PE(14:1(9Z)/P-16:0)ST000241AN0003738.460E-92.510E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(16:0/P-18:1(11Z))ST000241AN0003737.990E-92.420E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PE(16:1(9Z)/P-18:1(11Z))ST000241AN0003734.310E-101.710E-9Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
penem CGP31608ST000403AN0006436.090E-34.920E-2Glucose labelling;C13 glucose;unlabelled
penem CGP31608ST000539AN0008193.680E-37.790E-3Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608ST000539AN0008192.340E-21.950E-1timepoint;1 hour;20 hours
penem CGP31608ST001204AN0020041.040E-42.340E-4cell_type;iRBC;unRBC
penem CGP31608 2ST000539AN0008193.680E-37.790E-3Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608 2ST000539AN0008192.340E-21.950E-1timepoint;1 hour;20 hours
Penicilloic G acidST000242AN0003764.330E-67.430E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000333.970E-81.220E-7Material;Cells;Media
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.250E-31.160E-2Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINEST000016AN0000334.630E-21.260E-1Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE (*)ST000106AN0001758.680E-31.090E-1Sampling time;0 min;60 min
PentazocinetransacidST000047AN0000803.910E-22.470E-1Cognitive Status;AD;CN;MCI
Pentonic acidsST000586AN0009014.330E-141.120E-13Plasma Volume;0 uL;150 uL;700 uL
Pentonic acidsST000589AN0009041.050E-271.510E-27Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
PentosidineST000355AN0005811.370E-103.400E-9Diagnosis;Breast cancer;Control
PentosidineST000355AN0005812.550E-86.320E-7Stage;1;2;3;4;-
Peonidin 3-O-glucoside-13C0[+QDA adduct]+ST000142AN0002258.640E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C12[+QDA adduct]+ST000142AN0002253.270E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C1[+QDA adduct]+ST000142AN0002254.080E-326.130E-31Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C9[+QDA adduct]+ST000142AN0002259.560E-326.280E-31Treatment;13C-Glc;unlabeled
perchlorateST000403AN0006439.390E-31.300E-1timepoint;1 hour;20 hours
PEUCENINST000047AN0000804.500E-22.500E-1Cognitive Status;AD;CN;MCI
PEUCENIN+7.86186ST000047AN0000804.280E-22.500E-1Cognitive Status;AD;CN;MCI
PGE2-d4ST001000AN0018803.480E-38.480E-3Diagnosis;CD;Control;UC
PGF2a ethanolamideST000241AN0003732.030E-43.160E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PGP(18:0/18:1(11Z))ST000241AN0003734.490E-25.140E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Phe-Ala-Phe-AlaST000553AN0008451.670E-82.830E-8Sample type;Plasma;Urine
phe-FMDPST001201AN0019991.930E-54.060E-5cell_type;iRBC;unRBC
phenol redST000974AN0015952.570E-27.900E-2REGION;AHRI;MRC;SUN
PhenolsulfonphthaleinST000403AN0006438.450E-83.130E-7Cell type;Mature erythrocyte;Reticulocyte
PhenolsulfonphthaleinST000539AN0008193.570E-71.580E-6Cell type;Mature erythrocyte;Reticulocyte
PhenolsulfonphthaleinST001201AN0019993.910E-27.400E-1treatment_duration_(h);-;0.5;1.5;3
PhenolsulfonphthaleinST001202AN0020014.920E-231.700E-22cell_type;iRBC;unRBC
PhenolsulfonphthaleinST001202AN0020017.220E-41.460E-3treatment_duration_(h);-;1.5;3;6;9
PhenolsulfonphthaleinST001204AN0020052.650E-25.050E-2cell_type;iRBC;unRBC
PhenolsulfonphthaleinST001205AN0020075.280E-31.960E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
PhenylacetonitrileST001201AN0019983.100E-88.030E-8cell_type;iRBC;unRBC
phenylalanine-d8ST001192AN0019842.550E-22.800E-1Diet;-;Omnivore;Vegetarian
Phenylalanine-HCOOHST000954AN0015644.390E-22.340E-1race;1;2
Phenyl beta-D-glucopyranosideST000566AN0008691.020E-34.490E-3group;Old-Curcumin;Old-Placebo;young
Phenyl beta-D-glucopyranosideST000567AN0008711.270E-35.030E-3groups;Old-Curcumin;Old-Placebo;young
PhenylglycineST001048AN0017169.020E-1092.040E-107Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Phenylglyoxylate-13C0[+13CD3 QDA]+ST000148AN0002357.610E-33.960E-2Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C1[+13CD3 QDA]+ST000148AN0002356.480E-33.560E-2Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C6[+QDA adduct]+ST000142AN0002257.140E-326.130E-31Treatment;13C-Glc;unlabeled
Phorbol 12-tiglate 13-decanoate-13C0[+Na]+ST000148AN0002356.110E-33.400E-2Treatment;13C-Glc;unlabeled
Phorbol butanoate-13C0[+QDA adduct]+ST000148AN0002351.900E-31.700E-2Treatment;13C-Glc;unlabeled
Phosphatidyl glycerolST000242AN0003774.150E-101.590E-8Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
phosphinomethylisomalateST001205AN0020071.600E-38.280E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
phosphinomethylmalateST000403AN0006435.360E-39.830E-3Cell type;Mature erythrocyte;Reticulocyte
PhosphoagmatineST000291AN0004642.910E-31.420E-1Treatment ;Baseline urine;Urine after drinking apple juice;U...
Phosphohydroxypyruvate-13C0[+H]+ST000142AN0002251.100E-316.910E-31Treatment;13C-Glc;unlabeled
Phosphonic acidST001037AN0016985.960E-57.300E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
phthalate esterST000417AN0014488.910E-69.890E-5Group;AIR;NO2PM;PM
phthalate esterST000420AN0006622.430E-55.280E-5Group;nonsmoker;smoker
P-HydroxydesmethylgliquidoneST000422AN0006682.860E-22.930E-1treatment;ND;T1D good glycemic control
P-Hydroxyphenylacetate/2-HydroxyphenylacetateST001317AN0021934.515E-181.522E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-HydroxyphenylacetateST001317AN0021934.515E-181.522E-17SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
p-HydroxyphenylbutazoneglucuronideST000046AN0000791.880E-29.110E-2Cognitive Status;AD;CN;MCI
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)ST000403AN0006432.240E-122.420E-11Cell type;Mature erythrocyte;Reticulocyte
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)ST000539AN0008197.170E-104.740E-9Cell type;Mature erythrocyte;Reticulocyte
Picrasin C-13C0[+13CD3 QDA]+ST000148AN0002352.450E-29.610E-2Treatment;13C-Glc;unlabeled
Picrasin C-13C0[+QDA adduct]+ST000148AN0002351.080E-25.150E-2Treatment;13C-Glc;unlabeled
Picrasin C-13C1[+13CD3 QDA]+ST000148AN0002353.230E-53.240E-3Treatment;13C-Glc;unlabeled
Picrasin F-13C0[+13CD3 QDA]+ST000142AN0002256.350E-326.130E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C1[+13CD3 QDA]+ST000142AN0002259.220E-326.150E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C19[+13CD3 QDA]+ST000142AN0002257.080E-326.130E-31Treatment;13C-Glc;unlabeled
Picrasin F-13C20[+13CD3 QDA]+ST000142AN0002253.170E-326.130E-31Treatment;13C-Glc;unlabeled
Pinacidil-N-OxideST000047AN0000801.680E-21.800E-1Cognitive Status;AD;CN;MCI
PIP(16:0/20:1(11Z))ST000241AN0003737.200E-135.890E-12Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PIPESST001201AN0019991.380E-27.050E-2treatment;DHA;DMSO;OZ277;OZ439
PIPESST001202AN0020013.860E-282.600E-27cell_type;iRBC;unRBC
PIPESST001202AN0020011.030E-42.540E-4treatment_duration_(h);-;1.5;3;6;9
Plasmalogen(20:4/p18:1)ST000450AN0007069.850E-61.620E-5gender;Female;Male
Plasmalogen(p18:0/20:4)ST000450AN0007064.610E-36.190E-3gender;Female;Male
plasmenyl-PC 19:0; [M+Na]+@2.31ST000665AN0010175.020E-34.350E-2Cell line;HepG2;HuH-7
plasmenyl-PC 37:0 (20:0/17:0) [M+Na]+ST001111AN0018051.140E-83.470E-8Sample;Benign;Cancer;Metastasis
plasmenyl-PC 40:2 (18:0/22:2(13Z.16Z)) [M+Na]+ST001111AN0018058.150E-135.670E-12Sample;Benign;Cancer;Metastasis
plasmenyl-PC 42:1 (18:0/24:1(15Z)) [M+Na]+ST001111AN0018053.640E-34.990E-3Sample;Benign;Cancer;Metastasis
plasmenyl-PE 34:1 (16:0/18:1(11E)) [M+H]+ST001111AN0018052.650E-101.050E-9Sample;Benign;Cancer;Metastasis
plasmenyl-PE 36:2 (18:0/18:2(2E.4E)) [M+H]+ST001111AN0018054.340E-35.870E-3Sample;Benign;Cancer;Metastasis
plasmenyl-PE 38:4 (16:0/22:4(7Z.10Z.13Z.16Z)) [M+H]+ST001111AN0018051.570E-32.250E-3Sample;Benign;Cancer;Metastasis
PO4-ALLST001049AN0018643.270E-21.310E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
possible sucroseST000420AN0006623.870E-25.480E-2Group;nonsmoker;smoker
POV-PCST000553AN0008451.410E-62.000E-6Sample type;Plasma;Urine
[PR] 9-Hydroxy-helminthosporolST000403AN0006431.300E-74.620E-7Cell type;Mature erythrocyte;Reticulocyte
[PR] 9-Hydroxy-helminthosporolST000539AN0008193.870E-38.130E-3Cell type;Mature erythrocyte;Reticulocyte
[PR] Citronellyl acetateST000403AN0006431.030E-63.220E-6Cell type;Mature erythrocyte;Reticulocyte
[PR] Citronellyl acetateST000539AN0008191.560E-55.150E-5Cell type;Mature erythrocyte;Reticulocyte
Prednisolone 21-all-cis-farnesylate-13C0[+QDA adduct]+ST000142AN0002257.370E-326.130E-31Treatment;13C-Glc;unlabeled
Pregnanolone sulfateST000567AN0008716.830E-301.950E-28Time point;Post;Pre;Baseline
Pregnanolone sulfateST000567AN0008717.860E-69.360E-5groups;Old-Curcumin;Old-Placebo;young
PregnetriolST000241AN0003731.090E-41.780E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Prephenate-13C0[+H]+ST000142AN0002256.440E-326.130E-31Treatment;13C-Glc;unlabeled
Pro258-13C0ST000076AN0001222.440E-27.760E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C0ST000114AN0001946.630E-33.690E-2Treatment;None;Tetracycline
Pro258-13C1ST000114AN0001947.140E-46.620E-3Treatment;None;Tetracycline
Pro258-13C2ST000076AN0001224.320E-69.390E-5Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C2ST000114AN0001941.470E-27.290E-2Treatment;None;Tetracycline
Pro258-13C3ST000076AN0001221.350E-24.900E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C4ST000076AN0001224.200E-43.460E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C5ST000076AN0001225.230E-44.150E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-13C5ST000114AN0001943.210E-22.630E-1Oxygen Condition;hypoxia;normoxia
Pro258-13C6ST000076AN0001229.020E-51.270E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
Pro258-ALLST000113AN0001911.940E-22.590E-1Treatment;None;Tetracycline
Pro258-ALLST000114AN0001943.070E-46.100E-3Treatment;None;Tetracycline
Procollagen 5-(D-galactosyloxy)-L-lysineST001201AN0019982.300E-44.530E-4cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysineST001202AN0020004.120E-231.200E-22cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysineST001202AN0020001.380E-42.650E-4treatment_duration_(h);-;1.5;3;6;9
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+ST000741AN0011563.950E-21.740E-1subject type;Healthy control;Mild disease;POOLED;Severe dise...
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+ST000775AN0012231.510E-21.160E-1Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+ST000823AN0013077.090E-34.330E-1Dysplasia;LGD;N/A
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+ST000823AN0013073.450E-27.330E-1Diagnosis;IPMN;MCN;SCA
Progtaglandin F2aST001229AN0020423.460E-196.910E-19Sample Source;Feces;Serum;Tissues
Prohydrojasmon-13C0[+13CD3 QDA]+ST000142AN0002252.850E-21.570E-1Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+13CD3 QDA]+ST000148AN0002355.970E-33.350E-2Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+H]+ST000142AN0002252.740E-326.130E-31Treatment;13C-Glc;unlabeled
Propiomazine hydrochloride-13C0[+13CD3 QDA]+ST000142AN0002255.850E-326.130E-31Treatment;13C-Glc;unlabeled
PropionylglycinemethylesterST000046AN0000774.200E-42.090E-2Cognitive Status;AD;CN;MCI
PropionylglycinemethylesterST000046AN0000793.800E-21.350E-1Cognitive Status;AD;CN;MCI
Propionylglycinemethylester+6.2598743ST000046AN0000776.910E-39.840E-2Cognitive Status;AD;CN;MCI
PropoxypheneST000421AN0006637.470E-31.460E-1treatment;ND;T1D poor glycemic control
propyl 4-hydroxybenzoate sulfateST000899AN0014641.910E-24.070E-2Type;Control;Crohn disease;Ulcerative Colitis
Prostaglandin E2 ethanolamideST000241AN0003732.180E-22.620E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
protocatechualdehydeST001201AN0019981.470E-53.170E-5cell_type;iRBC;unRBC
Prunetin or similar isoflavoneST000586AN0009011.230E-21.540E-2Plasma Volume;0 uL;150 uL;700 uL
Prunetin or similar isoflavoneST000589AN0009042.090E-22.160E-2Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
[PS(18:1)] 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoserineST001205AN0020072.030E-25.570E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
Pseudo uridine penta-tmsST000978AN0016021.140E-181.110E-16Competitive_RRTvsDeath;.;N;RRT;DEATH
Pseudo uridine penta-tmsST000978AN0016021.340E-179.810E-16Cox_RRT;.;N;Y
Pseudo uridine penta-tmsST000978AN0016029.440E-109.220E-8Cox_Composite_DeathRRT;.;N;Y
psicoselysineST000403AN0006428.630E-63.920E-4Glucose labelling;C13 glucose;unlabelled
psicoselysineST000539AN0008181.800E-22.970E-1Glucose labelling;C13 glucose;unlabelled
psicoselysineST001201AN0019987.260E-579.460E-55cell_type;iRBC;unRBC
psicoselysineST001204AN0020041.390E-252.700E-24cell_type;iRBC;unRBC
p-Toluic acid-M+0ST001167AN0019307.990E-114.020E-10Time points;0.25h;0h;12h;24h;4h;6days
p-Toluic acid-M+1ST001167AN0019306.730E-41.310E-3Time points;0.25h;0h;12h;24h;4h;6days
p-Toluic acid-M+3ST001167AN0019301.280E-38.600E-3Cell lines;RWPE1;VCaP
p-Toluic acid-M+3ST001167AN0019308.090E-31.320E-2Time points;0.25h;0h;12h;24h;4h;6days
PUFAST001223AN0020362.500E-65.420E-6Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
PUFA (PC)ST000545AN0008302.420E-68.290E-6Sample Type;Control;Replicate
PUFA (PC) / MUFA (PC)ST000545AN0008307.370E-61.550E-5Sample Type;Control;Replicate
PUFA (PC) / SFA (PC)ST000545AN0008305.060E-123.220E-10Sample Type;Control;Replicate
PutreanineST001205AN0020061.240E-35.890E-3parasite_line;Cam3.IIR539T;Cam3.IIrev
Putrescine / OrnST000544AN0008262.420E-122.060E-11Sample Type;Control;Replicate
Putrescine / OrnST000545AN0008292.850E-33.560E-2Sample Type;Control;Replicate
PyrazinoicacidST000046AN0000771.610E-21.370E-1Cognitive Status;AD;CN;MCI
PyrazinoicacidST000047AN0000815.710E-37.210E-2Cognitive Status;AD;CN;MCI
PYRIDINE CARBOXYLIC ACIDST000016AN0000337.130E-162.720E-14Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
PYRIDINE CARBOXYLIC ACIDST000016AN0000333.870E-25.420E-2Material;Cells;Media
PYRIDINE CARBOXYLIC ACIDST000044AN0000683.110E-21.900E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
PYRIDINE CARBOXYLIC ACIDST000044AN0000691.420E-26.450E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
PYRIDINE CARBOXYLIC ACIDST000105AN0001744.260E-23.540E-1Gender;Female;Male
PYRIDINE CARBOXYLIC ACIDST000106AN0001755.350E-34.280E-1Visit;1;2
pyroGlu-13C0ST001049AN0018642.510E-21.160E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C1ST001049AN0018644.350E-21.570E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C3ST001045AN0017097.170E-37.720E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroGlu-13C4ST001049AN0018641.430E-29.730E-2protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-13C5ST001049AN0018641.670E-21.000E-1protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
pyroGlu-ALLST001045AN0017092.330E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Pyroglutamate/OxoprolineST001317AN0021925.592E-353.914E-34SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pyroglutamate/OxoprolineST001317AN0021925.592E-353.914E-34SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
pyroglutamylglycineST000974AN0015955.620E-42.640E-3REGION;AHRI;MRC;SUN
pyroglutamylglycineST000975AN0015964.210E-43.140E-2TIMEPOINT;BL;M06;M18
pyroglutamylglycineST000975AN0015963.150E-34.850E-2GROUP;case;control
PyroglutamylglycineST000553AN0008471.420E-41.670E-4Sample type;Plasma;Urine
pyroglutamylisoleucineST000974AN0015951.570E-25.210E-2REGION;AHRI;MRC;SUN
pyroglutamylisoleucineST000975AN0015967.810E-56.650E-3GROUP;case;control
pyroglutamylphenylalanine*ST000974AN0015952.040E-41.120E-3REGION;AHRI;MRC;SUN
pyroglutamylphenylalanine*ST000975AN0015962.330E-21.540E-1GROUP;case;control
Quinoclamin-13C0[+H]+ST000142AN0002256.030E-326.130E-31Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+Na]+ST000142AN0002258.930E-326.150E-31Treatment;13C-Glc;unlabeled
(R)-2-EthylmalateST001202AN0020001.660E-152.870E-15cell_type;iRBC;unRBC
(R)-2-EthylmalateST001202AN0020006.630E-39.340E-3treatment_duration_(h);-;1.5;3;6;9
(R)-3-HydroxybutanoateST000403AN0006431.580E-29.310E-2Glucose labelling;C13 glucose;unlabelled
(R)-3-HydroxybutanoateST000539AN0008193.030E-25.100E-2Cell type;Mature erythrocyte;Reticulocyte
(R)-3-Hydroxy-Octadecanoic acidST000241AN0003731.570E-42.500E-4Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
(R)-3-Methyl-2-oxobutanoateST000047AN0000822.820E-21.590E-1Cognitive Status;AD;CN;MCI
(R)-3-((R)-3-Hydroxybutanoyloxy)butanoateST001201AN0019991.780E-22.890E-2cell_type;iRBC;unRBC
(R)-AMAAST000403AN0006434.500E-38.360E-3Cell type;Mature erythrocyte;Reticulocyte
(R)-AMAAST000539AN0008192.540E-35.690E-3Cell type;Mature erythrocyte;Reticulocyte
(R)-AMAAST000539AN0008193.740E-22.360E-1timepoint;1 hour;20 hours
(R)-AMAAST000539AN0008193.850E-22.830E-1Glucose labelling;C13 glucose;unlabelled
Rehmaionoside C-13C0[+Na]+ST000142AN0002257.870E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C0[+13CD3 QDA]+ST000142AN0002257.020E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C1[+13CD3 QDA]+ST000142AN0002256.260E-326.130E-31Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C2[+13CD3 QDA]+ST000142AN0002258.350E-326.130E-31Treatment;13C-Glc;unlabeled
ribitol (likely)ST000420AN0006624.220E-112.210E-10Group;nonsmoker;smoker
ribose-5-P/ribulose5-PST001142AN0018769.640E-101.350E-9Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
ribose-5-P/ribulose5-PST001142AN0018761.850E-63.640E-6Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Rifamycin S-13C0[+QDA adduct]+ST000142AN0002252.520E-326.130E-31Treatment;13C-Glc;unlabeled
Rimocidine-13C0[+H]+ST000148AN0002357.180E-33.810E-2Treatment;13C-Glc;unlabeled
RitodrineglucuronideST000046AN0000786.490E-41.100E-2Cognitive Status;AD;CN;MCI
(R)-piperidine-3-carboxylateST001205AN0020063.010E-26.900E-2parasite_line;Cam3.IIR539T;Cam3.IIrev
S-(3-hydroxypropyl)mercapturic acid (HPMA)ST000975AN0015962.290E-53.120E-3GROUP;case;control
S-(3-hydroxypropyl)mercapturic acid (HPMA)ST000975AN0015961.500E-41.300E-3GENDER;F;M
saccharic acidST000087AN0001391.960E-33.430E-3Time Point;18 hours;4 hours
saccharic acidST000369AN0006033.350E-26.820E-2Organ;Plasma;Serum
saccharic acidST000386AN0006213.400E-27.070E-2Organ;Plasma;Serum
saccharic acidST000412AN0006527.370E-72.380E-6Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
saccharic acidST000412AN0006524.560E-21.340E-1Collection Time;1 Hr;2 Hr;3 Hr;-
S-AdenosylmethionimineST000241AN0003731.420E-173.870E-16Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
SALICYLATE #2 (M-H)-ST000523AN0007992.030E-62.710E-5Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
SALICYLATE #2 (M-H)-ST000523AN0007997.210E-31.970E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
SALICYLATE #2 (M-H)-ST000523AN0007992.090E-27.390E-2Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
SALICYLATE #2 (M-H)-ST000713AN0011132.000E-63.580E-5level of dysplasia;HGD;HGD & PDA;LGD;N/A
SALICYLATE #2 (M-H)-ST000748AN0011721.580E-124.630E-12Sample type;Cells;Culture Media
SALICYLATE #2 (M-H)-ST000841AN0013492.830E-33.280E-2Subject group;HIGH-FA;LOW-FA;MID-FA;N/A
SALICYLATE #2 (M-H)-ST000842AN0013568.540E-51.080E-4Sample type;Muscles;Plasma;Pooled sample
SALICYLURIC GLUCURONIDE (*)ST000105AN0001741.260E-22.400E-1PCOS;No PCOS;PCOS
SALICYLURIC GLUCURONIDE (*)ST000105AN0001742.870E-21.130E-1Sampling;After SWS onset;Morning fasting
SAPPANONE A 7-METHYL ETHERST000421AN0006643.590E-31.710E-1treatment;ND;T1D poor glycemic control
SAPPANONEA7-METHYLETHERST000046AN0000793.370E-21.280E-1Cognitive Status;AD;CN;MCI
SARCOSINE/BETA-ALANINEST000475AN0007401.370E-69.790E-6Treatment;-;MDH inhib
SARCOSINE/BETA-ALANINEST000919AN0015079.210E-65.430E-4Gender;Female;Male
SB N-(15Z-tetracosenoyl)-sphing-4-enine (d18:1(4E)/24:1(15Z)) [M-H]-ST001111AN0018063.190E-81.150E-7Sample;Benign;Cancer;Metastasis
SB N-(9Z-octadecenoyl)-sphinganine (d18:0/18:1(9Z)) [M-H]-ST001111AN0018061.430E-32.860E-3Sample;Benign;Cancer;Metastasis
SB N-(docosanoyl)-sphing-4-enine (d18:1(4E)/22:0) [M-H]-ST001111AN0018061.120E-21.960E-2Sample;Benign;Cancer;Metastasis
SB N-(eicosanoyl)-sphing-4-enine (d18:1(4E)/20:0) [M-H]-ST001111AN0018062.230E-45.180E-4Sample;Benign;Cancer;Metastasis
SB N-(hexadecanoyl)-sphing-4-enine (d18:1(4E)/16:0) [M-H]-ST001111AN0018069.140E-104.100E-9Sample;Benign;Cancer;Metastasis
SB N-(octadecanoyl)-sphing-4-enine (d18:1(4E)/18:0) [M-H]-ST001111AN0018061.790E-33.500E-3Sample;Benign;Cancer;Metastasis
S-BudesonideST001317AN0021937.378E-61.164E-5SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-BudesonideST001317AN0021937.378E-61.164E-5SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
SC-1271-13C0[+QDA adduct+Na]+ST000142AN0002258.850E-326.150E-31Treatment;13C-Glc;unlabeled
SC-514ST000567AN0008711.690E-96.710E-9Time point;Post;Pre;Baseline
SC-514ST000567AN0008712.900E-26.810E-2groups;Old-Curcumin;Old-Placebo;young
SDMA/ADMAST001142AN0018755.730E-313.680E-30Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
SDMA/ADMAST001142AN0018753.570E-117.220E-11Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
SDMA / ArgST000544AN0008263.530E-82.180E-7Sample Type;Control;Replicate
SDMA / ArgST000545AN0008292.180E-21.360E-1Sample Type;Control;Replicate
Sedoheptulose phosphate-13C0[+Na]+ST000142AN0002252.130E-326.130E-31Treatment;13C-Glc;unlabeled
SELENOCYSTAMINEST000016AN0000336.950E-31.100E-2Material;Cells;Media
SELENOCYSTAMINEST000105AN0001735.980E-35.240E-2Sampling;After SWS onset;Morning fasting
Se-MethylselenocysteineST000356AN0005833.580E-81.180E-7Diagnosis;breast cancer;control
Se-MethylselenocysteineST000356AN0005831.660E-76.310E-7stage;-;2;3
SenecivernineST000566AN0008702.910E-71.330E-6Time point;Post;Pre;Baseline
SeratoninST000490AN0007561.250E-24.980E-2Disease;cardiovascular disease;sleep apnea
Serotonin / TrpST000545AN0008292.620E-33.560E-2Sample Type;Control;Replicate
SertralineST000356AN0005831.090E-94.250E-9Diagnosis;breast cancer;control
SertralineST000356AN0005831.960E-88.160E-8stage;-;2;3
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucosideST001202AN0020006.560E-108.720E-10cell_type;iRBC;unRBC
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucosideST001202AN0020003.120E-45.650E-4treatment_duration_(h);-;1.5;3;6;9
Sethoxydim-13C0[+H]+ST000142AN0002258.690E-326.130E-31Treatment;13C-Glc;unlabeled
SFA (PC)ST000545AN0008302.590E-23.560E-2Sample Type;Control;Replicate
Sialyllactosamine-13C0[+QDA adduct+Na]+ST000142AN0002255.350E-326.130E-31Treatment;13C-Glc;unlabeled
sinapoyltyramineST000403AN0006434.210E-163.790E-14Cell type;Mature erythrocyte;Reticulocyte
sinapoyltyramineST000539AN0008191.310E-133.910E-12Cell type;Mature erythrocyte;Reticulocyte
SLC1GST001104AN0017967.640E-317.640E-31Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
SM (d18:1/17:0) iSTDST001211AN0020194.140E-51.870E-4Group;Control;Methotrexate
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000450AN0007065.060E-243.530E-23gender;Female;Male
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000465AN0007261.640E-35.870E-2Treatment;Control;Englerin (100 nM)
SM(d18:1/25:0) or SM(d18:1/24:1 OH)ST000617AN0009463.450E-23.110E-1Treatment;CFS;Control
S-Methyl-5-thio-D-ribose 1-phosphateST001201AN0019995.200E-486.980E-47cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphateST001204AN0020052.750E-141.370E-13cell_type;iRBC;unRBC
S-Methyl-5-thio-D-ribose 1-phosphateST001204AN0020052.440E-25.980E-1treatment;DHA;DMSO;OZ277;OZ439
(S)-Methylmalonate semialdehydeST000403AN0006431.300E-91.170E-7Glucose labelling;C13 glucose;unlabelled
(S)-Methylmalonate semialdehydeST000539AN0008195.900E-133.160E-10Glucose labelling;C13 glucose;unlabelled
(S)-Methylmalonate semialdehydeST000539AN0008193.550E-22.310E-1timepoint;1 hour;20 hours
sn-caldarchaeo-1-phosphoethanolamineST000445AN0006961.410E-25.500E-2Treatment;FSH;LH
sodium chlorovulone IIIST000422AN0006681.810E-22.180E-1treatment;ND;T1D good glycemic control
sodium dodecyl sulfateST000403AN0006434.350E-37.140E-2timepoint;1 hour;20 hours
sodium dodecyl sulfateST000539AN0008194.740E-31.070E-1timepoint;1 hour;20 hours
Sodium equilin sulfate-13C0[+13CD3 QDA]+ST000142AN0002255.060E-326.130E-31Treatment;13C-Glc;unlabeled
Sodium ortho-phenylphenateST000292AN0004662.050E-22.180E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
SodiumtetradecylsulfateST000046AN0000782.560E-32.730E-2Cognitive Status;AD;CN;MCI
Source Fragment TRPST000919AN0015062.580E-32.420E-2Gender;Female;Male
Source Fragment TRPST000954AN0015643.170E-31.020E-1race;1;2
Spectinomycin adenylateST000242AN0003773.160E-52.020E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Spectinomycin dihydrochloride-13C0[+QDA adduct+Na]+ST000142AN0002259.010E-326.150E-31Treatment;13C-Glc;unlabeled
Spermidine / PutrescineST000544AN0008262.630E-31.030E-2Sample Type;Control;Replicate
Spermidine / PutrescineST000545AN0008291.970E-33.560E-2Sample Type;Control;Replicate
Spermine / SpermidineST000545AN0008294.900E-22.400E-1Sample Type;Control;Replicate
Sphinganine-phosphateST000612AN0009372.330E-22.560E-1Condition;Control;Glaucomatous
Sphinganine-phosphate (d18:0)ST000553AN0008451.120E-131.210E-12Sample type;Plasma;Urine
Sphinganine-phosphate (d18:0)ST000553AN0008462.200E-94.400E-9Sample type;Plasma;Urine
Sphingosine(18:0)-13C0[+H]+ST000148AN0002359.610E-34.710E-2Treatment;13C-Glc;unlabeled
Stanolone benzoate-13C0[+Na]+ST000142AN0002254.070E-326.130E-31Treatment;13C-Glc;unlabeled
Steryl sulfateST000566AN0008695.390E-202.960E-19Time point;Post;Pre;Baseline
Steryl sulfateST000566AN0008692.790E-72.230E-6group;Old-Curcumin;Old-Placebo;young
SucccinateST001038AN0016991.250E-53.640E-5Timepoint;15 min;1 hr;24 hr;30 min;<5 min
SucccinateST001038AN0016995.900E-38.160E-3Placenta_Surface;Fetal;Maternal
succinate/methylmalonateST001142AN0018762.420E-292.380E-28Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
succinate/methylmalonateST001142AN0018761.080E-82.890E-8Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
succinic acid2ST000417AN0014483.390E-52.020E-4Group;AIR;NO2PM;PM
succiteST001000AN0018794.890E-29.130E-2Diagnosis;CD;Control;UC
SucroseAndDischarrides-13C11[-H+]-ST000367AN0006011.830E-29.070E-2Tissue type;nontumor;tumor
SucroseAndDischarrides-13C12[-H+]-ST000367AN0006014.690E-21.150E-1Tissue type;nontumor;tumor
SucroseAndDischarrides-13C6[-H+]-ST000367AN0006011.500E-29.070E-2Tissue type;nontumor;tumor
SucroseAndDischarrides-13C9[-H+]-ST000367AN0006012.450E-29.070E-2Tissue type;nontumor;tumor
Sucrose and similar disaccharidesST000586AN0009018.950E-162.450E-15Plasma Volume;0 uL;150 uL;700 uL
Sucrose monopalmitateST001205AN0020071.750E-69.200E-5parasite_line;Cam3.IIR539T;Cam3.IIrev
Sucrose / TrehaloseST001048AN0017162.700E-53.290E-5Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Sucrose / Trehalose / LactoseST001040AN0017025.180E-31.480E-2Sample Type/Matrix;Pooled quality control sample;urine;Water...
Sulfacetamide sodium anhydrousST000292AN0004662.570E-52.380E-3Treatment ;Baseline plasma;Plasma after drinking apple juice...
sulfa d18:1 N16:0ST000362AN0005942.160E-36.220E-3Gender;1;2
sulfa d18:1 N20:0ST000362AN0005941.660E-21.260E-1Chronic_Bronchitis;1;-
sulfa d18:1 N20:0ST000362AN0005942.350E-24.150E-2Gender;1;2
sulfa d18:1 N22:0ST000362AN0005941.910E-51.220E-4Gender;1;2
sulfa d18:1 N22:0ST000362AN0005941.450E-34.880E-2Chronic_Bronchitis;1;-
sulfa d18:1 N22:0ST000362AN0005944.230E-26.260E-1Severe_Exacerbations;1;2;3;5;-
Sulfadoxine suflateST000421AN0006644.070E-23.270E-1treatment;ND;T1D poor glycemic control
sulfateST000899AN0014641.940E-51.370E-4Type;Control;Crohn disease;Ulcerative Colitis
sulfate*ST000974AN0015959.000E-61.910E-4GENDER;F;M
sulfate*ST000975AN0015961.260E-37.480E-3GENDER;F;M
SulfateST000046AN0000791.770E-29.010E-2Cognitive Status;AD;CN;MCI
SulfateST001202AN0020015.520E-242.210E-23cell_type;iRBC;unRBC
SulfateST001202AN0020011.070E-53.010E-5treatment_duration_(h);-;1.5;3;6;9
SulfateST001204AN0020055.160E-236.330E-22cell_type;iRBC;unRBC
Sulfate - 1.053629ST000422AN0006681.240E-21.690E-1treatment;ND;T1D good glycemic control
sulfate of piperine metabolite C16H19NO3 (2)*ST000974AN0015952.720E-82.260E-7REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (2)*ST000974AN0015958.070E-43.160E-2GROUP;case;control
sulfate of piperine metabolite C16H19NO3 (2)*ST000975AN0015967.780E-55.210E-3REGION;MAK;SUN
sulfate of piperine metabolite C16H19NO3 (3)*ST000974AN0015951.190E-101.280E-9REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (3)*ST000974AN0015952.710E-41.890E-2GROUP;case;control
sulfate of piperine metabolite C16H19NO3 (3)*ST000975AN0015963.820E-41.240E-2REGION;MAK;SUN
Sulfinopyruvate-13C0[+QDA adduct+Na]+ST000148AN0002352.290E-29.160E-2Treatment;13C-Glc;unlabeled
Sulfinopyruvate-13C1[+QDA adduct+Na]+ST000148AN0002355.760E-33.300E-2Treatment;13C-Glc;unlabeled
Sulfinpyrazone sulfoneST000566AN0008692.700E-23.970E-2Time point;Post;Pre;Baseline
SulfiteST000421AN0006644.380E-23.270E-1treatment;ND;T1D poor glycemic control
SulfoacetateST000403AN0006432.480E-22.460E-1timepoint;1 hour;20 hours
SulfoacetateST000403AN0006433.310E-25.340E-2Cell type;Mature erythrocyte;Reticulocyte
SulfoacetateST000539AN0008196.190E-31.240E-2Cell type;Mature erythrocyte;Reticulocyte
SulforaphaneST001202AN0020013.780E-167.440E-16cell_type;iRBC;unRBC
SulforaphaneST001202AN0020018.990E-62.650E-5treatment_duration_(h);-;1.5;3;6;9
t-aconitate-13C0ST000076AN0001228.690E-51.270E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C0ST001045AN0017091.710E-33.910E-2protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C1ST001045AN0017092.270E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C2ST000076AN0001222.250E-27.270E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C2ST001045AN0017094.310E-21.510E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-13C4ST000076AN0001222.050E-27.010E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-13C4ST001045AN0017092.400E-21.140E-1protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-ALLST000076AN0001221.850E-26.410E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
t-aconitate-ALLST000114AN0001942.400E-28.780E-2Treatment;None;Tetracycline
Tafluprost free acidST000444AN0006952.450E-25.210E-2Sample Treatment;Bubbled;Control
tartrazineST001202AN0020011.910E-353.490E-34cell_type;iRBC;unRBC
tartrazineST001202AN0020014.130E-25.740E-2treatment_duration_(h);-;1.5;3;6;9
Tartronic acidST000589AN0009044.310E-508.090E-50Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Taurine DimerST000380AN0006148.550E-126.600E-11Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Taurine DimerST000380AN0006142.660E-34.350E-3Time;10min;1hr;24hr;6hr
taurodeoxycholate/taurochenodeoxycholateST001000AN0018791.200E-22.670E-2Diagnosis;CD;Control;UC
taurodeoxycholate/taurochenodeoxycholateST001142AN0018767.860E-317.730E-30Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
taurodeoxycholate/taurochenodeoxycholateST001142AN0018762.810E-218.730E-21Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Tecomine-13C0[+13CD3 QDA]+NH4ST000148AN0002352.390E-31.850E-2Treatment;13C-Glc;unlabeled
Tepraloxydim-13C0[+13CD3 QDA]+ST000142AN0002254.220E-326.130E-31Treatment;13C-Glc;unlabeled
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilaneST000978AN0016027.170E-34.470E-2Cox_RRT;.;N;Y
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilaneST000978AN0016021.970E-21.010E-1Competitive_RRTvsDeath;.;N;RRT;DEATH
Testosterone decanoate-13C0[+13CD3 QDA]+ST000142AN0002259.330E-326.180E-31Treatment;13C-Glc;unlabeled
Testosterone isocaproate-13C9[+Na]+ST000142AN0002256.080E-326.130E-31Treatment;13C-Glc;unlabeled
tetcyclacisST001204AN0020052.730E-36.140E-3cell_type;iRBC;unRBC
tetrahydro-1-methyl-beta-carboline-3-carboxylateST000923AN0015145.430E-31.420E-2Diagnosis;CD;nonIBD;UC
tetrahydro-beta-carboline-carboxylic acidST001000AN0018783.160E-151.120E-13Diagnosis;CD;Control;UC
tetrahydrogeranylgeranyl-bacteriopheophytinST001204AN0020053.400E-48.270E-4cell_type;iRBC;unRBC
tetrahydrogeranylgeranyl-bacteriopheophytinST001204AN0020052.040E-22.300E-1treatment_duration_(h);-;3;6;9
TetrahydroneopterinST000356AN0005838.300E-133.640E-12Diagnosis;breast cancer;control
TetrahydroneopterinST000356AN0005835.290E-92.260E-8stage;-;2;3
Tetrahydrothiophene sulfoxideST000422AN0006674.530E-25.950E-1treatment;ND;T1D good glycemic control
tetranor 12-HETEST000916AN0014918.660E-103.330E-8Diagnosis;Cirrhosis;NASH;Normal;Steatosis
TetrasaccharideST000589AN0009047.160E-239.520E-23Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
TexanolST000583AN0008943.330E-37.050E-2caries status;caries-active;caries-free
Theobromine /TheophyllineST000553AN0008471.330E-92.680E-9Sample type;Plasma;Urine
Theobromine /Theophylline/ ParaxanthineST001317AN0021922.012E-143.521E-14SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Theobromine /Theophylline/ ParaxanthineST001317AN0021922.012E-143.521E-14SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
thioprolineST000899AN0014625.610E-32.570E-2Type;Control;Crohn disease;Ulcerative Colitis
thioprolineST000974AN0015958.090E-31.110E-1GROUP;case;control
thioprolineST000975AN0015966.910E-37.640E-2GROUP;case;control
threo-Isocitricacid-1.0347548ST000047AN0000822.220E-21.420E-1Cognitive Status;AD;CN;MCI
Threonine /HomoserineST000553AN0008477.040E-101.510E-9Sample type;Plasma;Urine
threo-sphingosineST001236AN0020545.220E-41.780E-2OS_Censor (1 means the time is a censoring time and 0 means ...
threo-sphingosineST001237AN0020551.150E-22.130E-2CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
threosphingosineST000923AN0015138.280E-43.460E-3Diagnosis;CD;nonIBD;UC
threosphingosineST001000AN0018784.590E-52.590E-4Diagnosis;CD;Control;UC
Thujaplicin-13C0[+13CD3 QDA]+ST000142AN0002251.090E-26.280E-2Treatment;13C-Glc;unlabeled
THYMIDINE-5`-DIPHOSPHO-ALPHA-D-GLUCOSEST000044AN0000693.580E-21.290E-1Pancreas tissue type;Normal area of the pancreas with tumor;...
thymine-d4ST001192AN0019854.910E-23.720E-1Diet;-;Omnivore;Vegetarian
TiletamineST000566AN0008701.350E-42.060E-4Time point;Post;Pre;Baseline
tocopherol beta NISTST000061AN0000992.000E-26.190E-2Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
?-TocotrienolST000553AN0008452.520E-22.780E-2Sample type;Plasma;Urine
Tolmetin sodiumST000292AN0004664.660E-23.250E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
TolylacetonitrileST001202AN0020002.530E-261.040E-25cell_type;iRBC;unRBC
TolylacetonitrileST001202AN0020003.260E-71.260E-6treatment_duration_(h);-;1.5;3;6;9
Tos-Lys-CH2ClST000292AN0004664.730E-23.250E-1Treatment ;Baseline plasma;Plasma after drinking apple juice...
Total AC / C0ST000544AN0008279.800E-34.590E-2Sample Type;Control;Replicate
Total AC / C0ST000545AN0008305.690E-38.170E-3Sample Type;Control;Replicate
Total AC-DC / Total ACST000544AN0008272.290E-41.570E-3Sample Type;Control;Replicate
Total AC-DC / Total ACST000545AN0008301.100E-52.190E-5Sample Type;Control;Replicate
Total AC-OH / Total ACST000544AN0008272.280E-51.810E-4Sample Type;Control;Replicate
Total AC-OH / Total ACST000545AN0008302.280E-54.240E-5Sample Type;Control;Replicate
Total DMA / ArgST000405AN0006452.220E-25.990E-1Group;No PA;PA;PoolAll
Total DMA / ArgST000544AN0008261.430E-111.080E-10Sample Type;Control;Replicate
Total DMA / ArgST000545AN0008291.410E-21.060E-1Sample Type;Control;Replicate
Total lysoPCST000545AN0008302.360E-71.880E-6Sample Type;Control;Replicate
Total lysoPC / Total PCST000545AN0008303.160E-55.630E-5Sample Type;Control;Replicate
Total PCST000545AN0008303.140E-68.880E-6Sample Type;Control;Replicate
Total PC aaST000545AN0008303.250E-68.880E-6Sample Type;Control;Replicate
Total PC aeST000545AN0008302.340E-68.290E-6Sample Type;Control;Replicate
Total (PC+SM)ST000545AN0008302.900E-68.880E-6Sample Type;Control;Replicate
Total SMST000545AN0008301.960E-67.970E-6Sample Type;Control;Replicate
Total SM-non OHST000545AN0008301.920E-67.970E-6Sample Type;Control;Replicate
Total SM-OHST000545AN0008301.400E-66.860E-6Sample Type;Control;Replicate
Total SM / Total PCST000544AN0008272.350E-51.810E-4Sample Type;Control;Replicate
Total SM / Total PCST000545AN0008303.210E-68.880E-6Sample Type;Control;Replicate
Total SM / Total (SM+PC)ST000544AN0008273.260E-52.320E-4Sample Type;Control;Replicate
Total SM / Total (SM+PC)ST000545AN0008307.360E-61.550E-5Sample Type;Control;Replicate
trans-Hexadec-2-enoyl carnitineST000355AN0005813.230E-28.950E-2Stage;1;2;3;4;-
trans-Hexadec-2-enoylcarnitineST000403AN0006422.680E-101.440E-9Cell type;Mature erythrocyte;Reticulocyte
trans-Hexadec-2-enoylcarnitineST000539AN0008181.960E-135.670E-12Cell type;Mature erythrocyte;Reticulocyte
trans-Hexadec-2-enoylcarnitineST001201AN0019981.260E-184.890E-18cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitineST001202AN0020008.190E-95.410E-8treatment_duration_(h);-;1.5;3;6;9
trans-Hexadec-2-enoylcarnitineST001204AN0020043.480E-141.850E-13cell_type;iRBC;unRBC
trans-OH-ProST000783AN0012391.570E-32.920E-1RACE;AA;EA
Triamcinolone diacetate-13C0[+QDA adduct+Na]+ST000142AN0002258.050E-326.130E-31Treatment;13C-Glc;unlabeled
TRIDESACETOXYKHIVORINST000046AN0000783.260E-21.230E-1Cognitive Status;AD;CN;MCI
TRIDESACETOXYKHIVORINST000421AN0006662.190E-22.330E-1treatment;ND;T1D poor glycemic control
TrifloxystrobinST001037AN0016983.430E-61.010E-4Description ;Blank;Reagent Blank;Serum Sample;Solvent
trihexcer d18:1 N16:0ST000362AN0005941.510E-22.820E-2Gender;1;2
Trihexosylceramide (d18:1/18:0)ST000241AN0003741.070E-23.970E-2Concentration (uM);0;500
Trihexosylceramide (d18:1/18:0)ST000241AN0003742.380E-22.380E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihexosylceramide (d18:1/24:0)ST000241AN0003737.560E-71.680E-6Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihexosylceramide (d18:1/9Z-18:1)ST000241AN0003731.590E-118.670E-11Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Trihydroxybutyric acidST000980AN0016065.570E-34.270E-2Classification;Mild;Moderate;Non-allergic;Severe
trihydroxypyrazine NISTST000369AN0006031.160E-151.750E-14Organ;Plasma;Serum
trihydroxypyrazine NISTST000386AN0006219.980E-151.640E-13Organ;Plasma;Serum
trimethylbenzeneST000923AN0015134.950E-31.460E-2Diagnosis;CD;nonIBD;UC
trimethylbenzeneST001000AN0018788.220E-32.180E-2Diagnosis;CD;Control;UC
Trimethylsilyl 3-((trimethylsilyl)thio)propanoateST000978AN0016023.630E-21.330E-1Cox_RRT;.;N;Y
TrinexapacST001037AN0016987.790E-32.800E-2Description ;Blank;Reagent Blank;Serum Sample;Solvent
Trinexapac-ethyl-13C0[+Na]+ST000142AN0002258.640E-326.130E-31Treatment;13C-Glc;unlabeled
TriphosphateST000241AN0003733.510E-24.150E-2Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Tris(2-chloroethyl)phosphateST000566AN0008694.530E-101.590E-9Time point;Post;Pre;Baseline
TrisaccharideST000586AN0009018.180E-81.580E-7Plasma Volume;0 uL;150 uL;700 uL
TrisaccharideST000589AN0009047.830E-611.670E-60Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
TriterpenoidST000241AN0003736.640E-92.030E-8Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
TROMETHAMINEST000047AN0000818.710E-39.240E-2Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.1856112ST000046AN0000766.090E-41.160E-2Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.4366517ST000046AN0000766.150E-51.540E-3Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.7465215ST000046AN0000773.070E-21.690E-1Cognitive Status;AD;CN;MCI
TROMETHAMINE+5.9955096ST000046AN0000762.480E-21.200E-1Cognitive Status;AD;CN;MCI
Trp-Trp-Tyr-TyrST000403AN0006421.080E-42.520E-4Cell type;Mature erythrocyte;Reticulocyte
Trp-Trp-Tyr-TyrST000539AN0008181.070E-53.400E-5Cell type;Mature erythrocyte;Reticulocyte
Trp-Trp-Tyr-TyrST001202AN0020008.160E-561.100E-53cell_type;iRBC;unRBC
tthyl hexadecenoateST001000AN0018784.950E-28.890E-2Diagnosis;CD;Control;UC
Tyr-OEtST000403AN0006426.600E-72.140E-6Cell type;Mature erythrocyte;Reticulocyte
Tyr-OEtST000539AN0008182.780E-46.990E-4Cell type;Mature erythrocyte;Reticulocyte
Tyrphostin B44 (-)ST000242AN0003758.710E-41.180E-3Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Tyrphostin B44 (-)ST000242AN0003765.890E-71.410E-6Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
U 0521-13C0[+QDA adduct]+NH4ST000148AN0002351.890E-31.700E-2Treatment;13C-Glc;unlabeled
UDP-GLCUR-13C0+15N0ST000076AN0001218.720E-63.370E-3Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GLCUR-13C13+15N0ST000076AN0001217.780E-41.000E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C0+15N0ST000076AN0001211.070E-42.070E-2Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C11+15N0ST000076AN0001211.270E-24.230E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C12+15N0ST000076AN0001212.840E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C13+15N0ST000076AN0001217.600E-33.500E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C15+15N0ST000076AN0001211.700E-25.030E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C5+15N0ST000076AN0001214.290E-25.990E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C6+15N0ST000076AN0001214.360E-32.640E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
UDP-GNAc-13C7+15N0ST000076AN0001212.410E-25.980E-1Labeling;13C/15N-Gln;13C-Glc;unlabeled
undecanedicarboxylic acidST001000AN0018806.110E-41.710E-3Diagnosis;CD;Control;UC
undecanedionateST000923AN0015155.970E-42.170E-3Diagnosis;CD;nonIBD;UC
undecanedionateST001000AN0018802.230E-126.230E-11Diagnosis;CD;Control;UC
Undecanone-13C0[+13CD3 QDA]+ST000148AN0002358.510E-34.300E-2Treatment;13C-Glc;unlabeled
Undecanone-13C0[+H]+ST000148AN0002357.430E-33.890E-2Treatment;13C-Glc;unlabeled
Undecanone-13C0[+QDA adduct]+ST000148AN0002351.250E-25.750E-2Treatment;13C-Glc;unlabeled
Undecanone-13C2[+QDA adduct]+ST000148AN0002354.130E-21.450E-1Treatment;13C-Glc;unlabeled
Undecanone-13C6[+QDA adduct]+ST000148AN0002353.280E-61.080E-3Treatment;13C-Glc;unlabeled
Unknown_742.54(-)@5.61ST000818AN0012984.840E-88.070E-8Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Unknown_742.54(-)@5.61ST000818AN0012982.650E-54.310E-5Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Unknown_742.54(-)@5.61ST000818AN0012984.970E-26.530E-2Country;Ethiopia;Tanzania;Botswana
Unknown_742.54(-)@6.25ST000818AN0012982.110E-104.500E-10Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Unknown_742.54(-)@6.25ST000818AN0012981.050E-85.050E-8Country;Ethiopia;Tanzania;Botswana
Unknown_742.54(-)@6.25ST000818AN0012989.880E-82.210E-7Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Unknown_742.54(-)@6.25ST000818AN0012981.810E-32.940E-3Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
Uracil 5-carbaldehyde-13C1[+QDA adduct]+ST000142AN0002256.390E-326.130E-31Treatment;13C-Glc;unlabeled
URACIL;UracilST000956AN0015681.700E-68.170E-6Treatment;Condition-1;Condition-2;Condition-3;Control
urea (partial derivative)ST000092AN0001464.290E-59.970E-5Urease Treatment;No treatment;Urease pre-treatment;Water pre...
urea (partial derivative)ST000092AN0001468.150E-31.130E-2Solution Added;N/A;None;Urease;Water
UrethaneST000403AN0006425.350E-61.540E-5Cell type;Mature erythrocyte;Reticulocyte
UrethaneST000539AN0008183.420E-37.180E-3Cell type;Mature erythrocyte;Reticulocyte
URETHANEST000421AN0006633.130E-22.630E-1treatment;ND;T1D poor glycemic control
Urethane 2ST000539AN0008183.420E-37.180E-3Cell type;Mature erythrocyte;Reticulocyte
uridine-5-diphosphate bromoacetolST000403AN0006434.900E-39.080E-3Cell type;Mature erythrocyte;Reticulocyte
uridine-5-diphosphate bromoacetolST000403AN0006431.600E-29.310E-2Glucose labelling;C13 glucose;unlabelled
uridine-5-diphosphate bromoacetolST000539AN0008199.140E-52.210E-2timepoint;1 hour;20 hours
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000269.620E-32.220E-1TGF;NO_TGF;TGF
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000261.620E-25.110E-2FCS;FCS;NO_FCS
URIDINE 5`-DIPHOSPHOGLUCOSEST000010AN0000263.390E-28.170E-2Hours;72;0;12;24;2
URIDINE 5`-DIPHOSPHOGLUCOSEST000044AN0000695.650E-33.340E-2Pancreas tissue type;Normal area of the pancreas with tumor;...
URIDINE 5`-DIPHOSPHOGLUCURONIC ACIDST000010AN0000262.450E-22.870E-1TGF;NO_TGF;TGF
urobilinogenST001237AN0020556.100E-32.360E-2Time point;baseline;week 4;week 8
urobilin - targetedST000923AN0015139.370E-198.800E-17Diagnosis;CD;nonIBD;UC
urobilin - targetedST000923AN0015131.270E-31.180E-2sex;Female;Male
URSINIC ACIDST000422AN0006684.300E-23.560E-1treatment;ND;T1D good glycemic control
URSINICACIDST000046AN0000763.870E-21.510E-1Cognitive Status;AD;CN;MCI
URSINICACIDST000046AN0000774.750E-22.140E-1Cognitive Status;AD;CN;MCI
URSODIOL-2 WATERST000691AN0010672.780E-23.250E-2Progression;Pooled plasma;Y
UscharidinST000242AN0003771.210E-58.960E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Uscharidin-13C0[+QDA adduct+Na]+ST000148AN0002351.720E-27.330E-2Treatment;13C-Glc;unlabeled
ValacyclovirST000291AN0004651.140E-35.000E-2Treatment ;Baseline urine;Urine after drinking apple juice;U...
valerate/isovalerateST000923AN0015149.270E-55.910E-4Diagnosis;CD;nonIBD;UC
VALERYLSALYCILATEST000047AN0000801.530E-35.600E-2Cognitive Status;AD;CN;MCI
VALERYLSALYCILATEST000047AN0000816.920E-42.450E-2Cognitive Status;AD;CN;MCI
valine ionST000974AN0015955.140E-34.240E-2TIMEPOINT;BL;M06;M18
valine ionST000975AN0015961.670E-33.640E-2GROUP;case;control
ValproateST000150AN0002375.750E-31.740E-1Patient;Patient 1;Patient 2;Patient 3;Patient 4
Val-Tyr-Val iSTDST001211AN0020171.190E-24.060E-2Group;Control;Methotrexate
VanilloylglycineST000292AN0004671.970E-128.460E-11Treatment ;Baseline plasma;Plasma after drinking apple juice...
vanilylmandelic acidST000420AN0006621.530E-132.140E-12Group;nonsmoker;smoker
VD2716ST000045AN0000752.890E-21.530E-1Treatment;Insulin Withdrawal;Saline Infusion
Very low density lipoproteinST001038AN0016996.960E-72.200E-6Placenta_Surface;Fetal;Maternal
Very low density lipoproteinST001038AN0016991.480E-32.970E-3Timepoint;15 min;1 hr;24 hr;30 min;<5 min
VGAHAGEYGAEALER*ST000093AN0001494.500E-22.860E-1condition;FFA affected ;FFA unaffected ;Scalp biopsy normal
VGAHAGEYGAEALER*ST000093AN0001494.500E-22.860E-1location;frontal scalp;occipital scalp;NA
Vinylbacteriochlorophyllide a-13C0[+Na]+ST000142AN0002253.150E-326.130E-31Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C1[+Na]+ST000142AN0002252.720E-326.130E-31Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C9[+Na]+ST000142AN0002253.510E-326.130E-31Treatment;13C-Glc;unlabeled
WestiellamideST000242AN0003755.420E-58.300E-5Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
X3.Methylhistidine.ST000435AN0006856.610E-54.740E-4treatment;ND;T1D good glycemic control;T1D poor glycemic con...
Xanthoxin-13C0[+QDA adduct]+ST000148AN0002352.540E-29.840E-2Treatment;13C-Glc;unlabeled
Xanthumin-13C0[+Na]+ST000142AN0002254.910E-22.600E-1Treatment;13C-Glc;unlabeled
XHWESASXXR*ST000974AN0015952.950E-41.540E-3REGION;AHRI;MRC;SUN
XHWESASXXR*ST000974AN0015952.190E-34.850E-2GROUP;case;control
XHWESASXXR*ST000974AN0015955.480E-34.240E-2TIMEPOINT;BL;M06;M18
XylobioseST000403AN0006439.020E-73.050E-5Glucose labelling;C13 glucose;unlabelled
XylobioseST000539AN0008191.920E-67.360E-5Glucose labelling;C13 glucose;unlabelled
XylobioseST001201AN0019998.800E-112.830E-8treatment;DHA;DMSO;OZ277;OZ439
Yamogenin 3-O-neohesperidosideST000242AN0003771.210E-46.640E-4Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
YC-17-13C0[+Na]+ST000142AN0002256.070E-326.130E-31Treatment;13C-Glc;unlabeled
YM-201636ST000567AN0008712.430E-38.260E-3groups;Old-Curcumin;Old-Placebo;young
(Z)-4-Hydroxyphenylacetaldehyde-oximeST000403AN0006426.210E-35.450E-2Glucose labelling;C13 glucose;unlabelled
ZAPAST000403AN0006423.970E-34.260E-2Glucose labelling;C13 glucose;unlabelled
ZAPAST000539AN0008186.880E-51.950E-4Cell type;Mature erythrocyte;Reticulocyte
z dioctylphtalateST000054AN0000921.740E-179.070E-16treatment;Basal ;DCIS ;HER2 ;LumA ;LumB ;Reduction ;Total Po...
z dioctylphtalateST000054AN0000922.330E-111.030E-9pool aliquot;no;yes
z dioctylphtalateST000416AN0006581.900E-24.280E-2Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
z dioctylphtalateST000417AN0014481.470E-22.680E-2Group;AIR;NO2PM;PM
z dioctylphtalateST000417AN0014482.800E-26.220E-1Collection Time;24HRPOST;Post;Pre
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000689AN0010631.190E-37.300E-3Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010752.530E-61.330E-4Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010754.010E-62.630E-4Tamoxyfen;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010754.980E-63.280E-4Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.030E-63.310E-4Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.100E-62.850E-4TIMEPOINT;3 Month;Baseline;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.320E-63.500E-4Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000695AN0010755.580E-63.670E-4CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000697AN0010816.190E-51.200E-3Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000697AN0010816.500E-52.970E-3Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010835.200E-34.890E-2KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010838.840E-34.870E-2KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000698AN0010832.250E-21.080E-1Condition;no;Pooled melanoma;yes
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000741AN0011559.450E-42.990E-2subject type;Healthy control;Mild disease;POOLED;Severe dise...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012224.240E-72.470E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012223.350E-61.950E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-ST000775AN0012225.340E-63.110E-4Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000689AN0010642.320E-42.250E-3Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010763.040E-53.870E-3Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010766.690E-51.090E-2Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010768.830E-58.600E-3TIMEPOINT;3 Month;Baseline;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.100E-41.460E-2Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.200E-41.210E-2CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.570E-41.100E-2Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000695AN0010761.890E-41.840E-2Tamoxyfen;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000697AN0010826.590E-39.120E-2Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000697AN0010828.540E-35.750E-2Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010843.880E-164.790E-14KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010841.160E-151.440E-13KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000698AN0010841.180E-151.460E-13Condition;no;Pooled melanoma;yes
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000741AN0011561.660E-53.600E-4subject type;Healthy control;Mild disease;POOLED;Severe dise...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012231.290E-66.460E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012232.280E-61.370E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+ST000775AN0012236.260E-52.350E-3Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000689AN0010631.230E-37.300E-3Construct;-;Control lentivirus;Noxa knockdown
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010756.870E-62.590E-4Race;Black;White;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010758.590E-63.770E-4Tamoxyfen;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.180E-54.450E-4Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.180E-54.450E-4Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.230E-55.390E-4Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.350E-55.960E-4CASE_CONTROL;Case;Control;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000695AN0010751.460E-55.490E-4TIMEPOINT;3 Month;Baseline;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000697AN0010811.870E-55.430E-4Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000697AN0010813.700E-52.950E-3Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010834.260E-42.410E-2KD#1;no;yes;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010837.460E-41.120E-2KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000698AN0010831.650E-32.490E-2Condition;no;Pooled melanoma;yes
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000741AN0011551.220E-71.790E-5subject type;Healthy control;Mild disease;POOLED;Severe dise...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.520E-71.770E-5Treatment response;No;Yes;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.230E-61.430E-4Timepoint;T0;T2;Pooled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-ST000775AN0012221.260E-54.880E-4Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (M+Cl)-ST000523AN0007993.330E-27.870E-2Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012961.990E-1051.890E-103Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012964.770E-704.530E-68Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M+Cl)-ST000818AN0012961.260E-271.190E-25Country;Ethiopia;Tanzania;Botswana
ZEATIN [ISTD] (M+Cl)-ST000818AN0012965.160E-211.630E-19Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
ZEATIN [ISTD] (M+Cl)-ST000842AN0013564.840E-233.230E-22Sample type;Muscles;Plasma;Pooled sample
ZEATIN [ISTD] (M+CL)-ST000711AN0011101.380E-38.610E-2NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M+CL)-ST000713AN0011132.770E-32.480E-2malignant transformation;No;yes;Yes
ZEATIN [ISTD] (M+CL)-ST000726AN0011382.250E-97.500E-9Timepoint;-;270;120;30;90
ZEATIN [ISTD] (M+CL)-ST000726AN0011384.170E-22.170E-1DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (M+CL)-ST000748AN0011723.110E-96.040E-9Sample type;Cells;Culture Media
ZEATIN [ISTD] (M+H)+ST000711AN0011111.470E-34.130E-2NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M+H)+ST000721AN0011274.380E-22.480E-1Gender;Male;Female
ZEATIN [ISTD] (M+H)+ST000726AN0011396.280E-51.660E-3DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (M+H)+ST000744AN0011633.470E-24.360E-1Gender;female;male
ZEATIN [ISTD] (M+H)+ST000763AN0012023.000E-31.730E-2Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
ZEATIN [ISTD] (M+H)+ST000763AN0012024.600E-21.570E-1Type;Cath;Non-invasive
ZEATIN [ISTD] (M+H)+ST000823AN0013072.670E-24.330E-1Dysplasia;LGD;N/A
ZEATIN [ISTD] (M+H)+ST000842AN0013573.400E-533.940E-51Sample type;Muscles;Plasma;Pooled sample
ZEATIN [ISTD] (M-H)-ST000711AN0011101.930E-38.610E-2NTM pulmonary disease;no;yes
ZEATIN [ISTD] (M-H)-ST000726AN0011387.700E-34.490E-2Assay;BC TP;OGTT
ZEATIN [ISTD] (M-H)-ST000726AN0011381.260E-21.100E-1DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (M-H)-ST000748AN0011724.000E-97.450E-9Sample type;Cells;Culture Media
ZEATIN [ISTD] (M-H)-ST000818AN0012964.610E-1012.190E-99Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M-H)-ST000818AN0012961.690E-688.050E-67Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M-H)-ST000818AN0012964.320E-261.370E-24Country;Ethiopia;Tanzania;Botswana
ZEATIN [ISTD] (M-H)-ST000818AN0012967.320E-211.740E-19Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
z mstfa artifactST000420AN0006621.140E-31.950E-3Group;nonsmoker;smoker
(Z)-N-(2-hydroxyethyl)hexadec-7-enamideST000566AN0008701.410E-52.910E-5Time point;Post;Pre;Baseline

( Species:Human)
List of studies, analyses, submitted metabolite names, experimental conditions and RSD values

Replicate numbers reflect the number of replicates for each experimental condition where the measured value was not null
Name Study_id Analysis_id Factors Range(RSD) Replicates
  logo